



US 20150050647A1

(19) **United States**(12) **Patent Application Publication**
LUO et al.(10) **Pub. No.: US 2015/0050647 A1**(43) **Pub. Date: Feb. 19, 2015**(54) **METHODS FOR DIAGNOSING PROSTATE
CANCER AND PREDICTING PROSTATE
CANCER RELAPSE**(60) Provisional application No. 61/535,240, filed on Sep.
15, 2011.(71) Applicant: **University of Pittsburgh - of the
Commonwealth System of Higher
Education, Pittsburgh, PA (US)****Publication Classification**(51) **Int. Cl.**
C12Q 1/68 (2006.01)(52) **U.S. Cl.**
CPC **C12Q 1/6886** (2013.01); **C12Q 2600/112**
(2013.01)USPC **435/6.11; 435/6.14**(72) Inventors: **JIANHUA LUO**, Wexford, PA (US);
George Konstantine Michalopoulos,
Pittsburgh, PA (US); **Joel B. Nelson**,
Pittsburgh, PA (US); **Chi Song**, New
Haven, CT (US); **Chien-Cheng Tseng**,
Pittsburgh, PA (US); **Yanping Yu**,
Wexford, PA (US)(57) **ABSTRACT**(73) Assignee: **University of Pittsburgh - of the
Commonwealth System of Higher
Education, Pittsburgh, PA (US)**

The present invention relates to methods and compositions for diagnosing prostate cancer and/or determining whether a prostate cancer patient is at increased risk of suffering a relapse, or a rapid relapse, of his cancer. It is based, at least in part, on the results of a comprehensive genome analysis on 241 prostate cancer samples (104 prostate cancer, 85 matched bloods, 49 matched benign prostate tissues adjacent to cancer, and 3 cell lines) which indicate that (i) genome copy number variation (CNV) occurred in both cancer and non-cancer tissues, and (ii) CNV predicts prostate cancer progression.

(21) Appl. No.: **14/336,965**(22) Filed: **Jul. 21, 2014****Related U.S. Application Data**(63) Continuation of application No. 13/619,556, filed on
Sep. 14, 2012, now abandoned.




FIG. 1A




FIG. 1B




FIG. 1C




FIG. 1D




FIG. 2A




FIG. 2B




FIG. 2C




FIG. 3A




FIG. 3B




FIG. 3C




FIG. 3D




FIG. 4A




FIG. 4B




FIG. 4C




FIG. 4D




FIG. 5A




FIG. 5B




FIG. 5C




FIG. 5D




FIG. 6A




FIG. 6B




FIG. 6C




FIG. 6D




FIG. 7A




FIG. 7B




FIG. 8A




FIG. 8B




FIG. 8C




FIG. 8D




FIG. 9A




FIG. 9B




FIG. 9C




FIG. 9D




FIG. 10A




FIG. 10B




FIG. 10C




FIG. 10D




FIG. 10E




FIG. 10F

METHODS FOR DIAGNOSING PROSTATE CANCER AND PREDICTING PROSTATE CANCER RELAPSE

PRIORITY CLAIM

[0001] This application is a continuation of United States Ser. No. 13/619,556, filed Sep. 14, 2012, which claims priority to U.S. Provisional Application No. 61/535,240, filed Sep. 15, 2011, the contents of each of which is hereby incorporated by reference in its entirety herein, and to each of which priority is claimed.

GRANT SUPPORT

[0002] This invention was made with government support under Grant No. RO1-CA098249 awarded by the National Cancer Institute. The government has certain rights in the invention.

1. INTRODUCTION

[0003] The present invention relates to methods and compositions for diagnosing prostate cancer and/or determining whether a subject having prostate cancer is at increased risk for relapse or rapid relapse.

2. BACKGROUND OF THE INVENTION

[0004] Prostate cancer is one of the most common and lethal malignancies in men: The annual mortality rate reached 32,000 in the US in 2009 (1-3). Previous cytogenetic and other genome studies suggest a clear link between genome abnormalities and the prostate cancer (4-9). Currently, several treatment options are available for prostate cancer patients including watchful waiting, radiation, hormonal/chemotherapy and radical prostatectomy. Gleason's grading alone or in combination with other clinical indicators such as serum prostate specific antigen levels and pathological or clinical staging has been the guiding tool in selecting these treatment options. Significant numbers of prostate cancer patients, however, experienced relapse after surgical resection of the prostate gland. There is clearly a need for better prediction of the behavior of prostate cancer.

3. SUMMARY OF THE INVENTION

[0005] The present invention relates to methods and compositions for diagnosing prostate cancer and/or determining whether a prostate cancer patient is at increased risk of suffering a relapse, or a rapid relapse, of his cancer. It is based, at least in part, on the results of a comprehensive genome analysis on 241 prostate cancer samples (104 prostate cancer, 85 matched bloods, 49 matched benign prostate tissues adjacent to cancer, and 3 cell lines) which indicate that (i) genome copy number variation (CNV) occurred in both cancer and non-cancer tissues, and (ii) CNV predicts prostate cancer progression.

[0006] Armed with the present invention, the health care practitioner is better able to advise a prostate cancer patient whether or not to undergo more aggressive forms of therapy or whether watchful waiting would be an appropriate recommendation, where in subjects at higher risk more aggressive forms of therapy may be recommended, including but not limited to prostate resection, antiandrogen therapy, radiotherapy and/or chemotherapy.

4. BRIEF DESCRIPTION OF THE FIGURES

[0007] FIG. 1A-D. Deletion and amplification of segments of genomes in blood, benign prostate tissues adjacent to cancer, and prostate cancer samples, (A) Histograms of genome deletion (blue) or amplification (red) of blood (B), benign prostate tissues adjacent to tumor (AT), and tumor (T) in 23 pairs of human chromosomes. (B) Box plot of number of genes overlapping with CNV per sample. Outliers in B and AT samples are indicated. (C) Venn diagram of deleted or amplified genes occurring in at least one sample overlapping between B, AT and T. (D) The spectrum of genes that are amplified or deleted in B, AT, tumors that did not relapse (Tnone), tumors that relapsed and had PSADT at or after 15th months of radical prostatectomy (Tslow), and tumors that relapsed and had PSADT within 4 months of radical prostatectomy (Tfast).

[0008] FIG. 2A-C. Genome copy variation in prostate cancer predicts relapse. (A) Histograms of genome deletion (blue) or amplification (red) of Tnone, Tslow and Tfast in 23 pairs of human chromosomes. (B) Receiver operating characteristic (ROC) curves of predicting prostate cancer relapse. The prostate cancer were separated into a group that relapsed within 5 years of prostatectomy (n=75) and a group that did not relapse (n=27). Prediction using gene deletions or amplifications unique to relapsing group generated through "leave-one-out" analysis was carried out to produce the ROC chart. The dotted line represents random prediction baseline. The broken line represents prediction generated from Gleason's grading. (C) ROC curves of predicting prostate cancer fast relapse. The prostate cancer were separated into a group that had PSADT within 4 months of prostatectomy (n=33) and a group that did not (n=69). Prediction using gene deletions or amplifications unique to fast relapsing group generated through "leave-one-out" analysis was carried out to produce the ROC chart. The dotted line represents random prediction baseline. The broken line represents prediction generated from Gleason's grading.

[0009] FIG. 3A-D. Genome copy variation in benign prostate tissues adjacent to cancer predicts prostate cancer relapse. (A) Histograms of genome deletion (blue) or amplification (red) of AT no relapse, AT relapse, AT not fast relapse, AT fast relapse in 23 pairs of human chromosomes. (B) ROC curves of AT predicting prostate cancer relapse. The AT samples were separated into a group that relapsed within 5 years of prostatectomy (n=21) and a group that did not relapse (n=28). Prediction using gene deletions or amplifications unique to relapsing group generated through "leave-one-out" analysis was carried out to produce the ROC chart. The dotted line represents random prediction baseline. (C) ROC curves of AT predicting prostate cancer fast relapse. The AT samples were separated into a group that had PSADT within 4 months of prostatectomy (n=8) and a group that did not (n=41). Prediction using gene deletions or amplifications unique to fast relapsing group generated through "leave-one-out" analysis was carried out to produce the ROC chart. The dotted line represents random prediction baseline.

[0010] FIG. 4A-D. Median size variation of CNV of blood and tumor samples predicts prostate cancer relapse and fast relapse. (A) ROC curves of CNV median size of B predicting prostate cancer relapse. The B samples were separated as described in (A). Prediction using various CNV median sizes was carried out to produce the ROC chart. The dotted line represents random prediction baseline. The optimal prediction rates for CNV median size of B model are 86% (57/66)

sensitivity and 61% (11/18) specificity. (B) ROC curves of CNV median size of B predicting prostate cancer fast relapse. The B samples were separated into a group that had PSADT within 4 months of prostatectomy (n=31) and a group that did not (n=53). Prediction using various CNV median sizes was carried out to produce the ROC chart. The dotted line represents random prediction baseline. The optimal prediction rates for CNV median size of B model are 68% (21/31) sensitivity and 70% (37/53) specificity. (C) ROC curves of predicting prostate cancer relapse using median sizes of CNV from T samples. The prostate cancer were separated into a group that relapsed within 5 years of prostatectomy (n=75) and a group that did not relapse (n=27). Prediction using various CNV median sizes was carried out to produce the ROC chart. The dotted line represents random prediction baseline. The broken line represents prediction generated from Gleason's grading. The optimal prediction rates for CNV median size of T model are 71% (53/75) sensitivity and 89% (24/27) specificity. (D) ROC curves of predicting prostate cancer fast relapse using CNV median sizes from T samples. The prostate cancer were separated into a group that had PSADT within 4 months of prostatectomy (n=33) and a group that did not (n=69). Prediction using various CNV median sizes was carried out to produce the ROC chart. The dotted line represents random prediction baseline. The broken line represents prediction generated from Gleason's grading. The optimal prediction rates for CNV median size of T model are 61% (20/33) sensitivity and 90% (62/69) specificity.

[0011] FIG. 5A-D, (A.) Percent overlap of genome segment abnormalities of B, AT, and T, comparing results of study for FIG. 1 and further experiments including additional samples. (B.) Percent deletions with loss of heterozygosity. (C.) Results of quantitative PCR analysis for genes ARL17B, SCAPER, EPHA3 and ERBB4. (D) Sensitivity versus specificity.

[0012] FIG. 6A-D, (A,B) Sensitivity versus specificity in B samples, (C,D) Sensitivity versus specificity in T samples.

[0013] FIG. 7A-B, Sensitivity versus specificity in AT samples (A) and (B).

[0014] FIG. 8A-D, (A,B) Sensitivity versus specificity in B samples. (C,D) Sensitivity versus specificity in T samples.

[0015] FIG. 9A-D, (A), (B), (C) and (D) Sensitivity versus specificity in B samples.

[0016] FIG. 10A-F, Sensitivity versus specificity in T samples (A,D), B samples (C,F), and AT samples (B,E).

5. DETAILED DESCRIPTION OF THE INVENTION

[0017] In certain non-limiting embodiments, the present invention provides for methods and compositions for diagnosing prostate cancer in a subject. In other non-limiting embodiments, the present invention provides for methods and compositions for determining whether a prostate cancer patient is at increased risk of suffering a relapse, or a rapid relapse, of his cancer. In other non-limiting embodiments, the present invention provides for methods and compositions for determining whether a prostate cancer patient is at decreased risk of suffering a relapse, or a rapid relapse, of his cancer (in other words, is at increased risk or has an increased likelihood of not suffering a relapse).

[0018] A "prostate cancer patient" is a subject having or who has had a carcinoma of the prostate. The use of the term "patient" does not suggest that the subject has received any

treatment for the cancer, but rather that the subject has at some point come to the attention of the healthcare system. Said patient/subject, prior to or contemporaneous with the practicing of the invention, may be untreated for prostate cancer or may have received treatment, including but not limited to surgical, chemotherapeutic, antiandrogen, or radiologic treatment.

[0019] "Increased risk" means an increased likelihood that relapse will occur relative to other prostate cancer patients. In particular non-limiting embodiments, there is a statistically validated increase in the likelihood of relapse or rapid relapse relative to subjects without relapse or rapid relapse with a p value of 0.003 for relapse and <0.001 for fast relapse when using "gene specific" CNV of prostate cancer samples, 0.04 for relapse and 0.015 for fast relapse when using "gene specific" CNV of AT samples, <0.001 for relapse and 0.001 for fast relapse when using median sizes of CNV of blood samples from prostate cancer patients, <0.001 for both relapse and fast relapse when using "median sizes" CNV of prostate cancer samples, and 0.004 for relapse when using "mean sizes" of CNV of AT samples.

[0020] "Relapse," as that term is used herein, refers to a clinical course including one or more of the following: (i) where the cancer had been removed or put into remission, a recurrence of prostate cancer at the original site or occurrence at a new site, including metastatic spread; (ii) where the cancer had not been removed or put into remission, extension of the cancer and/or metastatic spread; (iii) whether or not the cancer had been treated, an advancement in the clinical grade, for example the Gleasons grade, of the cancer; and/or a prostate specific antigen ("PSA") doubling time of 15 months or longer.

[0021] By "rapid", or "relapse quickly", it is meant that relapse occurs within a period of 5 years. In certain embodiments, patients suffering a rapid relapse also manifest a PSA doubling time of 3 months or less or 4 months or less.

[0022] In particular, non-limiting embodiments, the method of the invention may be performed as follows. One or more sample may be obtained from a subject. For example, the sample may be a sample of malignant tumor (or presumptively malignant tumor, where a diagnosis has not yet been made) tissue (e.g., microdissection may be performed to achieve a tumor purity of at least about 70 percent or at least about 80 percent or greater than 80%). As another example, a sample may be tissue adjacent a malignant tumor tissue (e.g., prostate tissue that is not identified as tumor located in a prostate gland that contains tumor; in certain non-limiting embodiments the adjacent tissue is non-malignant prostate tissue located at least 3 mm from tumor tissue). As another example, a sample may be a tissue sample which is considered by a skilled artisan to appear abnormal (microscopically and/or macroscopically) and is to be tested to determine whether it is cancerous. As another example, a sample may be a blood sample that contains at least some nucleated cells (to serve as a source of DNA, e.g., whole blood or buffy coat). Multiple samples may be prepared for a single subject; for example, samples of tumor (meaning malignant) tissue, tissue adjacent tumor tissue, and blood may be prepared and the results of analysis of each may be compared.

[0023] For example, DNA may be extracted from a sample, for example using a Qiagen tissue kit or other method known in the art. Then genotyping may be performed to identify CNVs across the genome or a portion of the genome, for example, by fragmenting the DNA using restriction enzymes,

ligated with adaptors, amplifying the fragments using primers that correspond to the adaptor sequences (for example, Genome wide human snp NSP/STY assay kit, Affymetrix, CA), optionally performing an additional fragmentation step, labeling the amplified (optionally further fragmented) DNA product, and then hybridizing the resulting labeled DNA with a plurality of test DNA molecules representative of the genome or a genome portion of interest, for example, but not limited to, as provided in an array such as Affymetrix Genome-Wide Human SNP Array 6.0, under appropriate conditions (for example as described by the array manufacturer). The results may then be interpreted to determine the number or approximate number of CNVs in the genome or portion thereof. For example, Partek Genome Suite 6.6™ or a Affymetrix Genotyping Console may be used.

[0024] In one set of non-limiting embodiments of the invention, the number of CNVs across the genome are determined. The present invention provides for a method of diagnosing a prostate cancer in a subject comprising determining the number and/or size of CNVs in a tumor sample, a sample of tissue adjacent a tumor, and/or in a blood sample, where if the number and/or size of CNVs exceeds a particular threshold, a diagnosis of prostate cancer is indicated. The present invention also provides for a method of determining that a prostate cancer patient is at increased risk for relapse or rapid relapse comprising determining the number and/or size of CNVs in a prostate tumor sample, tissue adjacent a prostate tumor, and/or blood, where if the number and/or size of CNVs exceeds a particular threshold, the subject is deemed at risk for relapse or rapid relapse.

[0025] In another set of non-limiting embodiments of the invention, CNV of one or more particular gene or chromosome or chromosome region is determined. In specific, non-limiting embodiments of the invention, genes for which CNVs may be determined may include one or more of the genes listed in Tables 2-5, where a CNV in one of the genes listed is indicative of increased risk of relapse (in Table 2 based on a prostate cancer tissue sample or in Table 4 based on tissue adjacent to prostate cancer tissue) or rapid relapse (in Table 3 based on a prostate cancer tissue sample or in Table 5 based on tissue adjacent to prostate cancer tissue). The present invention provides for a method of determining that a prostate cancer patient is at increased risk for relapse or rapid relapse comprising determining the number and/or size of CNVs of a specific gene as listed in Table 2, 3, 4 or 5 in a prostate tumor sample, tissue adjacent a prostate tumor, and/or blood, where if the number of CNVs for the gene exceeds a particular threshold, a diagnosis of prostate cancer is indicated and/or the subject is deemed at risk for relapse or rapid relapse.

[0026] For clarity of description and not by way of limitation, the detailed description of the invention is divided into the following subsections:

- (i) Diagnosis based on CNV number and size;
- (ii) Assessment of risk based on CNV number and size;
- (iii) Assessment of risk based on CNV of particular genes; and
- (iv) Kits.

5.1 Diagnosis Based on CNV Number and Size

[0027] In non-limiting embodiments of the invention, the number of CNVs across the genome are determined. CNV may be detected using methodology known in the art, includ-

ing the hybridization to gene arrays and the analysis of the results of hybridization using software that determines copy number variation, including, but not limited to, the method using Affymetrix products described above. In non-limiting embodiments of the invention, the entire genome or a portion thereof may be analyzed; for example, in a subset of non-limiting embodiments, the chromosome region for which CNVs is determined is one or more of 8p, 13p, 16p, 17p, and/or 8q.

[0028] In certain non-limiting embodiments, the present invention provides for a method of diagnosing a prostate cancer in a subject comprising determining the number and/or size of CNVs in DNA from a tumor sample, a sample of tissue adjacent a tumor, and/or in a blood sample, where if the number and/or size of CNVs exceeds a particular threshold, a diagnosis of prostate cancer is indicated.

[0029] In a tissue, CNV in at least about 90 loci, each locus being at least 10 kb in length, is consistent with a diagnosis of prostate cancer rather than benign tissue. Accordingly, the present invention provides for a method of diagnosing a prostate cancer in a subject comprising determining the number and size of CNVs in DNA from a tumor or prostate tissue sample, where if the number of CNVs exceeds 90 loci, each locus being at least 10 kb in length, a diagnosis of prostate cancer is indicated.

[0030] In a blood sample, CNV in at least 4 loci, each locus being at least 10 kb in length, is consistent with a diagnosis of prostate cancer rather than no malignancy. Accordingly, the present invention provides for a method of diagnosing a prostate cancer in a subject, where said subject is a male having one or more of the following clinical findings: increased serum prostate specific antigen, enlarged prostate on physical exam, difficulty urinating and/or urinary retention, comprising determining the number and/or size of CNVs in DNA from a blood sample from the subject, where if the number of CNVs exceeds 4 loci, each locus being at least 10 kb in length, a diagnosis of prostate cancer is indicated.

[0031] In a tissue or a blood sample, a deletion of at least 3 megabases in one or more of the following chromosome regions is consistent with a diagnosis of prostate cancer rather than benign tissue: 8p, 13p, 16q, and/or 17p. Deletions in these regions can be deduced from CNV information. Accordingly, the present invention provides for a method of diagnosing a prostate cancer in a subject comprising determining the presence of deletions in one or more of chromosome regions 8p, 13p, 16q, and/or 17p in DNA from a prostate tissue or a blood sample from the subject, where if there is a deletion of at least 3 megabases in one or more of these regions, a diagnosis of prostate cancer is indicated.

[0032] In a tissue or a blood sample, an amplification of a locus in chromosome region 8q and/or X is consistent with a diagnosis of prostate cancer rather than benign tissue. Amplification in these regions can be deduced using CNV information. Accordingly, the present invention provides for a method of diagnosing a prostate cancer in a subject comprising determining the presence of amplification in one or more of chromosome regions 8q and X in DNA from a prostate tissue or a blood sample from the subject, where if there is an amplification of a locus in one or more of these regions, a diagnosis of prostate cancer is indicated.

[0033] If a diagnosis of prostate cancer is indicated, a healthcare provider may optionally take the further step of recommending and/or performing a further diagnostic test, such as a biopsy or prostate ultrasound, and/or recommending

and/or performing a therapeutic procedure, for example but not limited to surgical excision, radiotherapy, and/or chemotherapy.

5.2 Assessment of Risk Based on CNV Size

[0034] In non-limiting embodiments of the invention, CNVs across the genome are determined. CNV may be detected using methodology known in the art, including the hybridization to gene arrays and the analysis of the results of hybridization using software that determines copy number variation, including, but not limited to, the method using Affymetrix products described above. In non-limiting embodiments of the invention, the entire genome or a portion thereof may be analyzed; for example, in a subset of non-limiting embodiments, the chromosome region for which CNVs is determined is one or more of 8p, 13p, 16p, 17p, and/or 8q.

[0035] In non-limiting embodiments, the present invention provides for a method of determining that a prostate cancer patient is at decreased risk for relapse or rapid relapse comprising determining the size of CNVs in a prostate tumor sample, tissue adjacent a prostate tumor, and/or blood, where if the size of CNVs is less than a particular threshold, the patient is deemed to be at decreased risk for relapse or rapid relapse.

[0036] In non-limiting embodiments, the present invention provides for a method of determining that a prostate cancer patient is at decreased risk for relapse or rapid relapse comprising determining the mean and/or median size of CNVs in a prostate tumor sample, tissue adjacent a prostate tumor, and/or blood, where if the mean or median size of CNVs is less than a particular threshold, the patient is deemed to be at decreased risk for relapse or rapid relapse.

[0037] In non-limiting embodiments, the present invention may utilize the average (mean) size of CNV to assess the likelihood that a prostate cancer will relapse. CNV size may be determined using the same genotyping analysis techniques as described above and as are known in the art. In particular non-limiting embodiments of the invention, using the Partek software described above, segments with copy number change may be obtained (including amplification and deletions), and those with the criteria $p < 0.001$, length > 2000 bp and > 10 markers, may be selected and then the mean length of the CNVs thus identified may be determined.

[0038] In certain non-limiting embodiments, the present invention provides for a method of determining that a prostate cancer patient is at decreased risk for relapse comprising determining the size of CNVs in DNA from a blood sample from the patient, where if the average (i.e., mean) size of CNVs is 40 kb or less or 33 kb or less, the patient is deemed to be at decreased risk for relapse.

[0039] In certain non-limiting embodiments, the present invention provides for a method of determining that a prostate cancer patient is at decreased risk for relapse comprising determining the size of CNVs in DNA from a sample of tissue adjacent a prostate cancer from the patient, where if the mean size of CNVs is 95 kb or less or 81.1 kb or less, the patient is deemed to be at decreased risk for relapse.

[0040] In certain non-limiting embodiments, the present invention provides for a method of determining that a prostate cancer patient is at decreased risk for relapse comprising determining the size of CNVs in DNA from a sample of prostate cancer tissue from the patient, where if the mean size

of CNVs is 385 kb or less or 105 kb or less, the patient is deemed to be at decreased risk for relapse.

[0041] In further non-limiting embodiments, the present invention provides for a method of determining that a prostate cancer patient is at increased risk for relapse or rapid relapse comprising determining the mean or median size of CNVs in a prostate tumor sample, tissue adjacent a prostate tumor, and/or blood, where if the mean or median size of CNVs exceeds a particular threshold, the patient is deemed to be at increased risk for relapse or rapid relapse.

[0042] In one non-limiting embodiment, in a blood sample from a prostate cancer patient, an average (mean) CNV size of 70 kb or more, is consistent with a likelihood that the prostate cancer will relapse. Accordingly, the present invention provides for a method of determining that a prostate cancer patient is at increased risk for relapse comprising determining the mean size of CNVs in DNA from a blood sample from the patient, where if the average (i.e., mean) size of CNVs is 70 kb or more, the patient is deemed to be at increased risk for relapse.

[0043] In other non-limiting embodiments, the present invention provides for a method of determining that a prostate cancer patient is at increased risk for relapse comprising determining the mean size of CNVs in DNA from a sample of tissue adjacent to prostate cancer from the patient, where if the mean size of CNVs is 246 kb or more, the patient is deemed to be at increased risk for relapse.

[0044] In other non-limiting embodiments, the present invention provides for a method of determining that a prostate cancer patient is at increased risk for relapse comprising determining the mean size of CNVs in DNA from a sample of prostate cancer tissue from the patient, where if the mean size of CNVs is 817 kb or more, the patient is deemed to be at increased risk for relapse.

[0045] In other non-limiting embodiments, the present invention provides for a method of determining that a prostate cancer patient is at increased risk for rapid relapse comprising determining the mean size of CNVs in DNA from a sample of prostate cancer tissue from the patient, where if the mean size of CNVs is 1060 kb or more, the patient is deemed to be at increased risk for rapid relapse.

[0046] In further non-limiting embodiments, the present invention may utilize the median size of CNV to assess the likelihood that a prostate cancer will relapse. CNV size may be determined using the same genotyping analysis techniques as described above and as are known in the art. In particular non-limiting embodiments of the invention, using the Partek software described above, segments with copy number change may be obtained (including amplification and deletions), and those with the criteria $p < 0.001$, length > 2000 bp and > 10 markers, may be selected and then the median length of the CNVs thus identified may be determined.

[0047] In one non-limiting embodiment, in a blood sample from a prostate cancer patient, a median CNV size of about 17 kb or less is consistent with a likelihood that the prostate cancer will not relapse. Accordingly, the present invention provides for a method of determining that a prostate cancer patient is at decreased risk for relapse comprising determining the median size of CNVs in a blood sample, where if the median size of CNVs is 17 kb or less, the subject is deemed to be at decreased risk for relapse.

[0048] In certain non-limiting embodiments, the present invention provides for a method of determining that a prostate cancer patient is at decreased risk for relapse comprising

determining the median size of CNVs in DNA from a sample of tissue adjacent to a prostate cancer from the patient, where if the median size of CNVs is 16 kb or less, the patient is deemed to be at decreased risk for relapse.

[0049] In certain non-limiting embodiments, the present invention provides for a method of determining that a prostate cancer patient is at decreased risk for relapse comprising determining the median size of CNVs in DNA from a sample of prostate cancer tissue from the patient, where if the median size of CNVs is 185 kb or less, the patient is deemed to be at decreased risk for relapse.

[0050] In certain other non-limiting embodiments, the present invention provides for a method of determining that a prostate cancer patient is at increased risk for relapse comprising determining the median size of CNVs in DNA from a blood sample from the patient, where if the median size of CNVs is 23 kb or more, the patient is deemed to be at increased risk for relapse.

[0051] In other non-limiting embodiments, the present invention provides for a method of determining that a prostate cancer patient is at increased risk for relapse comprising determining the median size of CNVs in DNA from a sample of tissue adjacent to prostate cancer from the patient, where if the median size of CNVs is 17384 or more or 18 kb or more, the patient is deemed to be at increased risk for relapse.

[0052] In other non-limiting embodiments, the present invention provides for a method of determining that a prostate cancer patient is at increased risk for rapid relapse comprising determining the median size of CNVs in DNA from a sample of tissue adjacent to prostate cancer from the patient, where if the median size of CNVs is 32651 bp or more, or 33 kb or more, the patient is deemed to be at increased risk for rapid relapse.

[0053] In other non-limiting embodiments, the present invention provides for a method of determining that a prostate cancer patient is at increased risk for relapse comprising determining the median size of CNVs in DNA from a sample of prostate cancer tissue from the patient, where if the median size of CNVs is 647 kb or more, the patient is deemed to be at increased risk for relapse.

[0054] If it is determined that the patient is at increased risk for relapse or rapid relapse, a healthcare provider may optionally take the further step of recommending and/or performing frequent monitoring of the patient for recurrence (e.g., a PSA test or imaging (e.g. ultrasound, CT scan, MRI or PET scan)) and/or recommending and/or performing a therapeutic procedure, for example but not limited to surgical excision, radiotherapy, and/or chemotherapy.

5.3 Assessment of Risk by CNV of Particular Genes

[0055] In non-limiting embodiments of the invention, the number of CNVs across the genome are determined, CNV may be detected using methodology known in the art, including the hybridization to gene arrays and the analysis of the results of hybridization using software that determines copy number variation, including, but not limited to, the method using Affymetrix products described above. In non-limiting embodiments of the invention, the entire genome or a portion thereof may be analyzed; for example, in a subset of non-limiting embodiments, the chromosome region for which CNVs is determined is one or more of 8p, 13p, 16p, 17p, and/or 8q. Further, the CNV of particular genes may be determined and utilized as set forth in this section.

[0056] In further non-limiting embodiments, a CNV in a gene in a prostate cancer tissue from a subject, where the gene is listed in Table 2, indicates that the subject is likely to relapse. In further non-limiting embodiments, a CNV in a gene in a prostate cancer tissue from a subject, where the gene is listed in Table 3, indicates that the subject is likely to experience rapid relapse.

[0057] In further non-limiting embodiments, a CNV in a gene in a tissue adjacent to prostate cancer tissue from a subject, where the gene is listed in Table 4, indicates that the subject is likely to relapse. In further non-limiting embodiments, a CNV in a gene in a tissue adjacent to prostate cancer tissue from a subject, where the gene is listed in Table 5, indicates that the subject is likely to experience rapid relapse.

[0058] In one set of non-limiting embodiments, the present invention provides for a gene-based prediction in any one or more of four scenarios: relapse or fast relapse prediction in tumor (T) or tissues adjacent to tumor (AT). According to this set of embodiments, the methods for these four scenarios are the same except for the gene lists used are different. In particular, for each scenario, two gene lists are utilized: one list for genes amplified (list "a") and one list for genes deleted (list "b"). Using Partek, the copy number change status of each gene for each sample could be determined; the status could be amplified, deleted or unchanged.

[0059] For a given T sample, the number of genes in list "a" that are amplified and the number of genes in list "b" that are deleted are counted, and the number of amplified genes in list "a" may be designated "a" and the number of deleted genes in list "b" may be designated "b". Genes in list "a" for relapse include HECTD1, MIR1827, UBXN8, SMAP1, C6orf147, DDX43, SLC17A5, LRRIQ4, LRRC31, SAMD7, LOC100128164, SEC62, GPR160, and PHC3. Genes in list "b" for relapse include SLC7A5, CA5A, BANP, ZFPM1, ZC3H18, IL17C, CYBA, MVD, MGC23284, SNAI3, RNF166, GALNS, TRAPPC2L, CBFA2T3, ACSF3, C16orf81, CDH15, ANKRD11, SPG7, RPL13, SNORD68, CDK10, SPATA2L, C16orf7, ZNF276, SYT16, GRIN2B, BCAT1, OVC1, BEYLA, GPR125, and GBA3. If the number (a+b) is larger than a pre-set cutoff C (i.e. $a+b > C$), the corresponding sample is assigned the risk designation relapse or fast relapse, depending upon the list that is drawn from. In a particular non-limiting embodiment, in $a+b > C$, $C=0$ meaning that the threshold is 0 so that if a or b is a non-zero number, there is an increased risk of relapse.

[0060] In non-limiting embodiments, the invention provides for a method of determining that a prostate cancer patient is at increased risk for relapse comprising determining whether a gene is amplified or whether a gene is deleted in DNA from a sample of prostate cancer tissue from the patient, wherein (a) if one or more gene is amplified from the group consisting of HECTD1, MIR1827, UBXN8, SMAP1, C6orf147, DDX43, SLC17A5, LRRIQ4, LRRC31, SAMD7, LOC100128164, SEC62, GPR160, and PHC3 and/or (b) if one or more gene is deleted from the group consisting of SLC7A5, CA5A, BANP, ZFPM1, ZC3H18, IL17C, CYBA, MVD, MGC23284, SNAI3, RNF166, GALNS, TRAPPC2L, CBFA2T3, ACSF3, C16orf81, CDH15, ANKRD11, SPG7, RPL13, SNORD68, CDK10, SPATA2L, C16orf7, ZNF276, SYT16, GRIN2B, BCAT1, OVCH1, BEYLA, GPR125, and GBA3, then the patient is deemed to be at increased risk for relapse.

[0061] In other non-limiting embodiments, genes in list "a" for rapid relapse include BRMS1L, KCNMB4, MIR548A1,

ORC3L, SDAD1, CXCL9, ART3, CXCL10, CXCL11, Genes in list “b” for rapid relapse include GALNTL1, FLJ44817, KIAA0247, LOC100289511, SFRS5, SLC10A1, SLC8A3, SNORD56B, PABPC3, MTMR6, ATP8A2, NAV2, ZC3H12C, FDX1, ARHGAP20, C11orf88, LAYN, and CD28. In a particular non-limiting embodiment, in $a+b>C$, $C=0$, meaning that the threshold is 0 so that if a or b is a non-zero number, there is an increased risk of rapid relapse.

[0062] In non-limiting embodiments, the invention provides for a method of determining that a prostate cancer patient is at increased risk for relapse comprising determining whether a gene is amplified or whether a gene is deleted in DNA from a sample of prostate cancer tissue from the patient, wherein (a) if one or more gene is amplified from the group consisting of BRMS1L, KCNMB4, MIR548A1, ORC3L, SDAD1, CXCL9, ART3, CXCL10, and CXCL11 and/or (b) if one or more gene is deleted from the group consisting of GALNTL1, FLJ44817, KIAA0247, LOC100289511, SFRS5, SLC10A1, SLC8A3, SNORD56B, PABPC3, MTMR6, ATP8A2, NAV2, ZC3H12C, FDX1, ARHGAP20, C11orf88, LAYN, CD28, then the patient is deemed to be at increased risk for rapid relapse.

[0063] In related embodiments applied to AT, two gene lists are utilized: one list for genes amplified (list “c”) and one list for genes deleted (list “d”). Using Partek, the copy number change status of each gene for each sample could be determined; the status could be amplified, deleted or unchanged. For a given T sample, the number of genes in list “c” that are amplified and the number of genes in list “d” that are deleted are counted, and the number of amplified genes in list “c” may be designated “c” and the number of deleted genes in list “d” may be designated “d”. Genes in list “c” for relapse include DZIP1, ZHX2, DERL1, WDR67, COL22A1, BHLHE40 and, in a non-limiting embodiment, there is no gene in list “d”. In a particular non-limiting embodiment, in $a+b>C$, $C=0$ meaning that the threshold is 0 so that if c or d is a non-zero number, there is a likelihood of relapse. In other non-limiting embodiments applied to AT, genes in list “c” for rapid relapse include MAGEL2, NDN, RSU1, ADCY2, UBE2E1 and genes in list “d” for rapid relapse based on AT include RPL23AP82, RABL2B, CA10, C13orf36, SMAD9, ALG5, RETNLB, TRAT1, GUCA1C, MORC1. In a particular non-limiting embodiment, in $a+b>C$, $C=1$ meaning that the threshold is 1 so that if the sum of c and d is greater than one, there is a likelihood of rapid relapse.

[0064] In non-limiting embodiments, the invention provides for a method of determining that a prostate cancer patient is at increased risk for relapse comprising determining whether a gene is amplified in DNA from a sample of tissue adjacent to prostate cancer tissue from the patient, wherein if one or more genes is amplified from the group consisting of DZIP1, ZHX2, DERL1, WDR67, COL22A1, BHLHE40 then the patient is deemed to be at increased risk for relapse.

[0065] In non-limiting embodiments, the invention provides for a method of determining that a prostate cancer patient is at increased risk for rapid relapse comprising determining whether a gene is amplified or whether a gene is deleted in DNA from a sample of tissue adjacent to prostate cancer tissue from the patient, wherein (a) if one or more genes is amplified from the group consisting of MAGEL2, NDN, RSU1, ADCY2, UBE2E1 and/or (b) one or more genes is deleted from the group consisting of RPL23AP82, RABL2B, CA10, C13orf36, SMAD9, ALG5, RETNLB, TRAT1, GUCA1C, MORC1, wherein the total number of

genes amplified from the group listed in (a) and/or deleted from the group listed in (b) is greater than or equal to 2, then the patient is deemed to be at increased risk for rapid relapse.

[0066] If it is determined that the patient is at increased risk for relapse or rapid relapse, a healthcare provider may optionally take the further step of recommending and/or performing frequent monitoring of the patient for recurrence (e.g., a PSA test or imaging (e.g. ultrasound, CT scan, MRI or PET scan), digital rectal exam) and/or recommending and/or performing a therapeutic procedure, for example but not limited to surgical excision, radiotherapy, and/or chemotherapy.

[0067] If it is determined that the patient is at decreased risk for relapse, a healthcare provider may optionally take the further step of recommending that the patient not seek imminent further treatment and/or performing frequent monitoring of the patient for recurrence (e.g., a PSA test or imaging (e.g. ultrasound, CT scan, MRI or PET scan), digital rectal exam) (“watchful waiting”).

5.4 Kits

[0068] In non-limiting embodiments, the present invention provides for kits that may be used to practice the invention. Such kits may include an array comprising nucleic acid representing at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 15, at least 20, at least 30, at least 40, or at least 50 of the following genes, where the genes listed below constitute up to 50 percent or up to 60 percent or up to 70 percent or up to 80 percent or up to 90 percent or up to 95 percent or up to 100 percent of the total set of genes represented in the array:

[0069] genes listed in Table 2;

[0070] genes listed in Table 3;

[0071] genes listed in Table 4;

[0072] genes listed in Table 5;

[0073] HECTD1, MIR1827, UBXN8, SMAP1, C6orf147, DDX43, SLC17A5, LRRIQ4, LRRC31, SAMD7, LOC100128164, SEC62, GPR160, PHC3, SLC7A5, CA5A, BANP, ZFPM1, ZC3H18, IL17C, CYBA, MVD, MGC23284, SNAI3, RNF166, GALNS, TRAPPC2L, CBFA2T3, ACSF3, C16orf81, CDH15, ANKRD11, SPG7, RPL13, SNORD68, CDK10, SPATA2L, C16orf7, ZNF276, SYT16, GRIN2B, BCAT1, OVCH1, BEYLA, GPR125, GBA3, BRMS1L, KCNMB4, MIR548A1, ORC3L, SDAD1, CXCL9, ART3, CXCL10, CXCL11, GALNTL1, FLJ44817, KIAA0247, LOC100289511, SFRS5, SLC10A1, SLC8A3, SNORD56B, PABPC3, MTMR6, ATP8A2, NAV2, ZC3H12C, FDX1, ARHGAP20, C11orf88, LAYN, CD28, DZIP1, ZHX2, DERL1, WDR67, COL22A1, BHLHE40, MAGEL2, NDN, RSU1, ADCY2, UBE2E1, RPL23AP82, RABL2B, CA10, C13orf36, SMAD9, ALG5, RETNLB, TRAT1, GUCA1C, and MORC1.

[0074] For example, but not by way of limitation, an array may comprise sets of genes as listed above for lists “a”, “b”, “c” and/or “d”.

[0075] Such kits may optionally comprise software, or Internet access to software, in electronically readable form, that determines the number and size of CNVs in the genes represented in the array, and optionally software, or internet access to software, in electronically readable form, that determines whether CNVs in a DNA sample exceed or fall below a threshold set forth herein that indicates an increased risk of relapse or an increased risk of rapid relapse of prostate cancer.

6. EXAMPLE

Genome Abnormalities Precede Prostate Cancer and Predict Clinical Relapse

[0076] 6.1 Materials and Methods

[0077] Tissue Processing, DNA Extraction, Amplicon Generation, Labeling, Hybridization, Washing and Scanning of SNP 6.0 Chips.

[0078] Prostate cancer samples were obtained from the University of Pittsburgh Medical Center Tissue Bank, Pittsburgh, Pa. These samples were collected from 1998 to 2009. To make the analysis balance, samples of short prostate specific antigen doubling time ("PSADT") (<4 months), long PSADT (>15 months), and no relapse (cancer free for >5 years after radical prostatectomy) each were made to constitute approximately one third of the total number. Whenever possible, nonrelapse samples were chosen to match pathological stages and Gleason grades of relapse samples. A total of 214 samples were from whites, whereas 5 samples were from African Americans and 19 samples were from patients with an unknown race. The patients whom these samples were obtained from either experienced relapse or had no relapse for at least 5 years, based on chemical (serum PSA) and radiological evidence. Frozen tissues were used for blood, prostate cancer, and benign prostate tissue adjacent to cancer. Clinical follow-up was conducted by office examination record, blood PSA survey, and radiographical follow-up. These follow-up visits were performed for up to a 10-year period after the patient underwent a radical prostatectomy. The protocol was approved by the Institutional Review Board. For prostate cancer, microdissection was performed to achieve tumor purity >80%. For benign prostate tissues adjacent to cancer, benign tissues away from prostate cancer (at least 3 mm) were microdissected. Whenever available, whole blood or buffy coat from the same patients was used as a normal control. PC3, DU145, and LNCaP cells were obtained from American Type Culture Collection Inc. (Manassas, Va.) in 2000, 2001, and 2007, respectively. The genomes of these cell lines were tested for short tandem repeat DNA profiling on eight different loci (CSF1PO, D13S317, D16S539, D5S818, D7S820, TH01, TPOX, and vWA) of the genomes by PCR using the following sets of primers:

CSF1PO, 5'-AACCTGAGTCTGCCAAGGACTAGC-3' (SEQ ID NO: 1)
and
5'-TTCCACACACCACTGGCCATCTTC-3'; (SEQ ID NO: 2)

D13S317, 5'-ACAGAAGTCTGGGATGTGGA-3' (SEQ ID NO: 3)
and
5'-GCCCAAAAAGACAGACAGAA-3'; (SEQ ID NO: 4)

D16S539, 5'-GATCCCAAGCTCTTCCTCTT-3' (SEQ ID NO: 5)
and
5'-ACGTTTGTGTGTCATCTGT-3'; (SEQ ID NO: 6)

D5S818, 5'-GGGTGATTTCTCTTTGGT-3' (SEQ ID NO: 7)
and
5'-TGATTCCAATCATAGCCACA-3'; (SEQ ID NO: 8)

-continued

D7S820, 5'-TGTCATAGTTTAGAACGAACAAACG-3' (SEQ ID NO: 9)
and
5'-CTGAGGTATCAAAAACCTCAGAGG-3'; (SEQ ID NO: 10)

TH01, 5'-GTGGGCTGAAAAGCTCCCGATTAT-3' (SEQ ID NO: 11)
and
5'-ATTCAAAGGGTATCTGGGCTCTGG-3'; (SEQ ID NO: 12)

TPOX, 5'-CTGGCACAGAACAGGCACTTAGG-3' (SEQ ID NO: 13)
and
5'-GGAGGAACTGGGAACACACAGGT-3'; (SEQ ID NO: 14)

vWA, 5'-CCCTAGTGGATGATAAGAATAATCAGTATG-3' (SEQ ID NO: 15)
and
5'-GGACAGATGATAAATACATAGGATGGATGG-3'. (SEQ ID NO: 16)

These cell lines were authenticated because the short tandem repeat profiles of the cell lines have a perfect match with those published by American Type Culture Collection Inc. DNA was then extracted using a Qiagen tissue kit (Qiagen, Valencia, Calif.). Detailed case information is shown in Tables 1A-D. Genome DNA (500 ng), was digested with StyI and NspI for 2 hours at 37° C. The digested DNA was purified and ligated with primer/adaptors at 16° C. for 12 to 16 hours. Amplicons were generated by performing PCR using primers provided by the manufacturer (Affymetrix, Santa Clara, Calif.) on the ligation products using the following program: 94° C. for 3 minutes and then 35 cycles of 94° C. for 30 seconds, 60° C. for 45 seconds, and 65° C. for 1 minute. This was followed by extension at 68° C. for 7 minutes. The PCR products were then purified and digested with DNaseI for 35 minutes at 37° C. to fragment the amplified DNA. The fragmented DNA was then labeled with biotinylated nucleotide through terminal deoxynucleotide transferase for 4 hours at 37° C. Fragmented DNA, 250 µg, was hybridized with a pre-equilibrated Affymetrix SNP 6.0 chip at 50° C. for 18 hours. Procedures of washing and scanning of SNP 6.0 chips followed the manuals provided by Affymetrix.

[0079] SYBR-Green Real Time Quantitation PCR:

[0080] LightCycler FastStart DNA Master SYBR-Green I kit was used for real time PCR amplification. The reaction was carried out in a MasterCycler Realplex™ (Eppendorf, Hauppauge, N.Y.). A quantitation standard curve of normal male DNA from 50,000 to 500,000 copies of genome was generated using known amounts of template copies. Twenty nanograms of genomic DNA were used for all of the experimental and control samples. Tag DNA polymerase was activated with a 2 min pre-incubation step at 94° C. Amplification of the following primers was performed:

ARL17B (ACTGTCATAGCAGTGCTGAGG (SEQ ID NO: 17) /
ACTTACCTACTGTAGGACGG (SEQ ID NO: 18)),

SCAPER (AGGAAGGCCTATTCGTTCTCG (SEQ ID NO: 19) /
GAACAGTAGGGAGGAGTTTCG (SEQ ID NO: 20)),

WWOX (GCCAGTTGATGTGACAACTGC (SEQ ID NO: 21) /
CAGCTGAGAGTGGTTTCTTTGC (SEQ ID NO: 22)),

-continued

EPHA3 (ATCAGGACTTACCAGGTGTGC (SEQ ID NO: 23) /
ACCGTGTCTGGAAACATAGCC (SEQ ID NO: 24)),
and

ERBB4 (AGTGGCCTGTCTTCTTATC (SEQ ID NO: 25) /
CAGAGCAACAATTCTGACCGG (SEQ ID NO: 26))

with 35 cycles of the following program: 94° C. for 30 s, 62° C. for 30 s, and 68° C. for 3 min. Realplex™ data software was used to quantify and to fit the data with a standard curve. A separate β -actin (TCTTTGCACTTTCTGCATGTCCCC (SEQ ID NO: 27)/GTCCATCACGATGCCAGTGGTAC (SEQ ID NO: 28)) DNA quantification was also performed as an internal control for each analysis.

[0081] Statistical Analysis:

[0082] Two hundred forty-one cell files were analyzed with the Genotyping console 4.0 from Affymetrix, Inc. for quality control analysis. Samples with QC call above 80% and QC contrast ratio above 0.4 were admitted into the analysis. To analyze CNV, cell files were imported into Partek Genome-Suite 6.6 to generate copy number from raw intensity. To plot the histograms, GC adjust was performed. Deletion or amplification of genomes were analyzed by first limiting to the regions with p-value less than 0.05/total number of regions detected, i.e. family-wise error rate (FWER) is controlled using Bonferroni's correction (10). The selected regions were subsequently filtered by limiting to the regions with at least 100 markers and 10 kb. The regions were then mapped to known genes. For a subset of the sample (i.e. tumor or relapse with rapid progression), the frequencies of amplification/deletion are calculated on the gene level. The frequencies were plotted to the genome corresponding to the gene locations.

[0083] Prediction Analysis and ROC Curve:

[0084] The following prediction analysis for the comparison of (1) non-relapse versus fast-relapse+slow-relapse; (2) non-relapse+slow-relapse versus fast-relapse was performed. A test sample was first left out from prediction model construction. The remaining samples were used as the training set. Loci with more than r %, amplification or r % deletion in the case group but none locus aberration in the control group were selected as predictive loci. To predict the left-out test sample, the percentage of locus aberration (amplification or deletion) among the identified predictive loci was calculated. The test sample was predicted as a case if the percent of aberration is greater than p % threshold, and control otherwise. The "leave-one-out" cross-validation was repeated until each sample was left out and predicted. In this prediction scheme, r is a parameter that determines the number of predictive loci used in the model. For a given r, the threshold p % was varied to locus rate an ROC curve with sensitivity/specificity trade-off. We selected r that produced the best "area under curve" (AUC)(11). To report the best sensitivity and specificity trade-off and overall accuracy rate, we chose the threshold p % such that the Youden index (sensitivity+specificity-1) is maximized. This criterion gave equal importance to sensitivity and specificity. To further evaluate whether the prediction result is better than obtained by random, AUC was used as a test statistics, and permutation analysis was performed to assess the statistical significance. Specifically, class labels (case and control) were randomly shuffled and AUC calculation was performed. Such permutations were repeated for 1000 times to generate the null distribution. The p-value was calculated as the percentage that the 1000 null AUCs from permutation are greater than the observed AUC.

The genes that are overlapped with the loci used in the test and the frequency of utilization are listed in Tables 2-5. For Gleason score prediction, the ROC curve was generated by varying Gleason score threshold. AUC and its associated p-value were similarly calculated. For CNV size prediction, CNV was limited to >2 kb, p<0.001 and >10 markers. The ROC curve was generated by varying sizes of CNV threshold. AUC and its associated p-value were similarly calculated.

[0085] Prediction Analysis for Blood Versus Tumor:

[0086] To predict blood versus tumor, the total number of aberrations in each sample was counted instead of the predictive locus selection described above. The ROC curve, AUC and the associated p-value were similarly generated.

[0087] 6.2 Results

[0088] The SNP 6.0 chip hybridization results were analyzed through Partek Genome Suite 6.6™, using blood (B) samples as normal references. As shown in histograms of FIG. 1A, abnormalities of genome in copy number can be found in all chromosomes in prostate cancer. An average of 91.6 loci (minimum of 10 kb) per sample involving 1092 genes were identified either amplified or deleted in prostate cancer genomes as determined by more than 100 markers, $p<5.5\times 10^{-9}$ (Bonferroni correction, FIG. 1B). Deletions of large segments of (>3 megabases) chromosome 8p, 13p, 16q and 17p occurred with high frequencies, while amplification of 8q and X chromosomes occurred in a subset of prostate cancer samples. Similar amplification and deletion of the same regions also occurred in benign prostate tissues adjacent to cancer, albeit with smaller sizes and lower frequency. Unexpectedly, the blood of prostate cancer patients contains significant abnormalities in genomes (1329 genes total, or 4.4 loci and 32.6 genes/sample). Most of these abnormalities are not unique and are overlapped with those of prostate cancer samples (FIG. 1C). Prostate cancers were then sub-divided based on clinical behavior: those with no relapse after prostatectomy (Tnone); those with relapse and slow increase in serum prostate specific antigen (PSA, doubling in more than 15 months) (Tslow); those with relapse and rapid increase in serum PSA (doubling in less than 4 months) (Tfast). The kinetics of PSA increase after prostatectomy is predictive of prostate-cancer specific death, with rapid increases highly associated with lethal prostate cancer(12). The spectrum of locus abnormalities increases from blood to prostate cancer in an incremental fashion: the least in blood to the most in rapidly progressive prostate cancer (Tfast) (FIG. 1D).

[0089] To assess the reproducibility of these analyses, a large set of reference normal samples (n=800) available to public through Partek, Inc. was used. This re-analysis showed genome segment abnormalities of B, AT and T overlapped at least 93 percent between these two analyses (FIG. 5A). In addition, a third analysis using a different set of normal samples (GeneSpring GX11, n=265) was performed, showing that 94% to 99% of the amplified or deleted genome segments from B, AT and T overlap with those obtained from Partek Genome Suite analyses using blood as baseline (FIG. 5A). Affymetrix SNP6.0 contains separate probe sets for SNP and CNV detection. The majority of large genome deletions are accompanied with loss of heterozygosity (LOH). Profiles of LOH for B, AT and T samples were generated to validate the deletions detected by CNV analysis. Genome deletion frequently accompanied LOH (91% to 98%), with average matches for B, AT and T ranging from 93% to 96% (FIG. 5B). This suggests that the analyses are reproducible and robust.

[0090] Five loci from chromosomes 16, 17, 3, 2 and 15 with deletions of at least 10 kb and overlapping with nearby genes were selected for quantitative-PCR analysis. As shown in FIG. 5C, a deletion by Q-PCR was found in 4 of 5 samples predicted to have a deletion in the region overlapping with ARL17B, a gene homologous to ADP-ribosylation factor located at 17q2113. Similar confirmation was found in Q-PCR of SCAPER, the S-phase cyclin A-associated protein in the ER located at 15q2414 (5 of 5 samples), of WWOX, WW domain containing oxidoreductase located at 16q2315-17 (5 of 5 samples), of EPHA3 or ephrin receptor 3, a protein tyrosine receptor frequently mutated in a variety of human cancers 18-20 (4 of 5 samples), and of ERBB4 or v-erb-a erythroblastic leukemia viral oncogene homolog 421,22 (5 of 5 samples) in blood samples from prostate cancer patients. The concordance rate of Q-PCR and copy number analysis was 92%. Our analysis indicates that copy number variation is not limited to prostate cancer or benign prostate tissue adjacent to cancer, but is also found in blood from prostate cancer patients.

[0091] To investigate whether the CNV profiles of B, AT and T are distinctive from each other, classification analysis was performed to predict genomes of blood versus those of prostate cancer, by aggregating genome loci that have differential amplification or deletion proportion between blood and prostate cancer (see methods for more detail). The prediction accuracy under unbiased “leave-one-out” cross-validation (23) was 89% for blood (76/85) and 94% for prostate cancer (98/104). The overall accuracy was 92% (174/189, FIG. 5D). To investigate whether AT is genetically more related to cancer or “normal” tissues, the CNV profiles of B and T samples were constructed into a logistic regression model as “normal” and “prostate cancer” training sets, respectively. This model was then utilized to classify each of the 49 AT samples as either “normal” or “prostate cancer”. Such analysis predicts that 42 of 49 (86%) putatively benign prostate tissue is “cancer”, while only 7 of the AT tissues were classified as “normal”. All prostate cancer cell lines were classified as “cancer”. These analyses clearly indicate that majority of AT samples have copy number profiles similar to prostate cancer’s rather than to normal’s, resembling a field effect similarly found for gene expression profiling (24).

[0092] The vast majority of prostate cancers are not lethal (25). Prediction analysis with “leave-one-out” cross-validation based on loci that have significant proportion of amplification or deletion in the group of relapse but none in the non-relapsed group was performed. The resulting Receiver Operating Characteristic curves (ROC) were generated by varying sensitivity-specificity trade-off (FIGS. 2A,B). The cutoff that generates the best Youden index (i.e. sensitivity+specificity-1) has an accuracy of 73% (74/102, ROC p=0.003, positive prediction=76% [57/75], negative prediction=63% [17/27]) for relapse prediction. Gleason’s grading has been a strong predictor of recurrence but in this analysis it was statistically insignificant from baseline (ROC p=0.32) and much worse than CNV analysis.

[0093] Prostate cancers with rapid progression, as defined by rates of PSA rise, are lethal 1(2,26). Those with PSA doubling time (PSADT)<4 months after relapse and those who died of prostate cancer were compared to those with PSADT>15 months or having no relapse. A similar prediction with “Leave-One-Out” cross-validation analysis was performed to examine the accuracy of CNV profiling (see the genes listed in TABLE 3) in predicting rapidly progressing

prostate cancer. As shown in FIG. 2C, the accuracy of predicting rapid progression was 75% (p<0.001) with positive and negative predictive value of 58% and 83%, respectively. In contrast, the histology of the cancer, as defined by Gleason grading, failed to achieve >50% predictive values simultaneously on positive and negative predictions (ROC p=0.074).

[0094] Since the genome alterations in AT are most similar to those of T, the CNV of AT to predict relapse was examined using cross-validation. As shown in FIGS. 3A and 3C, the CNV profile of AT is moderately predictive of prostate cancer relapse: a sensitivity of 76% and a specificity at 56% (ROC p=0.041) were observed. Surprisingly, the CNV profile of AT is more accurate in predicting fast relapse (88% sensitivity and 75% specificity, p=0.015, FIGS. 3B&D). Using the same approach, the CNV profiles from B failed to generate a ROC statistically different from baseline in predicting relapse or fast relapse. However, our analysis showed that the average and median sizes of CNV are significantly larger in blood samples (70 Kb and 23 kb, respectively) from patients with relapse than those without (40 kb and 17 kb). Based on the sizes of CNV, highly statistically significant ROCs were generated (FIGS. 4A-B), predicting 81% (p<0.001) relapse and 69% (p=0.001) fast relapse correctly through median CNV sizes. The CNV size correlation with relapse was also found in T (817 kb mean and 647 kb median for relapse vs. 385 kb and 185 kb for non-relapse) and AT samples (246 kb mean and 18 kb median for relapse vs. 95 kb and 16 kb for non-relapse), suggesting a larger CNV size a common feature for prostate cancer relapse regardless tissues. Both median and mean sizes of CNV from T and B, and mean size of CNV from AT predict prostate cancer relapse, while mean and median sizes of CNV from T and B predict fast relapse (FIGS. 4A-D, 6A-D and 7A-B). Interestingly, similar relapse prediction results were also replicated using the sizes of either amplified or deleted loci of blood (FIGS. 8A-D and 9A-D).

[0095] To rule out aging being a factor in our analysis, correlation analyses between our gene-specific or size-based model and the patient age were performed, and revealed no significant correlation between age and our prediction methods, Age did not predict outcomes (FIG. 10A-F).

[0096] To investigate the reproducibility of our prediction models, we collected an additional 25 samples, including 10 tumors, 10 benign tissues adjacent to tumors, and 5 blood samples from patients with prostate cancer. These experiments and analyses were performed in a separate time period and by different personnel. By using a genespecific model, we correctly predicted 7 of 10 relapse and 8 of 10 short PSADT from tumor samples, whereas we correctly predicted 7 of 10 for both relapse and short PSADT from AT samples. By using mean size of CNV from tumor, we correctly predicted 7 of 10 cases of both relapse and short PSADT, 7 of 10 for relapse from AT, and 4 of 5 for relapse and 4 of 5 for short PSADT from blood. By using median size of CNV from tumors, we correctly predicted 6 of 10 for relapse and 7 of 10 for short PSADT, whereas from blood, we correctly predicted 5 of 5 for relapse and 4 of 5 for short PSADT. Taken together, the gene-specific CNV model has an overall prediction rate of 72.5% in the replication data set, similar to those found in the first set of data. The mean CNV sizes of blood, tumor, and benign prostate tissues have an overall prediction rate of 72% for relapse, and the mean CNV sizes of blood and tumor samples have an overall prediction rate of 73% for short PSADT, whereas the median CNV sizes of blood and tumor have overall prediction rates of 73% for relapse and 80% for

short PSADT. These results are also similar to those found in the original study, reflecting good consistency and reproducibility of our prediction models.

[0097] 6.3 Discussion

[0098] Genome-wide analyses of prostate cancer using other methodologies were performed previously (27-30). However, there was no attempt to construct a model to predict the prognosis of prostate cancer. The genome abnormality found in blood from prostate cancer patients in this study is novel. Even though a tiny amount (<0.1% of blood cell population) of circulating tumor cells may exist in the blood sample (31, 32), the stringency of CNV analysis (>30% contamination to be detected) ruled out contamination of tumor cells in the blood as a contending interpretation. Analysis of some of the previously published matched normal samples of other malignancies (33,34) also reveals significant CNV. This suggests that CNV is widely present in tissues of patients carrying malignancies. However, it is unclear whether healthy individuals carry these abnormalities. The CNV of blood may be somatic and acquired through aging; this alteration would tend to be random and spontaneous. Alternatively, genome copy number abnormalities may occur at germ line level. To distinguish these two possibilities, longitudinal blood samples of the same aging individual could identify if CNV is accumulated. Independent of the mechanism, however, genome CNV correlates with the eventual behavior of prostate cancer. This is observed in the primary prostate cancer, in the histologically normal tissue from a prostate gland containing cancer and in the blood of prostate cancer patient. The field effect of genome alterations appears to extend beyond the organ to the entire host.

[0099] Conceivably, CNV analysis offers a better option than Gleason's grading in predicting the behavior of prostate cancer not only because of a better prediction rate on the tumor samples, but also its applicability to non-tumor tissues. There are several salient potentials for clinical application using the CNV tests: For a patient being diagnosed of prostate cancer, CNV analysis done on the blood or perhaps other normal tissues from the patient would eliminate the need for additional invasive procedure to decide a treatment mode. For a patient already having a radical prostatectomy, the CNV analysis on tumor or blood sample may help to decide whether additional treatment is warranted to prevent relapse. When morphology becomes in-determinate in a biopsy sample, the gene specific CNV field effect in benign prostate tissues may help to obtain a firmer diagnosis. The main limitation of the genome CNV analysis for clinical test is its requirement of high quality genome DNA. Formalin-fixed paraffin-embedded tissues may not be suitable. When gene specific CNV prediction is performed, a training set containing samples with known outcome is required for the prediction (while there is no need of training set when size of CNV analysis is performed). Despite these limitations, CNV analysis on the genome of blood, normal prostate or tumor tissues of the prostate cancer patients holds promise to become a more efficient and accurate way to predict the behavior of prostate cancer.

7. REFERENCES

- [0100] 1. Jemal A, Bray F, Center M M, et al: Global cancer statistics. *CA Cancer J Clin*
- [0101] 2. Jemal A, Siegel R, Xu J, et al: Cancer statistics, 2010. *CA Cancer J Clin* 60:277-300
- [0102] 3. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2009. *CA Cancer J Clin* 59:225-49, 2009
- [0103] 4. Pang S T, Weng W H, Flores-Morales A, et al: Cytogenetic and expression profiles associated with transformation to androgen-resistant prostate cancer. *Prostate* 66:157-72, 2006
- [0104] 5. Matsui S, LaDuca J, Rossi M R, et al: Molecular characterization of a consistent 4.5-megabase deletion at 4q28 in prostate cancer cells. *Cancer Genet Cytogenet* 159:18-26, 2005
- [0105] 6. Bettendorf O, Schmidt H, Eltze E, et al: Cytogenetic changes and loss of heterozygosity in atypical adenomatous hyperplasia, in carcinoma of the prostate and in non-neoplastic prostate tissue using comparative genomic hybridization and multiplex-PCR. *Int J Oncol* 26:267-74, 2005
- [0106] 7. Teixeira M R, Ribeiro F R, Eknaes M, et al: Genomic analysis of prostate carcinoma specimens obtained via ultrasound-guided needle biopsy may be of use in preoperative decision-making. *Cancer* 101:1786-93, 2004
- [0107] 8. Macoska J A, Paris P, Collins C, et al: Evolution of 8p loss in transformed human prostate epithelial cells. *Cancer Genet Cytogenet* 154:36-43, 2004
- [0108] 9. Kraus J, Pantel K, Pinkel D, et al: High-resolution genomic profiling of occult micrometastatic tumor cells. *Genes Chromosomes Cancer* 36:159-66, 2003
- [0109] 10. Strassburger K, Bretz F: Compatible simultaneous lower confidence bounds for the Holm procedure and other Bonferroni-based closed tests. *Stat Med* 27:4914-27, 2008
- [0110] 11. Hanczar B, Hua J, Sima C, et al: Small-sample precision of ROC-related estimates. *Bioinformatics* 26:822-30
- [0111] 12. Hanks G E, Hanlon A L, Lee W R, et al: Pre-treatment prostate-specific antigen doubling times: clinical utility of this predictor of prostate cancer behavior. *Int J Radiat Oncol Biol Phys* 34:549-53, 1996
- [0112] 13. Strausberg R L, Feingold E A, Grouse L H, et al: Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. *Proc Natl Acad Sci USA* 99:16899-903, 2002
- [0113] 14. Tsang W Y, Wang L, Chen Z, et al: SCAPER, a novel cyclin A-interacting protein that regulates cell cycle progression. *J Cell Biol* 178:621-33, 2007
- [0114] 15. Yang J, Cogdell D, Yang D, et al: Deletion of the WWOX gene and frequent loss of its protein expression in human osteosarcoma. *Cancer Lett* 291:31-8
- [0115] 16. Nunez M f, Rosen D O, Ludes-Meyers 3H, et al: WWOX protein expression varies among ovarian carcinoma histotypes and correlates with less favorable outcome. *BMC Cancer* 5:64, 2005
- [0116] 17. Yakicier M C, Legoix P, Vaury C, et al: Identification of homozygous deletions at chromosome 16q23 in aflatoxin B1 exposed hepatocellular carcinoma. *Oncogene* 20:5232-8, 2001
- [0117] 18. Blackford A, Parmigiani G, Kensler T W, et al: Genetic mutations associated with cigarette smoking in pancreatic cancer. *Cancer Res* 69:3681-8, 2009
- [0118] 19. Clifford N, Smith L M, Powell J, et al: The EphA3 receptor is expressed in a subset of rhabdomyosarcoma cell lines and suppresses cell adhesion and migration. *J Cell Biochem* 105:1250-9, 2008

- [0119] 20. Bae H J, Song J H, Nob J H, et al: Low frequency mutation of the Ephrin receptor A3 gene in hepatocellular carcinoma. *Neoplasma* 56:3314, 2009
- [0120] 21. Koutas A K, Fountzilas O, Kalogeras K T, et al: The upgraded role of HER3 and HER4 receptors in breast cancer, *Crit Rev Oncol Hematol* 74:73-8
- [0121] 22. Lee S Y, Kim M J, Jin G, et al: Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers. *J Thorac Oncol* 5:1734-40
- [0122] 23. Golub T R, Slonim D K, Tamayo P, et al: Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. *Science* 286:531-7, 1999
- [0123] 24. Yu Y P, Landsittel D, Jing L, et al: Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. *J Clin Oncol* 22:2790-9, 2004
- [0124] 25. Isaacs JT: Molecular markers for prostate cancer metastasis. Developing diagnostic methods for predicting the aggressiveness of prostate cancer. *Am J Pathol* 150: 1511-21, 1997
- [0125] 26. Stephenson A J, Shariat S F, Zelefsky M J, et al: Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. *Jama* 291:1325-32, 2004
- [0126] 27. Kim J H, Dhanasekaran S M, Mehra R, et al: Integrative analysis of genomic aberrations associated with prostate cancer progression. *Cancer Res* 67:8229-39, 2007
- [0127] 28. Zhao H, Kim Y, Wang P, et al: Genome-wide characterization of gene expression variations and DNA copy number changes in prostate cancer cell lines. *Prostate* 63:187-97, 2005
- [0128] 29. Ren B, Yu G, Tseng G C, et al: MCM7 amplification and overexpression are associated with prostate cancer progression. *Oncogene* 25:1090-8, 2006
- [0129] 30. Liu W, Laitinen S, Khan S, et al: Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. *Nat Med* 15:559-65, 2009
- [0130] 31. Cristofanilli M, Budd G T, Ellis M J, et al: Circulating tumor cells, disease progression, and survival in metastatic breast cancer, *N Engl J Med* 351:781-91, 2004
- [0131] 32. Moreno J G, Croce C M, Fischer R, et al: Detection of hematogenous micrometastasis in patients with prostate cancer. *Cancer Res* 52:6110-2, 1992
- [0132] 33. Green M R, Monti S, Rodig S J, et al: Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. *Blood* 116:3268-77, 2010
- [0133] 34. Parkin B, Erba H, Ouillet P, et al: Acquired genomic copy number aberrations and survival in adult acute myelogenous leukemia. *Blood* 116:4958-67, 2010
- [0134] Various publications are cited herein, the contents of which are hereby incorporated by reference in their entireties.

TABLE 1A

Case pathology grading, Clinical outcome and Age						
Sample	Type	Relapse	Relapse	Gleason's	Age	
		Fast	Simple	Grade		
LNCaP	C					
5772T	T	none	nf	n	7	60 s
3806T	T					
Du145	C					

TABLE 1A-continued

Case pathology grading, Clinical outcome and Age						
Sample	Type	Relapse	Relapse	Relapse	Gleason's	Age
		Fast	Simple	Grade		
20968T	T	slow	nf	y	7	50 s
15463T	T	none	nf	n	7	60 s
8629T	T	none	nf	n	6	50 s
PC3	C					
28685T	T	slow	nf	y	7	50 s
11423T	T	slow	nf	y	7	70 s
11462T	T	slow	nf	y	7	50 s
25265T	T	none	nf	n	7	60 s
25313T	T	none	nf	n	8	50 s
2671T	T	slow	nf	y	7	60 s
6647T	T	slow	nf	y	7	40 s
9122T	T	none	nf	n	7	50 s
678T	T	none	nf	n	9	70 s
7270T	T	none	nf	n	9	70 s
28925N	N					
1199T	T	slow	nf	y	8	50 s
27086T	T	none	nf	n	6	50 s
562T	T	none	nf	n	6	60 s
34N	N	Nnone	Nnf	Nn		
36N	N	Nnone	Nnf	Nn		
9122N	N	Nnone	Nnf	Nn		
28278T	T	none	nf	n	7	50 s
2691T	T	none	nf	n	7	50 s
8629N	N	Nnone	Nnf	Nn		
8378T	T	none	nf	n	7	60 s
8432T	T	none	nf	n	7	50 s
6837T	T	slow	nf	y	6	70 s
7943N	N	Nnone	Nnf	Nn		
8741T	T	none	nf	n	6	60 s
34T	T	none	nf	n	7	50 s
14878T	T	none	nf	n	8	60 s
25313N	N	Nnone	Nnf	Nn		
678N	N	Nnone	Nnf	Nn		
GB195T	T	slow	nf	y	7	60 s
HB591T	T	fast	f	y	7	60 s
IB071T	T	fast	f	y	7	60 s
JB426T	T	fast	f	y	7	60 s
PR079T	T	slow	nf	y	7	60 s
PR521T	T	slow	nf	y	7	50 s
TP08-S00530T	T	fast	f	y	7	60 s
TP09-S0006T	T	fast	f	y	8	50 s
16464T	T	slow	nf	y	7	60 s
16947T	T	slow	nf	y	8	70 s
DB237T	T	slow	nf	y	6	70 s
FB94T	T	slow	nf	y	7	60 s
JB378T	T	slow	nf	y	6	60 s
PR151T	T	slow	nf	y	7	60 s
PR304T	T	slow	nf	y	8	60 s
PR311T	T	slow	nf	y	8	60 s
2644T	T	slow	nf	y	9	50 s
19381T	T	none	nf	n	6	50 s
7943T	T	none	nf	n	7	60 s
TP09-S0420T	T	fast	f	y	7	50 s
18176N	N	Nslow	Nnf	Ny		
19381N	N	Nnone	Nnf	Nn		
IB071N	N	Nfast	Nf	Ny		
JB426N	N	Nfast	Nf	Ny		
PR304N	N	Nslow	Nnf	Ny		
2644N	N	Nslow	Nnf	Ny		
15733N	N	Nnone	Nnf	Nn		
15875N	N	Nnone	Nnf	Nn		
PR310T	T	fast	f	y	7	60 s
29671T	T	slow	nf	y	7	60 s
15733T	T	none	nf	n	7	50 s
18176T	T	slow	nf	y	6	50 s
5772N	N	Nnone	Nnf	Nn		
7504T	T	none	nf	n	9	70 s
28925T	T				7	50 s
15875T	T	none	nf	n	7	40 s
15922T	T	none	nf	n	7	60 s
28278N	N	Nnone	Nnf	Nn		
4308T	T	none	nf	n	6	60 s

TABLE 1A-continued

Case pathology grading, Clinical outcome and Age						
Sample	Type	Relapse	Relapse Fast	Relapse Simple	Gleason's Grade	Age
7504N	N	Nnone	Nnf	Nn		70 s
JB197T	T	fast	f	y	7	50 s
TP08-S00268N	N	Nfast	Nf	Ny		60 s
TP08-S00268T	T	fast	f	y	7	60 s
TP09-S0420N	N	Nfast	Nf	Ny		50 s
1199B	B	Bslow	Bnf	By		50 s
9122B	B	Bnone	Bnf	Bn		50 s
18176B	B	Bslow	Bnf	By		50 s
25313B	B	Bnone	Bnf	Bn		50 s
6634B	B	Bnone	Bnf	Bn		50 s
678B	B	Bnone	Bnf	Bn		70 s
7504B	B	Bnone	Bnf	Bn		70 s
16464B	B	Bnone	Bnf	Bn		60 s
4336B	B	Bslow	Bnf	By		60 s
28685B	B	Bslow	Bnf	By		50 s
4851B	B	Bnone	Bnf	Bn		60 s
1942B	B	Bfast	Bf	By		60 s
13563B	B	Bnone	Bnf	Bn		70 s
TP09-S0420B	B	Bfast	Bf	By		50 s
TP08-S00268B	B	Bfast	Bf	By		60 s
DB237B	B	Bslow	Bnf	By		70 s
PR151B	B	Bslow	Bnf	By		60 s
13745B	B					60 s
TP09-S0006B	B	Bfast	Bf	By		50 s
PR331B	B	Bslow	Bnf	By		60 s
28685B2	B	Bslow	Bnf	By		50 s
IB071B	B	Bfast	Bf	By		60 s
PR304B	B	Bslow	Bnf	By		60 s
JB426B	B	Bfast	Bf	By		60 s
7270B	B	Bnone	Bnf	Bn		70 s
27086B	B	Bnone	Bnf	Bn		50 s
TP09-S0420B2	B	Bfast	Bf	By		50 s
DB237B2	B	Bslow	Bnf	By		70 s
PR151B2	B	Bslow	Bnf	By		60 s
PR310B	B	Bfast	Bf	By		60 s
FB586B	B	Bslow	Bnf	By		50 s
6634B2	B	Bnone	Bnf	Bn		50 s
JB378B	B	Bslow	Bnf	By		60 s
FB94B	B	Bslow	Bnf	By		60 s
GB195B	B	Bslow	Bnf	By		60 s
PR490B	B	Bslow	Bnf	By		60 s
PR303B	B	Bslow	Bnf	By		70 s
PR018B	B	Bslow	Bnf	By		60 s
TP08-S00542B	B	Bfast	Bf	By		50 s
GB400B	B	Bfast	Bf	By		60 s
HB603B	B	Bfast	Bf	By		60 s
DB237N	N	Nslow	Nnf	Ny		70 s
11423N	N	Nslow	Nnf	Ny		70 s
25265N	N	Nnone	Nnf	Nn		60 s
8378N	N	Nnone	Nnf	Nn		60 s
8432N	N	Nnone	Nnf	Nn		50 s
15463N	N	Nnone	Nnf	Nn		60 s
27086N	N	Nnone	Nnf	Nn		50 s
4308N	N	Nnone	Nnf	Nn		60 s
562N	N	Nnone	Nnf	Nn		60 s
FB183T	T	slow	nf	y	7	60 s
GB400T	T	fast	f	y	7	60 s
HB021T	T	fast	f	y	6	50 s
HB261T	T	none	nf	n	7	50 s
HB312T	T	slow	nf	y	8	70 s
HB526T	T	fast	f	y	6	60 s
HB951T	T	fast	f	y	7	60 s
IB134T	T	none	nf	n	9	70 s
IB273T	T	fast	f	y	7	50 s
IB298T	T	slow	nf	y	7	60 s
20968N	N	Nslow	Nnf	Ny		50 s
6647N	N	Nslow	Nnf	Ny		40 s
15922N	N	Nnone	Nnf	Nn		60 s
8741N	N	Nnone	Nnf	Nn		60 s
FB183N	N	Nslow	Nnf	Ny		60 s
HB526N	N	Nfast	Nf	Ny		60 s
HB568T	T	fast	f	y	7	60 s

TABLE 1A-continued

Case pathology grading, Clinical outcome and Age						
Sample	Type	Relapse	Relapse Fast	Relapse Simple	Gleason's Grade	Age
PR236T	T	fast	f	y	10	60 s
PR300T	T	fast	f	y	7	50 s
PR303N	N	Nslow	Nnf	Ny		70 s
PR434T	T	slow	nf	y	7	60 s
TPG8-S00542N	N	Nfast	Nf	Ny		50 s
FB120T	T	slow	nf	y	7	60 s
FB174T	T	fast	f	y	7	60 s
HB603T	T	slow	nf	y	7	60 s
IB113T	T	slow	nf	y	7	70 s
IB483T	T	fast	f	y	7	50 s
IB684T	T	slow	nf	y	7	60 s
KB170T	T	fast	f	y	7	70 s
PR018T	T	slow	nf	y	7	60 s
PR151N	N	Nslow	Nnf	Ny		60 s
PR303T	T	slow	nf	y	6	70 s
PR311N	N	Nslow	Nnf	Ny		60 s
11462N	N	Nslow	Nnf	Ny		50 s
29671N	N	Nslow	Nnf	Ny		60 s
14878N	N	Nnone	Nnf	Nn		60 s
16464N	N	Nnone	Nnf	Nn		60 s
PR521B	B	Bslow	Bnf	By		50 s
PR363B	B	Bslow	Bnf	By		60 s
FB174B	B	Bfast	Bf	By		60 s
FB421B	B	Bfast	Bf	By		60 s
FB421T	T	fast	f	y	7	60 s
HB033T	T	none	nf	n	7	50 s
HB526N2	N	Nfast	Nf	Ny		60 s
IB113B	B	Bslow	Bnf	By		70 s
IB483T2	T	fast	f	y	7	50 s
TP08-S00542T	T	fast	f	y	7	50 s
TP09-S0006N	N	Nfast	Nf	Ny		50 s
PR079B	B	Bslow	Bnf	By		60 s
FB183B	B	Bslow	Bnf	By		60 s
FB120B	B	Bslow	Bnf	By		60 s
HB305B	B	Bfast	Bf	By		60 s
HB305T	T	fast	f	y	6	60 s
IB362T	T	slow	nf	y	7	50 s
IB684B	B	Bslow	Bnf	By		60 s
JB770B	B	Bfast	Bf	By		60 s
JB770T	T	fast	f	y	8	60 s
TP10-S093B	B	Bslow	Bnf	By		60 s
TP10-S093T	T	slow	nf	y	7	60 s
TP09-S0408B	B	Bfast	Bf	By		70 s
TP09-S0408T	T	fast	f	y	8	70 s
2691N	N	Nnone	Nnf	Nn		50 s
28278N2	N	Nnone	Nnf	Nn		50 s
4336T	T	slow	nf	y	6	60 s
6634N	N	Nnone	Nnf	Nn		50 s
6837T2	T	slow	nf	y	6	70 s
7221T	T	fast	f	y	7	50 s
4308B	B	Bnone	Bnf	Bn		60 s
5396B	B	Bnone	Bnf	Bn		60 s
9122B2	B	Bnone	Bnf	Bn		50 s
TP08-S00530B	B	Bfast	Bf	By		60 s
562B	B	Bnone	Bnf	Bn		60 s
KB170B	B	Bfast	Bf	By		70 s
IB298B	B	Bslow	Bnf	By		60 s
HB591B	B	Bfast	Bf	By		60 s
HB261B	B	Bnone	Bnf	Bn		50 s
PR300B	B	Bfast	Bf	By		50 s
PR236B	B	Bfast	Bf	By		60 s
PR434B	B	Bslow	Bnf	By		60 s
HB568B	B	Bfast	Bf	By		60 s
IB134B	B	Bnone	Bnf	Bn		70 s
IB483B	B	Bfast	Bf	By		50 s
HB526B	B	Bfast	Bf	By		60 s
HB021B	B	Bfast	Bf	By		50 s
HB312B	B	Bslow	Bnf	By		70 s
HB033B	B	Bnone	Bnf	Bn		50 s
FB238T	T	slow	nf	y	7	60 s
FB493T	T	slow	nf	y	6	50 s
HB207T	T	fast	f	y	9	60 s

TABLE 1A-continued

Case pathology grading, Clinical outcome and Age						
Sample	Type	Relapse	Relapse Fast	Relapse Simple	Gleason's Grade	Age
HB235T	T	slow	nf	y	9	60 s
HB504T	T	fast	f	y	8	50 s
IB112T	T	slow	nf	y	7	60 s
IB136T	T	fast	f	y	8	50 s
PR306T	T	slow	nf	y	7	60 s
TP10-S0638T	T	fast	f	y	10	50 s
HB235B	B	Bslow	Bnf	By		60 s
PR375B	B	Bfast	Bf	By		50 s
FB238B	B	Bslow	Bnf	By		60 s
IB136B	B	Bfast	Bf	By		50 s
TP09-S0721B	B	Bfast	Bf	By		50 s
HB504B	B	Bfast	Bf	By		50 s
IB112B	B	Bslow	Bnf	By		60 s
HB207B	B	Bfast	Bf	By		60 s
PR306B	B	Bslow	Bnf	By		60 s
TP09-S0638B	B	Bfast	Bf	By		50 s
HB46B	B	Bslow	Bnf	By		60 s
FB493B	B	Bslow	Bnf	By		50 s
HB46T	T	slow	nf	y	8	60 s
PR375T	T	fast	f	y	7	50 s
TP09-S0721T	T	fast	f	y	10	50 s

TABLE 1B

Clinical and Pathological Characteristics of Prostate Cancer Samples				
	Relapse Status			
	None (n = 28)	Long PSADT (n = 42)	Short PSADT (n = 33)	
Mean Age (P = 0.0783)	56.07	59.29	56.06	
Cancer Stage (P = 0.0224)				
pT1	3 (2.9)	1 (1.0)	0 (0)	
pT2	10 (9.7)	9 (8.7)	7 (6.8)	
pT3a	7 (6.8)	18 (17.5)	6 (5.8)	
pT3b	8 (7.8)	14 (13.6)	20 (19.4)	
Gleason grade (P = 0.6569)				
6	6 (5.8)	8 (7.8)	3 (2.9)	
7	16 (15.5)	26 (25.2)	21 (20.4)	
8-10	6 (5.8)	8 (7.8)	9 (8.7)	
Race (P = 0.2349)				
Black	1	2	0	
Unknown	4	1	2	
White	23	39	31	
Median follow-up (months)	154	124.8	54.8	
Median time to progression (months)	NA	47.355	1.87	
Median PSADT (months)	NA	23.2	3.21	
Mean preoperative PSA (P = 0.42)	8.61	12.31	10.79	

Data are given as number (percentage) of the 103 samples unless otherwise indicated.
NA = not applicable

TABLE 1C

Clinical and Pathological Characteristics of Prostate Tissues Adjacent to Tumor			
	Relapse Status		
	None (n = 28)	Long PSADT (n = 13)	Short PSADT (n = 8)
Mean Age (P = 0.554)	55	57.69	56.06
Cancer Stage (P = 0.541)			
pT1	3 (6.1)	0 (0)	0 (0)
pT2	11 (22.4)	4 (8.2)	3 (6.1)
pT3a	7 (14.3)	6 (12.2)	1 (2.0)
pT3b	7 (14.3)	3 (6.1)	4 (8.2)
Gleason grade (P = 0.9849)			
5	1 (2.0)	0 (0)	0 (0)
6	7 (14.3)	3 (6.1)	2 (4.1)
7	16 (32.7)	7 (14.3)	5 (10.2)
8-10	4 (8.2)	3 (6.1)	1 (2.0)
Race (P = 0.08387)			
Black	0	1	0
Unknown	6	0	0
White	22	12	8
Median follow up (months)	155	149	29.205
Median time to progression (months)	NA	54.6	3.09
Median (PSADT) months	NA	26.9	2.46
Mean preoperative PSA (P = 0.074)	8.23	12.98	6.3

Data are given as number (percentage) of the 49 samples unless otherwise indicated.
NA = not applicable

TABLE 1D

Clinical and Pathological Characteristics of Blood Samples from Patients with Prostate Cancer			
	Relapse Status		
	None (n = 18)	Long PSADT (n = 35)	Short PSADT (n = 31)
Mean age (P = 0.268)	58.33	59.43	56.77
Cancer Stage (P = 0.003893)			
pT1	5 (6.0)	1 (1.2)	0 (0)
pT2	6 (7.1)	12 (14.3)	6 (7.1)
pT3a	1 (1.2)	10 (11.9)	5 (6.0)
pT3b	6 (7.1)	12 (14.3)	20 (23.8)
Gleason grade (P = 0.2248)			
6	5 (6.0)	8 (9.5)	3 (3.6)
7	7 (8.3)	21 (25.0)	18 (21.4)
8-10	6 (7.1)	6 (7.1)	10 (11.9)
Race (P = 0.08387)			
Black	0	1	0
Unknown	3	1	2
White	15	33	29
Median follow up (months)	152	109.14	54.8

TABLE 1D-continued

Clinical and Pathological Characteristics of Blood Samples from Patients with Prostate Cancer			
	Relapse Status		
	None (n = 18)	Long PSADT (n = 35)	Short PSADT (n = 31)
Median time to progression (months)	NA	47.27	3.23
Median PSADT (months)	NA	26	3.21

TABLE 1D-continued

Clinical and Pathological Characteristics of Blood Samples from Patients with Prostate Cancer			
	Relapse Status		
	None (n = 18)	Long PSADT (n = 35)	Short PSADT (n = 31)
Mean preoperative PSA (P = 0.868)	10.48	12.17	10.87
Data are given as number (percentage) of the 84 samples unless otherwise indicated. NA = not applicable			

TABLE 2

Gene list for predicting prostate cancer relapse using prostate cancer tissue										
Symbol	freq. use	freq. amp. c②	freq. del. cc②	freq. amp. c②	freq. del. cc②	Gene. Syn②	chromo- sor②	cyto- band	Trans- script②	Trans- script. end
psiTPTE22	1	0.106667	0.133333	0.444444	0	psiTPTE22	22	22q11.1	15462801	15509721
XKR3	1	0.133333	0.133333	0.481481	0	XKR3	22	22q11.1	15644306	15682585
DNAL4	1	0.413333	0.133333	0.777778	0	DNAL4	22	22q13.1	37504459	37520108
BRD1	1	0.48	0.12	0.814815	0	BRD1	22	22q13.33	48552941	48604457
LOC90834	1	0.48	0.12	0.814815	0	LOC90834	22	22q13.33	48557542	48559963
ZBED4	1	0.48	0.12	0.814815	0	ZBED4	22	22q13.33	48633501	48669731
ALG12	1	0.48	0.12	0.814815	0	ALG12	22	22q13.33	48682857	48698111
CRELD2	1	0.48	0.12	0.814815	0	CRELD2	22	22q13.33	48698287	48707191
PIM3	1	0.48	0.12	0.814815	0	PIM3	22	22q13.33	48740147	48743724
IL17REL	1	0.48	0.12	0.814815	0	IL17REL	22	22q13.33	48775069	48793183
TTLL8	1	0.48	0.12	0.814815	0	TTLL8	22	22q13.33	48795679	48835183
PANX2	1	0.48	0.12	0.814815	0	PANX2	22	22q13.33	48951287	48960851
TRABD	1	0.48	0.12	0.814815	0	TRABD	22	22q13.33	48966487	48980155
SELO	1	0.48	0.12	0.814815	0	SELO	22	22q13.33	48981535	48998173
TUBGCP6	1	0.48	0.12	0.814815	0	TUBGCP6	22	22q13.33	48998245	49025528
KIF16B	1	0.106667	0.12	0.074074	0	KIF16B	20	20p12.1	16200749	16502079
PCSK2	1	0.146667	0.133333	0.222222	0	PCSK2	20	20p12.1	17155631	17413223
LGALS13	1	0.333333	0.145667	0.740741	0	LGALS13	19	19q13.2	44785009	44789955
LGALS14	1	0.346667	0.12	0.740741	0	LGALS14	19	19q13.2	44886786	44891929
CLC	1	0.346667	0.12	0.740741	0	CLC	19	19q13.2	44913735	44920509
RPH3AL	1	0.48	0.12	0.814815	0	RPH3AL	17	17p13.3	62294	202577
VPS53	1	0.48	0.12	0.777778	0	VPS53	17	17p13.3	361480	564847
GEMIN4	1	0.48	0.12	0.777778	0	GEMIN4	17	17p13.3	594411	602252
ELP2P	1	0.48	0.12	0.777778	0	ELP2P	17	17p13.3	602650	605327
NXN	1	0.466667	0.133333	0.777778	0	NXN	17	17p13.3	649335	829761
TIMM22	1	0.466667	0.133333	0.777778	0	TIMM22	17	17p13.3	847107	852141
ABR	1	0.466667	0.133333	0.777778	0	ABR	17	17p13.3	853509	959075
YWHAE	1	0.453333	0.133333	0.777778	0	YWHAE	17	17p13.3	1194586	1250307
CRK	1	0.453333	0.133333	0.777778	0	CRK	17	17p13.3	1272208	1306295
INPP5K	1	0.466667	0.133333	0.777778	0	INPP5K	17	17p13.3	1344622	1366933
LOC1003c②	1	0.466667	0.133333	0.777778	0	LOC1003c②	17	17p13.3	1366963	1368139
PITPNA	1	0.466667	0.133333	0.777778	0	PITPNA	17	17p13.3	1368033	1412861
PRPF8	1	0.466667	0.133333	0.777778	0	PRPF8	17	17p13.3	1500673	1534927
WDR81	1	0.466667	0.133333	0.777778	0	WDR81	17	17p13.3	1566567	1588644
SERPINF2	1	0.466667	0.133333	0.777778	0	SERPINF2	17	17p13.3	1592880	1605310
SERPINF1	1	0.466667	0.133333	0.777778	0	SERPINF1	17	17p13.3	1612009	1527619
SMYD4	1	0.466667	0.133333	0.777778	0	SMYD4	17	17p13.3	1629579	1679926
RPA1	1	0.466667	0.133333	0.777778	0	RPA1	17	17p13.3	1680023	1749599
RTN4RL1	1	0.466667	0.133333	0.777778	0	RTN4RL1	17	17p13.3	1784721	1874929
SMG6	1	0.466667	0.133333	0.777778	0	SMG6	17	17p13.3	1909883	2153564
SRR	1	0.453333	0.133333	0.777778	0	SRR	17	17p13.3	2153998	2175304
METT10D	1	0.413333	0.133333	0.740741	0	METT10D	17	17p13.3	2266098	2361951
PAFAH1B1	1	0.413333	0.133333	0.740741	0	PAFAH1B1	17	17p13.3	2443673	2535660
KIAA0664	1	0.426667	0.133333	0.740741	0	KIAA0664	17	17p13.3	2539430	2561678
RAP1GAP2	1	0.426667	0.133333	0.740741	0	RAP1GAP2	17	17p13.3	2646482	2887786
OR3A2	1	0.28	0.146667	0.740741	0	OR3A2	17	17p13.3	3127934	3129019
TRPV3	1	0.413333	0.133333	0.740741	0	TRPV3	17	17p13.3	3363236	3408040
TRPV1	1	0.413333	0.133333	0.740741	0	TRPV1	17	17p13.3	3415490	3447086
SHPK	1	0.413333	0.133333	0.740741	0	SHPK	17	17p13.3	3458305	3486366
CTNS	1	0.413333	0.133333	0.740741	0	CTNS	17	17p13.3	3486511	3513147
TMEM93	1	0.413333	0.133333	0.740741	0	TMEM93	17	17p13.3	3518839	3519712
P2RX5	1	0.413333	0.133333	0.740741	0	P2RX5	17	17p13.3	3523271	3546333
ITGAE	1	0.413333	0.133333	0.740741	0	ITGAE	17	17p13.3	3564568	3651287
GSG2	1	0.413333	0.133333	0.740741	0	GSG2	17	17p13.3	3573946	3576742

TABLE 2-continued

Gene list for predicting prostate cancer relapse using prostate cancer tissue										
Symbol	freq. use	freq. amp. c②	freq. del. c②	freq. amp. c②	freq. del. c②	Gene. Syn②	chromo- sor②	cyto- band	Trans- script②	Trans- script. end
C17orf85	1	0.4	0.133333	0.740741	0	C17orf85	17	17p13.2	3661209	3696290
CAMKK1	1	0.413333	0.146667	0.777778	0	CAMKK1	17	17p13.2	3710366	3743087
P2RX1	1	0.413333	0.133333	0.777778	0	P2RX1	17	17p13.2	3746634	3766710
CDRT15P	1	0.106667	0.146667	0.296296	0	CDRT15P	17	17p12	13868540	13869641
MIR1288	1	0.32	0.12	0.481481	0	MIR1288	17	17p11.2	16126053	16126128
TRPV2	1	0.346667	0.12	0.518519	0	TRPV2	17	17p11.2	16259613	16281043
NCRNA001	1	0.346667	0.12	0.518519	0	NCRNA001	17	17p11.2	16283026	16286064
SNORD49B	1	0.346667	0.12	0.518519	0	SNORD49B	17	17p11.2	16283548	16283596
SNORD49A	1	0.346667	0.12	0.518519	0	SNORD49A	17	17p11.2	16284075	16284146
SNORD65	1	0.346667	0.12	0.518519	0	SNORD65	17	17p11.2	16285265	16285338
C17orf76	1	0.346667	0.12	0.518519	0	C17orf76	17	17p11.2	16286053	16336206
ZNF287	1	0.346667	0.12	0.518519	0	ZNF287	17	17p11.2	16394356	16413246
MPP3	1	0.466667	0.12	0.777778	0	MPP3	17	17q21.31	39233693	39266065
CD300LG	1	0.466667	0.12	0.777778	0	CD300LG	17	17q21.31	39280042	39291128
MPP2	1	0.466667	0.12	0.777778	0	MPP2	17	17q21.31	39308253	39340640
PPY	1	0.466667	0.133333	0.777778	0	PPY	17	17q21.31	39373698	39375360
PYY	1	0.466667	0.133333	0.777778	0	PYY	17	17q21.31	39385633	39437364
NAGS	1	0.466667	0.133333	0.777778	0	NAGS	17	17q21.31	39437558	39441963
TMEM101	1	0.466667	0.133333	0.777778	0	TMEM101	17	17q21.31	39444082	39447872
LSM12	1	0.466667	0.133333	0.777778	0	LSM12	17	17q21.31	39467530	39500514
G6PC3	1	0.466667	0.133333	0.777778	0	G6PC3	17	17q21.31	39503624	39509238
HDAC5	1	0.466667	0.133333	0.777778	0	HDAC5	17	17q21.31	39509647	39556541
C17orf53	1	0.466667	0.133333	0.777778	0	C17orf53	17	17q21.31	39574852	39595371
ASB16	1	0.466667	0.133333	0.777778	0	ASB16	17	17q21.31	39603600	39611978
C17orf65	1	0.466667	0.133333	0.777778	0	C17orf65	17	17q21.31	39608878	39619609
TMUB2	1	0.466667	0.133333	0.777778	0	TMUB2	17	17q21.31	39619880	39624626
ATXN7L3	1	0.466667	0.133333	0.777778	0	ATXN7L3	17	17q21.31	39624699	39631056
UBTF	1	0.466667	0.133333	0.777778	0	UBTF	17	17q21.31	39637927	39653777
SLC4A1	1	0.466667	0.133333	0.777778	0	SLC4A1	17	17q21.31	39681284	39701029
SLC25A39	1	0.466667	0.12	0.777778	0	SLC25A39	17	17q21.31	39752519	39757744
GRN	1	0.466667	0.12	0.777778	0	GRN	17	17q21.31	39778017	39785997
FAM171A2	1	0.466667	0.12	0.777778	0	FAM171A2	17	17q21.31	39786627	39796762
ITGA2B	1	0.466667	0.12	0.777778	0	ITGA2B	17	17q21.31	39805076	39822400
GPATCH8	1	0.466667	0.12	0.777778	0	GPATCH8	17	17q21.31	39828176	39936329
FZD2	1	0.426667	0.12	0.777778	0	FZD2	17	17q21.31	39990451	39992434
C17orf104	1	0.453333	0.12	0.777778	0	C17orf104	17	17q21.31	40089288	40108690
ADAM11	1	0.48	0.12	0.777778	0	ADAM11	17	17q21.31	40192094	40214741
HIGD1B	1	0.466667	0.12	0.777778	0	HIGD1B	17	17q21.31	40280805	40283375
EFTUD2	1	0.466667	0.12	0.777778	0	EFTUD2	17	17q21.31	40283181	40332520
KIF18B	1	0.48	0.12	0.777778	0	KIF18B	17	17q21.31	40358974	40380609
C1QL1	1	0.48	0.12	0.777778	0	C1QL1	17	17q21.31	40392587	40401171
DCAKD	1	0.48	0.12	0.777778	0	DCAKD	17	17q21.31	40456232	40484505
NMT1	1	0.48	0.12	0.777778	0	NMT1	17	17q21.31	40494206	40541909
PLCD3	1	0.48	0.12	0.777778	0	PLCD3	17	17q21.31	40544534	40565418
ACBD4	1	0.48	0.12	0.777778	0	ACBD4	17	17q21.31	40565493	40577325
HEXIM1	1	0.48	0.12	0.777778	0	HEXIM1	17	17q21.31	40580467	40585252
HEXIM2	1	0.48	0.12	0.777778	0	HEXIM2	17	17q21.31	40594047	40603190
FMNL1	1	0.48	0.12	0.777778	0	FMNL1	17	17q21.31	40655075	40680467
LOC10013②	1	0.48	0.12	0.777778	0	LOC10013②	17	17q21.31	40681086	40701780
C17orf46	1	0.48	0.12	0.777778	0	C17orf46	17	17q21.31	40687543	40695263
MAP3K14	1	0.48	0.12	0.777778	0	MAP3K14	17	17q21.31	40696271	40750198
ARHGAP27	1	0.48	0.12	0.777778	0	ARHGAP27	17	17q21.31	40827051	40839233
TNRC6A	1	0.32	0.12	0.666667	0	TNRC6A	16	16p12.1	24648550	24745049
FLI30679	1	0.413333	0.133333	0.666667	0	FLI30679	16	16q24.1	85146427	85148407
FOXC2	1	0.413333	0.133333	0.666667	0	FOXC2	16	16q24.1	85158358	85160037
FBXO31	1	0.426667	0.146667	0.665667	0	FBXO31	16	16q24.2	85920445	85974896
ZCCHC14	1	0.426667	0.146667	0.666667	0	ZCCHC14	16	16q24.2	85997353	86082962
JPH3	1	0.426667	0.173333	0.666667	0	JPH3	16	16q24.2	86194000	86289263
SLC7A5	1	0.426667	0.186667	0.666667	0	SLC7A5	16	16q24.2	86421130	86460602
CA5A	1	0.426667	0.186667	0.666667	0	CA5A	16	16q24.2	86479126	86527614
BANP	1	0.426667	0.186667	0.666667	0	BANP	16	16q24.2	86542539	86668426
ZFPM1	1	0.44	0.2	0.666667	0	ZFPM1	16	16q24.2	87047515	87129076
ZC3H18	1	0.44	0.2	0.666667	0	ZC3H18	16	16q24.2	87164290	87225873
IL17C	1	0.44	0.2	0.703704	0	IL17C	16	16q24.3	87232502	87234384
CYBA	1	0.44	0.2	0.703704	0	CYBA	16	16q24.3	87237198	87244959
MVD	1	0.44	0.2	0.703704	0	MVD	16	16q24.3	87245849	87256997
MGC23284	1	0.44	0.2	0.703704	0	MGC23284	16	16q24.3	87257282	87281054
SNAI3	1	0.44	0.2	0.703704	0	SNAI3	16	16q24.3	87271591	87280384
RNF166	1	0.44	0.2	0.703704	0	RNF166	16	16q24.3	87290410	87300302
GALNS	1	0.466667	0.2	0.703704	0	GALNS	16	16q24.3	87407643	87450876
TRAPPC2L	1	0.466667	0.2	0.703704	0	TRAPPC2L	16	16q24.3	87451007	87455022
CBFA2T3	1	0.466667	0.2	0.703704	0	CBFA2T3	16	16q24.3	87468768	87570903

TABLE 2-continued

Gene list for predicting prostate cancer relapse using prostate cancer tissue										
Symbol	freq. use	freq. amp. c②	freq. del. c②	freq. amp. c②	freq. del. c②	Gene. Syn②	chromo- sor②	cyto- band	Trans- script②	Trans- script②
ACSF3	1	0.466667	0.2	0.703704	0	ACSF3	16	16q24.3	87687755	87748499
C16orf81	1	0.466667	0.2	0.703704	0	C16orf81	16	16q24.3	87753129	87757585
CDH15	1	0.466667	0.2	0.703704	0	CDH15	16	16q24.3	87765664	87789402
ANKRD11	1	0.48	0.2	0.703704	0	ANKRD11	16	16q24.3	87861536	88084471
SPG7	1	0.48	0.186667	0.703704	0	SPG7	16	16q24.3	88102306	88151676
RPL13	1	0.48	0.186667	0.703704	0	RPL13	16	16q24.3	88154591	88157350
SNORD68	1	0.48	0.186667	0.703704	0	SNORD68	16	16q24.3	88155339	88155411
CDK10	1	0.48	0.186667	0.703704	0	CDK10	16	16q24.3	88280577	88290273
SPATA2L	1	0.48	0.186667	0.703704	0	SPATA2L	16	16q24.3	88290266	88295601
C16orf7	1	0.48	0.186667	0.703704	0	C16orf7	16	16q24.3	88301042	88314896
ZNF276	1	0.48	0.186667	0.703704	0	ZNF276	16	16q24.3	88314894	88334834
SPIRE2	1	0.48	0.173333	0.740741	0	SPIRE2	16	16q24.3	88422403	88465229
TUBB3	1	0.48	0.16	0.740741	0	TUBB3	16	16q24.3	88517246	88530007
DEF8	1	0.48	0.16	0.740741	0	DEF8	16	16q24.3	88542652	88553276
CENPBD1	1	0.48	0.16	0.740741	0	CENPBD1	16	16q24.3	88563702	88566444
OR11H4	1	0.08	0.12	0.111111	0	OR11H4	14	14q11.2	19780791	19781766
G2E3	1	0.026667	0.173333	0	0	G2E3	14	14q12	30098080	30158798
SCFD1	1	0.026667	0.133333	0	0	SCFD1	14	14q12	30161272	30274770
COCH	1	0.053333	0.133333	0	0	COCH	14	14q12	30413492	30429574
STRN3	1	0.16	0.053333	0	0	STRN3	14	14q12	30432756	30565359
AP4S1	1	0.173333	0.053333	0	0	AP4S1	14	14q12	30564434	30632390
HECTD1	1	0.186667	0.053333	0	0	HECTD1	14	14q12	30639075	30746441
AKAP6	1	0.04	0.146667	0	0	AKAP6	14	14q13.1	31868230	32372020
NPAS3	1	0.093333	0.133333	0	0	NPAS3	14	14q13.1	32478210	33343133
SAV1	1	0.12	0.013333	0	0.037037	SAV1	14	14q22.1	50170110	50204774
NIN	1	0.12	0	0	0.037037	NIN	14	14q22.1	50256231	50367590
BMP4	1	0.04	0.133333	0.037037	0	BMP4	14	14q22.2	53486205	53493305
SYT16	1	0.013333	0.2	0.037037	0	SYT16	14	14q23.2	61532294	61638181
GPHN	1	0.08	0.173333	0.185185	0	GPHN	14	14q23.3	66043878	66718279
ERH	1	0.186667	0.133333	0.333333	0	ERH	14	14q24.1	68916593	68934775
SMOC1	1	0.186667	0.12	0.333333	0	SMOC1	14	14q24.2	69415896	69568837
NRXN3	1	0.066667	0.173333	0.222222	0	NRXN3	14	14q24.3	77939846	79400514
LOC100101	1	0.106667	0.16	0.259259	0	LOC100101	13	13q12.11	18734941	18817114
TSC22D1	1	0.12	0.226667	0	0.111111	TSC22D1	13	13q14.11	43905655	44048702
RCBTB1	1	0.12	0.253333	0	0.148148	RCBTB1	13	13q14.3	49004083	49057721
ARL11	1	0.12	0.253333	0	0.148148	ARL11	13	13q14.3	49100625	49105733
EBPL	1	0.12	0.253333	0	0.148148	EBPL	13	13q14.3	49132811	49163625
KPNA3	1	0.12	0.253333	0	0.148148	KPNA3	13	13q14.3	49171445	49265057
LOC22042②	1	0.12	0.253333	0	0.148148	LOC22042②	13	13q14.3	49362546	49365518
C13orf1	1	0.12	0.253333	0	0.148148	C13orf1	13	13q14.3	49384843	49408627
NDUFA9	1	0.213333	0.133333	0.592593	0	NDUFA9	12	12p13.32	4628544	4666661
VWF	1	0.226667	0.133333	0.592593	0	VWF	12	12p13.31	5928301	6104098
GABARAPL	1	0.146667	0.133333	0.111111	0	GABARAPL	12	12p13.2	10256756	10266992
ETV6	1	0.066667	0.16	0.111111	0	ETV6	12	12p13.2	11694055	11939593
BCL2L14	1	0.173333	0.146667	0.148148	0	BCL2L14	12	12p13.2	12115145	12143895
LRP6	1	0.16	0.146667	0.148148	0	LRP6	12	12p13.2	12160228	12311079
MANSC1	1	0.16	0.146667	0.148148	0	MANSC1	12	12p13.2	12373485	12394437
LOH12CR2	1	0.16	0.146667	0.148148	0	LOH12CR2	12	12p13.2	12399611	12401269
LOH12CR1	1	0.16	0.146667	0.148148	0	LOH12CR1	12	12p13.2	12401287	12511106
DUSP16	1	0.133333	0.146667	0.111111	0	DUSP16	12	12p13.2	12520098	12606585
CREBL2	1	0.106667	0.16	0.074074	0	CREBL2	12	12p13.1	12656098	12689309
GPR19	1	0.106667	0.16	0.074074	0	GPR19	12	12p13.1	12705263	12740389
CDKN1B	1	0.106667	0.16	0.074074	0	CDKN1B	12	12p13.1	12761569	12766573
APOLD1	1	0.106667	0.16	0.074074	0	APOLD1	12	12p13.1	12770118	12835667
MIR613	1	0.106667	0.16	0.074074	0	MIR613	12	12p13.1	12808850	12808944
DDX47	1	0.133333	0.146667	0.074074	0	DDX47	12	12p13.1	12875747	12874183
RPL13AP2②	1	0.133333	0.146667	0.074074	0	RPL13AP2②	12	12p13.1	12919678	12920337
GPRC5A	1	0.133333	0.146667	0.074074	0	GPRC5A	12	12p13.1	12935223	12957868
MIR614	1	0.133333	0.146667	0.074074	0	MIR614	12	12p13.1	12960030	12960120
GPRC5D	1	0.133333	0.146667	0.074074	0	GPRC5D	12	12p13.1	12984976	12994586
HEBP1	1	0.133333	0.146667	0.074074	0	HEBP1	12	12p13.1	13019066	13044489
KIAA1467	1	0.12	0.146667	0.074074	0	KIAA1467	12	12p13.1	13088582	13127651
GRIN2B	1	0	0.186667	0.037037	0	GRIN2B	12	12p13.1	13605677	14024290
ST8SIA1	1	0.013333	0.16	0	0	ST8SIA1	12	12p12.1	22237592	22378916
KIAA0528	1	0.066667	0.146667	0.037037	0	KIAA0528	12	12p12.1	22492785	22588720
ETNK1	1	0.066667	0.146667	0.037037	0	ETNK1	12	12p12.1	22669343	22688617
BCAT1	1	0.013333	0.213333	0.037037	0	BCAT1	12	12p12.1	24855546	24993576
CASC1	1	0.066667	0.16	0	0	CASC1	12	12p12.1	25152490	25239362
IFLTD1	1	0.013333	0.12	0.037037	0	IFLTD1	12	12p12.1	25520283	25597446
OVCH1	1	0	0.213333	0	0	OVCH1	12	12p11.22	29471756	29541887
TMTC1	1	0.013333	0.12	0	0	TMTC1	12	12p11.22	29545024	29828960
FAM60A	1	0.186667	0.12	0.222222	0	FAM60A	12	12p11.21	31324794	31370389

TABLE 2-continued

Gene list for predicting prostate cancer relapse using prostate cancer tissue											
Symbol	freq. use	freq. amp. c②	freq. del. c②	freq. amp. c②	freq. del. c②	Gene. Syn②	chromo- sor②	cyto- band	Trans- script②	Trans- script. end	
SRGAP1	1	0.146667	0.04	0	0	SRGAP1	12	12q14.2	62524808	62827881	
RASSF3	1	0.16	0.013333	0	0.037037	RASSF3	12	12q14.2	63290560	63375460	
UHRF1BP1②	1	0.133333	0.093333	0	0	UHRF1BP1②	12	12q23.1	98954994	99060774	
MIR1827	1	0.213333	0.026667	0	0	MIR1827	12	12q23.1	99107793	99107859	
SCYL2	1	0.145667	0.026667	0	0	SCYL2	12	12q23.1	99185680	99258046	
SLC17A8	1	0.133333	0.026667	0	0	SLC17A8	12	12q23.1	99274988	99339968	
NR1H4	1	0.146667	0.026667	0	0	NR1H4	12	12q23.1	99391810	99481775	
GAS2L3	1	0.146667	0.026667	0	0	GAS2L3	12	12q23.1	99491620	99542817	
SLC5A8	1	0.106667	0.133333	0.111111	0	SLC5A8	12	12q23.2	1E+08	1E+08	
PAH	1	0.093333	0.12	0.148148	0	PAH	12	12q23.2	1.02E+08	1.02E+08	
C12orf42	1	0.106667	0.12	0.148148	0	C12orf42	12	12q23.2	1.02E+08	1.02E+08	
BTBD10	1	0.093333	0.12	0.148148	0	BTBD10	11	11p15.2	13366132	13441415	
OR5B12	1	0.08	0.133333	0.148148	0	OR5B12	11	11q12.1	57963256	57964201	
LPXN	1	0.08	0.133333	0.148148	0	LPXN	11	11q12.1	58050922	58102216	
RAB30	1	0.12	0.04	0	0	RAB30	11	11q14.1	82370126	82460533	
CCDC90B	1	0.053333	0.12	0	0	CCDC90B	11	11q14.1	82650150	82675026	
FAT3	1	0.04	0.173333	0	0	FAT3	11	11q14.3	91724910	92269284	
BIRC3	1	0.133333	0.066667	0	0.074074	BIRC3	11	11q22.2	1.02E+08	1.02E+08	
MMP7	1	0.12	0.066667	0	0.074074	MMP7	11	11q22.2	1.02E+08	1.02E+08	
DDX10	1	0.066667	0.16	0.111111	0	DDX10	11	11q22.3	1.08E+08	1.08E+08	
FRMPD2	1	0.226667	0.16	0.37037	0	FRMPD2	10	10q11.22	49034608	49152948	
ERCC6	1	0.226667	0.173333	0.333333	0	ERCC6	10	10q11.23	50334497	50417154	
PGBD3	1	0.226667	0.173333	0.333333	0	PGBD3	10	10q11.23	50393250	50402333	
SGMS1	1	0.133333	0.133333	0.222222	0	SGMS1	10	10q11.23	51735351	52053744	
FAM13C	1	0.12	0.133333	0	0.074074	FAM13C	10	10q21.1	60675896	60792359	
ARID5B	1	0.146667	0.026667	0	0	ARID5B	10	10q21.2	63331449	63526710	
ADO	1	0.146667	0.04	0	0	ADO	10	10q21.2	64234522	64238246	
EGR2	1	0.146667	0.04	0	0	EGR2	10	10q21.2	64241766	64246133	
JMJD1C	1	0.173333	0.026667	0	0	JMJD1C	10	10q21.2	64596994	64698989	
REEP3	1	0.173333	0.04	0	0	REEP3	10	10q21.3	64951129	65051979	
SLC24A2	1	0.026667	0.173333	0.037037	0	SLC24A2	9	9p22.1	19505978	19776927	
MLLT3	1	0.026667	0.133333	0	0	MLLT3	9	9p21.3	20334968	20612515	
IFNA13	1	0.04	0.146667	0	0	IFNA13	9	9p21.3	21357371	21358076	
IFNA1	1	0.026667	0.16	0	0	IFNA1	9	9p21.3	21430440	21431316	
LOC5542②	1	0.026667	0.16	0	0	LOC5542②	9	9p21.3	21444267	21549698	
IFNE	1	0.026667	0.16	0	0	IFNE	9	9p21.3	21470841	21472313	
1-Dec	1	0.12	0.133333	0.333333	0	1-Dec	9	9q33.1	1.17E+08	1.17E+08	
PAPPA	1	0.093333	0.12	0.259259	0	PAPPA	9	9q33.1	1.18E+08	1.18E+08	
TUBBP5	1	0.573333	0.12	0.851852	0	TUBBP5	9	9q34.3	1.4E+08	1.4E+08	
TMEM66	1	0.12	0.36	0	0.185185	TMEM66	8	8p12	30040173	30060192	
LEPROTL1	1	0.12	0.36	0	0.185185	LEPROTL1	8	8p12	30072464	30114755	
MBOAT4	1	0.12	0.36	0	0.185185	MBOAT4	8	8p12	30108729	30121743	
DCTN6	1	0.12	0.36	0	0.185185	DCTN6	8	8p12	30133355	30160603	
RBPMS	1	0.133333	0.36	0	0.185185	RBPMS	8	8p12	30361486	30549277	
UBXN8	1	0.186667	0.373333	0	0.185185	UBXN8	8	8p12	30721232	30744063	
TEX15	1	0.133333	0.386667	0	0.222222	TEX15	8	8p12	30808602	30826076	
BEYLA	1	0.173333	0.186667	0.185185	0	BEYLA	8	8q11.1	47871673	47886573	
NKAIN3	1	0.106667	0.133333	0.111111	0	NKAIN3	8	8q12.3	63324055	64066183	
STEAP1	1	0.146667	0.12	0	0.185185	STEAP1	7	7q21.13	89621625	89632078	
GTPBP10	1	0.12	0.053333	0	0.074074	GTPBP10	7	7q21.13	89813926	89854587	
CLDN12	1	0.12	0.053333	0	0.074074	CLDN12	7	7q21.13	89870732	89883205	
ENPP5	1	0.04	0.133333	0.111111	0	ENPP5	6	6p12.3	46235721	46246677	
CYP39A1	1	0.04	0.12	0.074074	0	CYP39A1	6	6p12.3	46525404	46728483	
MEP1A	1	0.04	0.12	0.074074	0	MEP1A	6	6p12.3	46869053	46915479	
SMAP1	1	0.186667	0.146667	0	0.185185	SMAP1	6	6q13	71434200	71628438	
C6orf147	1	0.2	0.186667	0	0.111111	C6orf147	6	6q13	74040583	74076810	
DDX43	1	0.186667	0.186667	0	0.111111	DDX43	6	6q13	74161006	74184004	
MTO1	1	0.173333	0.2	0	0.111111	MTO1	6	6q13	74228175	74267901	
SLC17A5	1	0.186667	0.186667	0	0.111111	SLC17A5	6	6q13	74359823	74420459	
CD109	1	0.12	0.16	0	0.111111	CD109	6	6q13	74462229	74594761	
MYO6	1	0.146667	0.173333	0	0.222222	MYO6	6	6q14.1	76515629	76685975	
GABRR1	1	0.12	0.2	0	0.185185	GABRR1	6	6q15	89943942	89984216	
GABRR2	1	0.133333	0.2	0	0.185185	GABRR2	6	6q15	90023958	90081687	
RRAGD	1	0.133333	0.2	0	0.185185	RRAGD	6	6q15	90131056	90178715	
ANKRD6	1	0.12	0.2	0	0.185185	ANKRD6	6	6q15	90199616	90400125	
GJA1	1	0.133333	0.213333	0	0.296296	GJA1	6	6q22.31	1.22E+08	1.22E+08	
ARHGAP18	1	0.013333	0.146667	0.037037	0	ARHGAP18	6	6q22.33	1.3E+08	1.3E+08	
C6orf191	1	0.013333	0.133333	0	0	C6orf191	6	6q22.33	1.3E+08	1.3E+08	
L3MBTL3	1	0.013333	0.133333	0	0	L3MBTL3	6	6q23.1	1.3E+08	1.31E+08	
SAMD3	1	0.026667	0.12	0	0	SAMD3	6	6q23.1	1.31E+08	1.31E+08	
RPS12	1	0.146667	0.026667	0	0	RPS12	6	6q23.2	1.33E+08	1.33E+08	
SNORD101	1	0.146667	0.026667	0	0	SNORD101	6	6q23.2	1.33E+08	1.33E+08	

TABLE 2-continued

Gene list for predicting prostate cancer relapse using prostate cancer tissue										
Symbol	freq. use	freq. amp. c②	freq. del. c②	freq. amp. c②	freq. del. c②	Gene. Syn②	chromo- sor②	cyto- band	Trans- script②	Trans- script.end
SNORD100	1	0.133333	0.04	0	0	SNORD100	6	6q23.2	1.33E+08	1.33E+08
SNORA33	1	0.133333	0.04	0	0	SNORA33	6	6q23.2	1.33E+08	1.33E+08
EYA4	1	0	0.133333	0	0	EYA4	6	6q23.2	1.34E+08	1.34E+08
AHI1	1	0	0.146667	0	0	AHI1	6	6q23.3	1.36E+08	1.36E+08
ADAT2	1	0	0.133333	0	0	ADAT2	6	6q24.2	1.44E+08	1.44E+08
CKMT2	1	0.12	0.093333	0	0.037037	CKMT2	5	5q14.1	80564895	80597974
DMXL1	1	0.16	0.106667	0	0.111111	DMXL1	5	5q23.1	1.18E+08	1.19E+08
LARS	1	0.16	0	0	0.037037	LARS	5	5q32	1.45E+08	1.46E+08
RBM27	1	0.16	0	0	0.037037	RBM27	5	5q32	1.46E+08	1.46E+08
ZNF718	1	0.253333	0.133333	0.703704	0	ZNF718	4	4p16.3	43277	146491
MIR572	1	0.04	0.12	0.074074	0	MIR572	4	4p15.33	10979549	10979643
C1QTNF7	1	0.013333	0.133333	0	0	C1QTNF7	4	4p15.33	14950658	15056889
CD38	1	0.12	0.053333	0	0	CD38	4	4p15.32	15389029	15459805
FGFBP1	1	0.133333	0.053333	0	0	FGFBP1	4	4p15.32	15546290	15549070
PROM1	1	0.133333	0.053333	0	0	PROM1	4	4p15.32	15578947	15694693
TAPT1	1	0.026667	0.146667	0	0	TAPT1	4	4p15.32	15771226	15837260
FLJ39653	1	0.026667	0.146667	0	0	FLJ39653	4	4p15.32	15837384	15868909
LDB2	1	0.026667	0.133333	0	0	LDB2	4	4p15.32	16112262	16509523
QDPR	1	0.146667	0.04	0	0	QDPR	4	4p15.32	17097118	17122956
CLRN2	1	0.146667	0.04	0	0	CLRN2	4	4p15.32	17125886	17137826
LAP3	1	0.146667	0.04	0	0	LAP3	4	4p15.32	17188025	17218689
FAM184B	1	0.146667	0.04	0	0	FAM184B	4	4p15.32	17242809	17392234
DCAF16	1	0.146667	0.04	0	0	DCAF16	4	4p15.32	17411376	17421480
GPR125	1	0.026667	0.226667	0	0	GPR125	4	4p15.31	21998097	22126771
GBA3	1	0.026667	0.213333	0	0	GBA3	4	4p15.31	22303646	22430291
PARM1	1	0.04	0.146667	0	0	PARM1	4	4q13.3	76077322	76194348
FRAS1	1	0.026667	0.12	0	0	FRAS1	4	4q21.21	79197748	79586810
SLC10A6	1	0.12	0.026667	0	0	SLC10A6	4	4q21.3	87963645	87989441
AFF1	1	0.146667	0.013333	0	0	AFF1	4	4q21.3	88075178	88281230
KLHL8	1	0.12	0.013333	0	0	KLHL8	4	4q22.1	88301238	88360699
HSD17B13	1	0.12	0.013333	0	0	HSD17B13	4	4q22.1	88443965	88463081
HSD17B11	1	0.12	0.013333	0	0	HSD17B11	4	4q22.1	88476715	88531480
NUDT9	1	0.12	0.013333	0	0	NUDT9	4	4q22.1	88562759	88598524
SPARCL1	1	0.12	0.013333	0	0	SPARCL1	4	4q22.1	88613512	88669680
PHF17	1	0.133333	0.08	0	0.185185	PHF17	4	4q28.2	1.3E+08	1.3E+08
HHIP	1	0.04	0.12	0	0	HHIP	4	4q31.22	1.46E+08	1.46E+08
TBC1D5	1	0.053333	0.16	0.148148	0	TBC1D5	3	3p24.3	17173659	17759245
LOC285401	1	0.013333	0.146667	0.037037	0	LOC285401	3	3p14.2	63063404	63085776
SYNPR	1	0.026667	0.133333	0.037037	0	SYNPR	3	3p14.2	63238954	63577638
SNTN	1	0.013333	0.12	0.037037	0	SNTN	3	3p14.2	63613384	63625932
SUCLG2	1	0.013333	0.146667	0.037037	0	SUCLG2	3	3p14.1	67507833	67787729
FAM19A4	1	0	0.133333	0.037037	0	FAM19A4	3	3p14.1	68863607	69064402
MINA	1	0.173333	0.173333	0	0.259259	MINA	3	3q11.2	99143351	99173915
TM4SF4	1	0.173333	0	0	0.037037	TM4SF4	3	3q25.1	1.51E+08	1.51E+08
WWTR1	1	0.133333	0	0	0.037037	WWTR1	3	3q25.1	1.51E+08	1.51E+08
SERP1	1	0.12	0	0	0	SERP1	3	3q25.1	1.52E+08	1.52E+08
EIF2A	1	0.12	0	0	0	EIF2A	3	3q25.1	1.52E+08	1.52E+08
SELT	1	0.12	0	0	0	SELT	3	3q25.1	1.52E+08	1.52E+08
FAM194A	1	0.12	0	0	0	FAM194A	3	3q25.1	1.52E+08	1.52E+08
SLAH2	1	0.12	0	0	0	SLAH2	3	3q25.1	1.52E+08	1.52E+08
KPNA4	1	0.053333	0.146667	0.037037	0	KPNA4	3	3q26.1	1.62E+08	1.62E+08
LRR1Q4	1	0.226667	0.013333	0	0.037037	LRR1Q4	3	3q26.2	1.71E+08	1.71E+08
LRRC31	1	0.226667	0.013333	0	0.037037	LRRC31	3	3q26.2	1.71E+08	1.71E+08
SAMD7	1	0.226667	0.013333	0	0.037037	SAMD7	3	3q26.2	1.71E+08	1.71E+08
LOC10012②	1	0.226667	0.013333	0	0.037037	LOC10012②	3	3q26.2	1.71E+08	1.71E+08
SEC62	1	0.226667	0.013333	0	0.037037	SEC62	3	3q26.2	1.71E+08	1.71E+08
GPR160	1	0.24	0.013333	0	0.037037	GPR160	3	3q26.2	1.71E+08	1.71E+08
PHC3	1	0.226667	0.013333	0	0.037037	PHC3	3	3q26.2	1.71E+08	1.71E+08
KCNMB2	1	0.053333	0.133333	0.037037	0	KCNMB2	3	3q26.32	1.8E+08	1.8E+08
CCDC50	1	0.133333	0.12	0	0.074074	CCDC50	3	3q28	1.93E+08	1.93E+08
MIR217	1	0	0.133333	0	0	MIR217	2	2p16.1	56063606	56063716
MIR216A	1	0	0.133333	0	0	MIR216A	2	2p16.1	56069590	56069699
MIR216B	1	0	0.133333	0	0	MIR216B	2	2p16.1	56081354	56081435
CCDC85A	1	0	0.173333	0	0	CCDC85A	2	2p16.1	56264762	56466814
NCRNA001	1	0.026667	0.12	0.074074	0	NCRNA001	2	2q21.2	1.33E+08	1.33E+08
B3GALT1	1	0.013333	0.133333	0.037037	0	B3GALT1	2	2q24.3	1.68E+08	1.68E+08
ABCB11	1	0	0.16	0.074074	0	ABCB11	2	2q31.1	1.69E+08	1.7E+08
MTX2	1	0.013333	0.133333	0.074074	0	MTX2	2	2q31.1	1.77E+08	1.77E+08
ELAVL4	1	0.08	0.16	0.333333	0	ELAVL4	1	1p33	50286273	50440128
LOC7294②	1	0.04	0.133333	0.148148	0	LOC7294②	1	1p32.1	59370198	59385068
FGGY	1	0.053333	0.12	0.111111	0	FGGY	1	1p32.1	59535213	60000991
HOOK1	1	0.04	0.146667	0.111111	0	HOOK1	1	1p32.1	60053121	60114639

TABLE 2-continued

Gene list for predicting prostate cancer relapse using prostate cancer tissue											
Symbol	freq. use	freq. amp. c②	freq. del. c②	freq. amp. c②	freq. del. c②	Gene. Syn②	chromo- sor②	cyto- band	Trans- script②	Trans- script. end	
C1orf87	1	0.053333	0.146667	0.111111	0	C1orf87	1	1p32.1	60228654	60312015	
RPE65	1	0.026667	0.133333	0.074074	0	RPE65	1	1p31.3	68667095	68688231	
ANKRD13C	1	0.133333	0.08	0	0.074074	ANKRD13C	1	1p31.1	70497273	70593006	
HHLA3	1	0.133333	0.08	0	0.074074	HHLA3	1	1p31.1	70593081	70606294	
CTH	1	0.146667	0.066667	0	0.074074	CTH	1	1p31.1	70549543	70677842	
DDAH1	1	0.013333	0.16	0.037037	0	DDAH1	1	1p22.3	85556757	85816635	
COL24A1	1	0.013333	0.146667	0.037037	0	COL24A1	1	1p22.3	85967504	86394710	
CLCA2	1	0.026667	0.173333	0	0	CLCA2	1	1p22.3	86662357	86694829	
CLCA1	1	0.026667	0.173333	0	0	CLCA1	1	1p22.3	86707114	86738563	
CLCA3P	1	0.013333	0.16	0	0	CLCA3P	1	1p22.3	86872547	86893647	
SH3GLB1	1	0.013333	0.146667	0	0	SH3GLB1	1	1p22.3	86942845	86986456	
GBP7	1	0.04	0.12	0.037037	0	GBP7	1	1p22.2	89370022	89414312	
GBP4	1	0.04	0.12	0.037037	0	GBP4	1	1p22.2	89419419	89437222	
LOC40075②	1	0.026667	0.133333	0.037037	0	LOC40075②	1	1p22.2	89645826	89663082	
LRRRC8B	1	0.013333	0.146667	0.037037	0	LRRRC8B	1	1p22.2	89762985	89836007	
LRRRC8C	1	0.013333	0.12	0.111111	0	LRRRC8C	1	1p22.2	89871232	89957682	
LRRRC8D	1	0.026667	0.12	0.074074	0	LRRRC8D	1	1p22.2	90059161	90174576	
EVIS	1	0.066667	0.12	0.111111	0	EVIS	1	1p22.1	92746841	93030550	
C1orf114	1	0.013333	0.146667	0.037037	0	C1orf114	1	1q24.2	1.68E+08	1.68E+08	
F5	1	0	0.12	0.037037	0	F5	1	1q24.2	1.68E+08	1.68E+08	
SELP	1	0	0.133333	0.037037	0	SELP	1	1q24.2	1.68E+08	1.68E+08	
SELL	1	0	0.133333	0.037037	0	SELL	1	1q24.2	1.68E+08	1.68E+08	
SELE	1	0.026667	0.12	0.037037	0	SELE	1	1q24.2	1.68E+08	1.68E+08	
C4BPA	1	0.146667	0.12	0.555556	0	C4BPA	1	1q32.2	2.05E+08	2.05E+08	
MIR548F3	1	0.04	0.146667	0.074074	0	MIR548F3	1	1q41	2.13E+08	2.13E+08	
CHRM3	1	0.026667	0.146667	0.037037	0	CHRM3	1	1q43	2.38E+08	2.38E+08	
FMN2	1	0.026667	0.133333	0.074074	0	FMN2	1	1q43	2.38E+08	2.39E+08	
GAB4	0.921569	0.333333	0.106667	0.518519	0	GAB4	22	22q11.1	15822827	15869113	
CECR6	0.921569	0.453333	0.106667	0.740741	0	CECR6	22	22q11.1	15977189	15982258	
CECR5	0.921569	0.453333	0.106667	0.740741	0	CECR5	22	22q11.1	15998410	16026178	
CECR4	0.921569	0.453333	0.106667	0.740741	0	CECR4	22	22q11.1	16020279	16026335	
CECR1	0.921569	0.453333	0.106667	0.740741	0	CECR1	22	22q11.1	16040192	16060546	
LOC64685②	0.921569	0.426667	0.106667	0.740741	0	LOC64685②	22	22q13.1	37304071	37382581	
ATF4	0.921569	0.453333	0.106667	0.814815	0	ATF4	22	22q13.1	38246515	38248638	
RPS19BP1	0.921569	0.453333	0.106667	0.814815	0	RPS19BP1	22	22q13.1	38255044	38258807	
PPARA	0.921569	0.48	0.106667	0.777778	0	PPARA	22	22q13.31	44925163	45018318	
TTC38	0.921569	0.48	0.106667	0.777778	0	TTC38	22	22q13.31	45042525	45068570	
CELSR1	0.921569	0.48	0.106667	0.777778	0	CELSR1	22	22q13.31	45135395	45311732	
HDAC10	0.921569	0.48	0.106667	0.814815	0	HDAC10	22	22q13.33	49025742	49031962	
SAPS2	0.921569	0.48	0.106667	0.814815	0	SAPS2	22	22q13.33	49128626	49230381	
ADM2	0.921569	0.48	0.106667	0.814815	0	ADM2	22	22q13.33	49266878	49271733	
MIOX	0.921569	0.48	0.106667	0.814815	0	MIOX	22	22q13.33	49272079	49275617	
LMF2	0.921569	0.48	0.106667	0.814815	0	LMF2	22	22q13.33	49288242	49293002	
NCAPH2	0.921569	0.48	0.106667	0.814815	0	NCAPH2	22	22q13.33	49293511	49305058	
SCO2	0.921569	0.48	0.106667	0.814815	0	SCO2	22	22q13.33	49308863	49310901	
DEFB115	0.921569	0.213333	0.106667	0.518519	0	DEFB115	20	20q11.21	29309128	29311097	
UQCR	0.921569	0.506667	0.106667	0.851852	0	UQCR	19	19p13.3	1548154	1556484	
TCF3	0.921569	0.506667	0.106667	0.851852	0	TCF3	19	19p13.3	1560293	1601287	
COPE	0.921569	0.48	0.106667	0.777778	0	COPE	19	19p13.1	18871323	18891200	
DDX49	0.921569	0.48	0.106667	0.777778	0	DDX49	19	19p13.11	18891494	18900437	
HOMER3	0.921569	0.48	0.106667	0.777778	0	HOMER3	19	19p13.11	18901010	18912162	
CEACAM7	0.921569	0.413333	0.106667	0.814815	0	CEACAM7	19	19q13.2	46869075	46883937	
ANKRD30B	0.921569	0.04	0.106667	0.074074	0	ANKRD30B	18	18p11.21	14738239	14842738	
CDRT4	0.921569	0.24	0.106667	0.407407	0	CDRT4	17	17p12	15280063	15311651	
PIGL	0.921569	0.32	0.106667	0.481481	0	PIGL	17	17p11.2	16051234	16170299	
TNFRSF13②	0.921569	0.453333	0.106667	0.740741	0	TNFRSF13②	17	17p11.2	16783123	16816128	
MPRIP	0.921569	0.466667	0.106667	0.740741	0	MPRIP	17	17p11.2	16886832	17029598	
PLD6	0.921569	0.466667	0.106667	0.740741	0	PLD6	17	17p11.2	17045036	17050372	
FLCN	0.921569	0.466667	0.106667	0.740741	0	FLCN	17	17p11.2	17056252	17081228	
COPS3	0.921569	0.466667	0.106667	0.740741	0	COPS3	17	17p11.2	17090864	17125317	
NT5M	0.921569	0.466667	0.106667	0.740741	0	NT5M	17	17p11.2	17147405	17191703	
MED9	0.921569	0.466667	0.106667	0.740741	0	MED9	17	17p11.2	17321025	17337260	
RASD1	0.921569	0.466667	0.106667	0.740741	0	RASD1	17	17p11.2	17338478	17340433	
PEMT	0.921569	0.466667	0.106667	0.740741	0	PEMT	17	17p11.2	17349602	17426471	
RAI1	0.921569	0.48	0.106667	0.740741	0	RAI1	17	17p11.2	17525512	17555491	
SREBF1	0.921569	0.466667	0.106667	0.740741	0	SREBF1	17	17p11.2	17655393	17681051	
MIR33B	0.921569	0.466667	0.106667	0.740741	0	MIR33B	17	17p11.2	17657875	17557971	
TOM1L2	0.921569	0.466667	0.106667	0.740741	0	TOM1L2	17	17p11.2	17687547	17816510	
LRRRC48	0.921569	0.466667	0.106667	0.740741	0	LRRRC48	17	17p11.2	17816852	17860915	
ATPAF2	0.921569	0.466667	0.106667	0.740741	0	ATPAF2	17	17p11.2	17862059	17883206	
MYO15A	0.921569	0.48	0.106667	0.740741	0	MYO15A	17	17p11.2	17952745	18023842	
ALKBH5	0.921569	0.466667	0.106667	0.740741	0	ALKBH5	17	17p11.2	18027592	18053993	

TABLE 2-continued

Gene list for predicting prostate cancer relapse using prostate cancer tissue										
Symbol	freq. use	freq. amp. c②	freq. del. c②	freq. amp. c②	freq. del. c②	Gene. Syn②	chromo- sor②	cyto- band	Trans- script②	Trans- script. end
SMCR8	0.921569	0.48	0.106667	0.740741	0	SMCR8	17	17p11.2	18159319	18172096
SHMT1	0.921569	0.48	0.106667	0.740741	0	SHMT1	17	17p11.2	18171912	18207582
EVPLL	0.921569	0.48	0.106667	0.740741	0	EVPLL	17	17p11.2	18221804	18233684
MEOX1	0.921569	0.466667	0.106667	0.777778	0	MEOX1	17	17q21.31	39073284	39094789
SOST	0.921569	0.466667	0.106667	0.777778	0	SOST	17	17q21.31	39186625	39191683
DUSP3	0.921569	0.466667	0.106667	0.777778	0	DUSP3	17	17q21.31	39199015	39211895
HS3ST2	0.921569	0.28	0.106667	0.666667	0	HS3ST2	16	16p12.1	22733361	22835161
PWRN1	0.921569	0.026667	0.106667	0.148148	0	PWRN1	15	15q11.2	22354397	22384018
AQP9	0.921569	0.04	0.106667	0.074074	0	AQP9	15	15q22.1	56217700	56265403
LOC91948	0.921569	0.04	0.106667	0.111111	0	LOC91948	15	15q26.2	96086850	96218664
ABHD12B	0.921569	0.106667	0	0	0.037037	ABHD12B	14	14q22.1	50408628	50441439
PYGL	0.921569	0.106667	0	0	0.037037	PYGL	14	14q22.1	50441686	50480999
PSPC1	0.921569	0.093333	0.106667	0.333333	0	PSPC1	13	13q12.11	19146896	19255084
DHRS12	0.921569	0.106667	0.226667	0	0.148148	DHRS12	13	13q14.3	51240132	51276295
FLI37307	0.921569	0.106667	0.226667	0	0.148148	FLI37307	13	13q14.3	51285484	51317288
ATP7B	0.921569	0.106667	0.226667	0	0.148148	ATP7B	13	13q14.3	51404806	51483632
ALG11	0.921569	0.106667	0.226667	0	0.148148	ALG11	13	13q14.3	51484551	51501782
UTP14C	0.921569	0.106667	0.226667	0	0.148148	UTP14C	13	13q14.3	51496828	51505736
NEK5	0.921569	0.106667	0.226667	0	0.148148	NEK5	13	13q14.3	51536901	51601216
NEK3	0.921569	0.106667	0.226667	0	0.148148	NEK3	13	13q14.3	51604780	51631998
THSD1	0.921569	0.106667	0.226667	0	0.148148	THSD1	13	13q14.3	51849305	51878631
HNRNPA1L	0.921569	0.106667	0.226667	0	0.148148	HNRNPA1L	13	13q14.3	52089606	52115921
LECT1	0.921569	0.106667	0.226667	0	0.148148	LECT1	13	13q14.3	52175400	52211949
ITPR2	0.921569	0.013333	0.106667	0.037037	0	ITPR2	12	12p11.23	26379552	26877399
CSRP2	0.921569	0.106667	0.106667	0	0.111111	CSRP2	12	12q21.2	75776627	75796931
PAWR	0.921569	0.106667	0.12	0	0.296296	PAWR	12	12q21.2	78509876	78608922
NEDD1	0.921569	0.066667	0.106667	0.074074	0	NEDD1	12	12q23.1	95825132	95871593
ANO4	0.921569	0.066667	0.106667	0	0	ANO4	12	12q23.1	99712505	1E+D8
GVIN1	0.921569	0.053333	0.106667	0.037037	0	GVIN1	11	11p15.4	6690954	6699687
APIP	0.921569	0.053333	0.106667	0.074074	0	APIP	11	11p13	34860419	34894516
FAM181B	0.921569	0.04	0.106667	0	0	FAM181B	11	11q14.1	82120694	82122555
HEPHL1	0.921569	0.04	0.106667	0.074074	0	HEPHL1	11	11q21	93394026	93487023
HTR3B	0.921569	0.213333	0.106667	0.37037	0	HTR3B	11	11q23.2	1.13E+08	1.13E+08
FLJ35024	0.921569	0.013333	0.106667	0.037037	0	FLJ35024	9	9p24.2	2525655	2612374
RFX3	0.921569	0.026667	0.106667	0.037037	0	RFX3	9	9p24.2	3214647	3515984
FREM1	0.921569	0.026667	0.106667	0	0	FREM1	9	9p22.3	14727151	14900235
BNC2	0.921569	0.04	0.106667	0.074074	0	BNC2	9	9p22.3	16399501	16860787
TLE4	0.921569	0.053333	0.106667	0.111111	0	TLE4	9	9q21.31	81376698	81531477
RASEF	0.921569	0.093333	0.106667	0.185185	0	RASEF	9	9q21.32	84787137	84867864
CCDC129	0.921569	0.053333	0.106667	0.037037	0	CCDC129	7	7p15.1	31523503	31659829
PDE1C	0.921569	0.053333	0.106667	0.037037	0	PDE1C	7	7p14.3	31795772	32077517
C7orf53	0.921569	0.106667	0.04	0	0.074074	C7orf53	7	7q31.1	1.12E+08	1.12E+08
CAV1	0.921569	0.106667	0.08	0	0.111111	CAV1	7	7q31.2	1.16E+08	1.16E+08
LOC10028②	0.921569	0.04	0.106667	0.074074	0	LOC10028②	6	6p12.3	46822658	46834901
IBTK	0.921569	0.106667	0.226667	0	0.333333	IBTK	6	6q14.1	82936675	83014168
PNRC1	0.921569	0.106667	0.2	0	0.185185	PNRC1	6	6q15	89847148	89851599
SFRS13B	0.921569	0.106667	0.2	0	0.185185	SFRS13B	6	6q15	89862397	89884520
CD180	0.921569	0.106667	0.146667	0	0.148148	CD180	5	5q13.1	66513860	66528374
ZCCHC9	0.921569	0.106667	0.106667	0	0.037037	ZCCHC9	5	5q14.1	80633158	80644720
ACOT12	0.921569	0.106667	0.106667	0	0.037037	ACOT12	5	5q14.1	80661703	80725745
PJA2	0.921569	0.106667	0.16	0	0.185185	PJA2	5	5q21.3	1.09E+08	1.09E+08
CDS1	0.921569	0.04	0.106667	0	0	CDS1	4	4q21.23	85723081	85791518
PTPN13	0.921569	0.106667	0.053333	0	0	PTPN13	4	4q21.3	87734492	87955353
OSTC	0.921569	0.106667	0	0	0.037037	OSTC	4	4q25	1.1E+08	1.1E+08
GAB1	0.921569	0.013333	0.106667	0	0	GAB1	4	4q31.21	1.44E+08	1.45E+08
SMARCA5	0.921569	0.013333	0.106667	0	0	SMARCA5	4	4q31.21	1.45E+08	1.45E+08
LOC4410②	0.921569	0.013333	0.106667	0	0	LOC4410②	4	4q31.21	1.45E+08	1.45E+08
FREM3	0.921569	0.013333	0.106667	0	0	FREM3	4	4q31.21	1.45E+08	1.45E+08
SCN10A	0.921569	0.106667	0.106667	0.259259	0	SCN10A	3	3p22.2	38713841	38810506
FHIT	0.921569	0.066667	0.106667	0.148148	0	FHIT	3	3p14.2	59710076	61212174
C3orf49	0.921569	0.026667	0.106667	0.037037	0	C3orf49	3	3p14.1	63780081	63809351
PROS1	0.921569	0.106667	0.173333	0	0.37037	PROS1	3	3q11.2	95074572	95175625
TMEM108	0.921569	0.066667	0.106667	0.074074	0	TMEM108	3	3q22.1	1.34E+08	1.35E+08
GYG1	0.921569	0.106667	0.026667	0	0.074074	GYG1	3	3q24	1.5E+08	1.5E+08
IQCJ	0.921569	0.053333	0.106667	0.037037	0	IQCJ	3	3q25.33	1.6E+08	1.6E+08
NMD3	0.921569	0.106667	0.04	0	0.074074	NMD3	3	3q26.1	1.62E+08	1.62E+08
TBL1XR1	0.921569	0.106667	0.013333	0	0	TBL1XR1	3	3q26.32	1.78E+08	1.78E+08
UTS2D	0.921569	0.106667	0.12	0	0.074074	UTS2D	3	3q28	1.92E+08	1.93E+08
LOC10027②	0.921569	0.013333	0.106667	0.074074	0	LOC10027②	2	2p22.1	39000093	39056093
SOS1	0.921569	0.013333	0.106667	0.074074	0	SOS1	2	2p22.1	39062194	39201109
GTF2A1L	0.921569	0.04	0.106667	0.222222	0	GTF2A1L	2	2p16.3	48698452	48813791
LHCGR	0.921569	0.04	0.106667	0.222222	0	LHCGR	2	2p16.3	48767417	48836385

TABLE 2-continued

Gene list for predicting prostate cancer relapse using prostate cancer tissue										
Symbol	freq. use	freq. amp. c②	freq. del. c②	freq. amp. c②	freq. del. c②	Gene. Syn②	chromo- sor②	cyto- band	Trans- script②	Trans- script. end
SGK1	0.009804	0.133333	0.026667	0.037037	0	SGK1	6	6q23.2	1.35E+08	1.35E+08
ALDH8A1	0.009804	0.12	0.026667	0.037037	0	ALDH8A1	6	6q23.3	1.35E+08	1.35E+08
C6orf217	0.009804	0	0.16	0	0.037037	C6orf217	6	6q23.3	1.36E+08	1.36E+08
PDE7B	0.009804	0	0.173333	0	0.037037	PDE7B	6	6q23.3	1.36E+08	1.37E+08
NHSL1	0.009804	0.146667	0.04	0.037037	0	NHSL1	6	6q23.3	1.39E+08	1.39E+08
CCDC28A	0.009804	0.146667	0.04	0.037037	0	CCDC28A	6	6q24.1	1.39E+08	1.39E+08
ECT2L	0.009804	0.146667	0.04	0.037037	0	ECT2L	6	6q24.1	1.39E+08	1.39E+08
C6orf115	0.009804	0.146667	0.04	0.037037	0	C6orf115	6	6q24.1	1.39E+08	1.39E+08
HECA	0.009804	0.146667	0.04	0.037037	0	HECA	6	6q24.1	1.39E+08	1.4E+08
TXLNB	0.009804	0.146667	0.04	0.037037	0	TXLNB	6	6q24.1	1.4E+08	1.4E+08
LOC15391②	0.009804	0	0.146667	0.037037	0.037037	LOC15391②	6	6q24.1 - 6c	1.43E+08	1.43E+08
MLLT4	0.009804	0.186667	0.106667	0.37037	0.037037	MLLT4	6	6q27	1.68E+08	1.68E+08
BASP1	0.009804	0.146667	0.013333	0.037037	0.037037	BASP1	5	5p15.1	17270750	17329944
TTC33	0.009804	0.173333	0	0.037037	0	TTC33	5	5p13.1	40747435	40791830
PRKAA1	0.009804	0.173333	0	0.037037	0	PRKAA1	5	5p13.1	40795238	40834055
RPL37	0.009804	0.173333	0	0.037037	0	RPL37	5	5p13.1	40867187	40871145
SNORD72	0.009804	0.173333	0	0.037037	0	SNORD72	5	5p13.1	40868515	40868595
CARD6	0.009804	0.173333	0	0.037037	0	CARD6	5	5p13.1	40877167	40891214
C7	0.009804	0.04	0.12	0	0.037037	C7	5	5p13.1	40945356	41018799
HEATR7B2	0.009804	0.013333	0.12	0	0.037037	HEATR7B2	5	5p13.1	41033879	41107202
C6	0.009804	0.013333	0.133333	0	0.037037	C6	5	5p13.1	41178093	41249425
PLCXD3	0.009804	0.013333	0.133333	0	0.037037	PLCXD3	5	5p13.1	41342805	41546488
OXCT1	0.009804	0.013333	0.12	0	0.037037	OXCT1	5	5p13.1	41765924	41906549
C5orf51	0.009804	0.013333	0.12	0	0.037037	C5orf51	5	5p13.1	41940227	41957496
FBXO4	0.009804	0.013333	0.12	0	0.037037	FBXO4	5	5p13.1	41961113	41977430
GHR	0.009804	0.013333	0.133333	0	0.037037	GHR	5	5p12	42459783	42757684
SEPP1	0.009804	0.04	0.12	0	0.037037	SEPP1	5	5p12	42835739	42847782
MGC42105	0.009804	0.146667	0	0.037037	0	MGC42105	5	5p12	43228084	43316710
HMGCS1	0.009804	0.146667	0	0.037037	0	HMGCS1	5	5p12	43325250	43349353
C5orf28	0.009804	0.16	0.013333	0.037037	0	C5orf28	5	5p12	43480111	43519750
PAIP1	0.009804	0.133333	0.04	0.037037	0	PAIP1	5	5p12	43562127	43592953
ARL15	0.009804	0.04	0.16	0	0.037037	ARL15	5	5q11.2	53216371	53642161
HSPB3	0.009804	0.026667	0.146667	0	0.037037	HSPB3	5	5q11.2	53787202	53787965
GZMA	0.009804	0.04	0.16	0.037037	0.057037	GZMA	5	5q11.2	54434231	54441838
CDC20B	0.009804	0.04	0.16	0.037037	0.037037	CDC20B	5	5q11.2	54444556	54504763
CCNO	0.009804	0.08	0.133333	0.037037	0.037037	CCNO	5	5q11.2	54562738	54565266
DHX29	0.009804	0.08	0.133333	0.037037	0.037037	DHX29	5	5q11.2	54587830	54639279
SKIV2L2	0.009804	0.08	0.133333	0.037037	0.037037	SKIV2L2	5	5q11.2	54639333	54757167
PPAP2A	0.009804	0.08	0.146667	0.037037	0.037037	PPAP2A	5	5q11.2	54756440	54866631
SLC38A9	0.009804	0.093333	0.146667	0.037037	0.037037	SLC38A9	5	5q11.2	54957433	55043921
BDP1	0.009804	0.146667	0.12	0.037037	0.074074	BDP1	5	5q13.2	70787198	70899406
MCCC2	0.009804	0.133333	0.12	0.037037	0.074074	MCCC2	5	5q13.2	70918871	70990287
TMEM174	0.009804	0.08	0.12	0.037037	0.037037	TMEM174	5	5q13.2	72504779	72506725
FOXDI	0.009804	0.066667	0.106667	0.037037	0.037037	FOXDI	5	5q13.2	72777841	72780109
SV2C	0.009804	0.013333	0.16	0.037037	0.037037	SV2C	5	5q13.3	75415061	75657173
F2R	0.009804	0.146667	0.08	0.037037	0.037037	F2R	5	5q13.3	76047624	76067352
F2R11	0.009804	0.133333	0.08	0.037037	0.037037	F2R11	5	5q13.3	76150589	76166896
S100Z	0.009804	0.133333	0.08	0.037037	0.037037	S100Z	5	5q13.3	76181882	76252813
LHFPL2	0.009804	0.106667	0.08	0.037037	0.037037	LHFPL2	5	5q14.1	77816794	77980405
DMGDH	0.009804	0.08	0.133333	0.037037	0.037037	DMGDH	5	5q14.1	78329185	78401206
BHMT2	0.009804	0.133333	0.08	0.037037	0.037037	BHMT2	5	5q14.1	78401339	78421032
BHMT	0.009804	0.133333	0.08	0.037037	0.037037	BHMT	5	5q14.1	78443360	78463870
JMY	0.009804	0.133333	0.08	0.037037	0.037037	JMY	5	5q14.1	78567710	78658793
HOMER1	0.009804	0.133333	0.08	0.037037	0.037037	HOMER1	5	5q14.1	78705542	78845457
CMYA5	0.009804	0.12	0.08	0.037037	0.037037	CMYA5	5	5q14.1	79021415	79131806
THBS4	0.009804	0.146667	0.08	0.037037	0.037037	THBS4	5	5q14.1	79366747	79414864
SERINC5	0.009804	0.146667	0.08	0.037037	0.037037	SERINC5	5	5q14.1	79443230	79587627
FAM151B	0.009804	0.146667	0.093333	0.037037	0.037037	FAM151B	5	5q14.1	79819556	79873963
MSH3	0.009804	0.08	0.12	0.037037	0.037037	MSH3	5	5q14.1	79986050	80208391
3-Mar	0.009804	0.106667	0.08	0.037037	0.074074	3-Mar	5	5q23.2	1.26E+08	1.26E+08
STK32A	0.009804	0.013333	0.133333	0	0.037037	STK32A	5	5q32	1.47E+08	1.47E+08
TTC1	0.009804	0.133333	0.026667	0.037037	0.074074	TTC1	5	5q33.3	1.59E+08	1.59E+08
HSP90AB2②	0.009804	0.013333	0.146667	0	0.037037	HSP90AB2②	4	4p15.33	12944135	12949024
RAB28	0.009804	0.013333	0.16	0	0.037037	RAB28	4	4p15.33	12978445	13095088
KCNIP4	0.009804	0.026667	0.213333	0	0.037037	KCNIP4	4	4p15.31	20339337	21308417
PPARGC1A	0.009804	0.026667	0.226667	0	0.037037	PPARGC1A	4	4p15.2	23402742	23500799
LGI2	0.009804	0.106667	0.053333	0.037037	0	LGI2	4	4p15.2	24609569	24641513
SEPSECS	0.009804	0.12	0.066667	0.037037	0	SEPSECS	4	4p15.2	24730726	24771303
PI4K2B	0.009804	0.12	0.053333	0.037037	0	PI4K2B	4	4p15.2	24844751	24889930
ZCCHC4	0.009804	0.12	0.053333	0.037037	0	ZCCHC4	4	4p15.2	24923494	24981104
TLR10	0.009804	0.053333	0.186667	0.037037	0.037037	TLR10	4	4p14	38450647	38460985
UCHL1	0.009804	0.106667	0.053333	0.037037	0	UCHL1	4	4p13	40953655	40965203

TABLE 2-continued

Gene list for predicting prostate cancer relapse using prostate cancer tissue										
Symbol	freq. use	freq. amp. c②	freq. del. c②	freq. amp. c②	freq. del. c②	Gene. Syn②	chromo- sor②	cyto- band	Tran- script②	Tran- script. end
LIMCH1	0.009804	0.106667	0.053333	0.037037	0	LIMCH1	4	4p13	41057561	41396819
PHOX2B	0.009804	0.133333	0.066667	0.037037	0	PHOX2B	4	4p13	41440856	41445745
TMEM33	0.009804	0.146667	0.053333	0.037037	0	TMEM33	4	4p13	41631894	41657582
SLC30A9	0.009804	0.16	0.053333	0.037037	0.037037	SLC30A9	4	4p13	41687280	41784309
BEND4	0.009804	0.16	0.053333	0.037037	0.037037	BEND4	4	4p13	41807629	41849653
RASL11B	0.009804	0.12	0	0.037037	0	RASL11B	4	4q12	53423252	53427760
SCFD2	0.009804	0.12	0	0.037037	0	SCFD2	4	4q12	53433908	53927000
PDGFRA	0.009804	0.106667	0.013333	0.037037	0	PDGFRA	4	4q12	54790021	54859170
AFP	0.009804	0.04	0.133333	0	0.037037	AFP	4	4q13.3	74520797	74540357
AFM	0.009804	0.04	0.133333	0	0.037037	AFM	4	4q13.3	74566326	74588583
RASSF6	0.009804	0.04	0.12	0	0.037037	RASSF6	4	4q13.3	74657726	74704999
CXCL6	0.009804	0.04	0.146667	0	0.037037	CXCL6	4	4q13.3	74921137	74923342
PPBPL1	0.009804	0.04	0.146667	0	0.037037	PPBPL1	4	4q13.3	74932447	74933418
PF4	0.009804	0.04	0.146667	0	0.037037	PF4	4	4q13.3	75065660	75066580
PPBP	0.009804	0.04	0.146667	0	0.037037	PPBP	4	4q13.3	75071620	75072765
CXCL3	0.009804	0.04	0.146667	0	0.037037	CXCL3	4	4q13.3	75121176	75123355
CXCL2	0.009804	0.04	0.146667	0	0.037037	CXCL2	4	4q13.3	75181618	75183862
MTHFD2L	0.009804	0.04	0.16	0	0.037037	MTHFD2L	4	4q13.3	75242693	75387677
AREG	0.009804	0.04	0.146667	0	0.037037	AREG	4	4q13.3	75699653	75709510
BTC	0.009804	0.066667	0.133333	0	0.037037	BTC	4	4q13.3	75890472	75938907
C4orf26	0.009804	0.133333	0.013333	0.037037	0	C4orf26	4	4q21.1	76700232	76708952
CDKL2	0.009804	0.106667	0.026667	0.037037	0	CDKL2	4	4q21.1	76720728	76774746
G3BP2	0.009804	0.12	0.013333	0.037037	0	G3BP2	4	4q21.1	76786977	76817368
ARD1B	0.009804	0.026667	0.226667	0	0.037037	ARD1B	4	4q21.21	80457296	80466196
GDEP	0.009804	0.026667	0.213333	0	0.037037	GDEP	4	4q21.21	80967649	81003424
PRDM8	0.009804	0.04	0.16	0	0.037037	PRDM8	4	4q21.21	81325448	81344507
C4orf22	0.009804	0.026667	0.16	0	0.037037	C4orf22	4	4q21.21	81475898	82103927
BMP3	0.009804	0.026667	0.186667	0	0.037037	BMP3	4	4q21.21	82171143	82197710
PRKG2	0.009804	0.026667	0.173333	0	0.037037	PRKG2	4	4q21.21	82228861	82345240
RASGEF1B	0.009804	0.053333	0.12	0	0.037037	RASGEF1B	4	4q21.21	82567243	82612086
TMEM15c②	0.009804	0.173333	0.04	0.037037	0	TMEM15c②	4	4q21.22	83624628	83702151
SCD5	0.009804	0.173333	0.04	0.037037	0	SCD5	4	4q21.22	83769714	83939035
SEC31A	0.009804	0.173333	0.04	0.037037	0	SEC31A	4	4q21.22	83958838	84031425
COPS4	0.009804	0.173333	0.04	0.037037	0	COPS4	4	4q21.22	84175263	84215996
PLAC8	0.009804	0.173333	0.04	0.037037	0	PLAC8	4	4q21.22	84230235	84250037
COQ2	0.009804	0.173333	0.04	0.037037	0	COQ2	4	4q21.23	84404002	84425092
HPSE	0.009804	0.173333	0.04	0.037037	0	HPSE	4	4q21.23	84435492	84475059
HELQ	0.009804	0.173333	0.04	0.037037	0	HELQ	4	4q21.23	84547523	84596050
MRPS18C	0.009804	0.173333	0.04	0.037037	0	MRPS18C	4	4q21.23	84596142	84601954
FAM175A	0.009804	0.173333	0.04	0.037037	0	FAM175A	4	4q21.23	84601120	84625315
AGPAT9	0.009804	0.173333	0.04	0.037037	0	AGPAT9	4	4q21.23	84676677	84746051
C4orf12	0.009804	0.026667	0.133333	0	0.037037	C4orf12	4	4q21.23	86106995	86147193
MAPK10	0.009804	0.026667	0.146667	0	0.037037	MAPK10	4	4q21.3	87155300	87593308
PKD2	0.009804	0.12	0.013333	0.037037	0	PKD2	4	4q22.1	89147844	89217954
ABCG2	0.009804	0.12	0.013333	0.037037	0	ABCG2	4	4q22.1	89230440	89299036
PPM1K	0.009804	0.133333	0.013333	0.037037	0	PPM1K	4	4q22.1	89400556	89424913
HERC6	0.009804	0.12	0.013333	0.037037	0	HERC6	4	4q22.1	89518915	89583272
HERC5	0.009804	0.12	0.013333	0.037037	0	HERC5	4	4q22.1	89597291	89646338
PIGY	0.009804	0.12	0.013333	0.037037	0	PIGY	4	4q22.1	89661158	89663979
ANK2	0.009804	0.16	0.053333	0.037037	0.074074	ANK2	4	4q25	1.14E+08	1.15E+08
CEP170L	0.009804	0.12	0.16	0.037037	0.185185	CEP170L	4	4q26	1.2E+08	1.2E+08
MFSD8	0.009804	0.146667	0.08	0.037037	0.111111	MFSD8	4	4q28.1 - 4c	1.29E+08	1.29E+08
C4orf29	0.009804	0.146667	0.08	0.037037	0.111111	C4orf29	4	4q28-2	1.29E+08	1.29E+08
LARP1B	0.009804	0.146667	0.066667	0.037037	0.111111	LARP1B	4	4q28.2	1.29E+08	1.29E+08
USP38	0.009804	0.013333	0.186667	0	0.037037	USP38	4	4q31.21	1.44E+08	1.44E+08
GYP A	0.009804	0.013333	0.16	0	0.037037	GYP A	4	4q31.22	1.45E+08	1.45E+08
TMEM18c②	0.009804	0.12	0	0.037037	0	TMEM18c②	4	4q31.23	1.49E+08	1.49E+08
PRMT10	0.009804	0.12	0	0.037037	0	PRMT10	4	4q31.23	1.49E+08	1.49E+08
ARHGAP10	0.009804	0.133333	0	0.037037	0	ARHGAP10	4	4q31.23	1.49E+08	1.49E+08
NR3C2	0.009804	0.106667	0	0.037037	0	NR3C2	4	4q31.23	1.49E+08	1.5E+08
DCLK2	0.009804	0.12	0.026667	0.037037	0.037037	DCLK2	4	4q31.3	1.51E+08	1.51E+08
LRBA	0.009804	0.133333	0.037037	0.037037	0.037037	LRBA	4	4q31.3	1.51E+08	1.52E+08
ANXA2P1	0.009804	0.186667	0.013333	0.037037	0.037037	ANXA2P1	4	4q31.3	1.54E+08	1.54E+08
MND1	0.009804	0.186667	0.013333	0.037037	0.037037	MND1	4	4q31.3	1.54E+08	1.55E+08
KIAA0922	0.009804	0.186667	0.013333	0.037037	0.037037	KIAA0922	4	4q31.3	1.55E+08	1.55E+08
DCHS2	0.009804	0.026667	0.12	0	0.037037	DCHS2	4	4q32.1	1.55E+08	1.56E+08
FGB	0.009804	0.026667	0.12	0	0.037037	FGB	4	4q32.1	1.56E+08	1.56E+08
FGA	0.009804	0.026667	0.12	0	0.037037	FGA	4	4q32.1	1.56E+08	1.56E+08
FGG	0.009804	0.026667	0.12	0	0.037037	FGG	4	4q32.1	1.56E+08	1.56E+08
RBM46	0.009804	0.026667	0.12	0	0.037037	RBM46	4	4q32.1	1.56E+08	1.56E+08
RXFP1	0.009804	0.08	0.106667	0	0.037037	RXFP1	4	4q32.1	1.6E+08	1.6E+08
SH3RF1	0.009804	0.12	0.026667	0.037037	0.037037	SH3RF1	4	4q32.3	1.7E+08	1.7E+08

TABLE 2-continued

Gene list for predicting prostate cancer relapse using prostate cancer tissue										
Symbol	freq. use	freq. amp. c②	freq. del. cc②	freq. amp. c②	freq. del. cc②	Gene. Syn②	chromo- sor②	cyto- band	Trans- script②	Trans- script. end
RYR2	0.009804	0.146667	0.053333	0.037037	0	RYR2	1	1q43	2.35E+08	2.36E+08
AKT3	0.009804	0.026667	0.146667	0.074074	0.037037	AKT3	1	1q44	2.42E+08	2.42E+08
LOC14832②	0.009804	0.106667	0.106667	0.222222	0.037037	LOC14882②	1	1q44	2.46E+08	2.46E+08
OR2C3	0.009804	0.106667	0.106667	0.222222	0.037037	OR2C3	1	1q44	2.46E+08	2.46E+08
OR2L13	0.009804	0.066667	0.186667	0.185185	0.037037	OR2L13	1	1q44	2.46E+08	2.46E+08
OR2M5	0.009804	0.066667	0.2	0.185185	0.037037	OR2M5	1	1q44	2.46E+08	2.46E+08

② indicates text missing or illegible when filed

TABLE 3

Gene list for predicting prostate cancer fast relapse using prostate cancer tissues										
Symbol	freq.use	freq.amp.c	freq.del.cc②	freq.amp.o	freq.del.cc②	Gene.Symt	chromoson	cytoband	Transcript②	Transcript.end
VAPA	1	0.242424	0.121212	0.26087	0	VAPA	18	18p11.22	9903955	9950019
C18orf19	1	0.181818	0.121212	0.217391	0	C18orf19	18	18p11.21	13653346	13716592
RNMT	1	0.181818	0.121212	0.217391	0	RNMT	18	18p11.21	13716704	13754555
ZNF267	1	0.181818	0.121212	0.434783	0	ZNF267	16	16p11.2	31792580	31836129
COCH	1	0.121212	0.060606	0	0.115942	COCH	14	14q12	30413492	30429574
BRMS1L	1	0.151515	0.060606	0	0.057971	BRMS1L	14	14q13.2	35365348	35410921
OTX2OS1	1	0.121212	0.060606	0	0.014493	OTX2OS1	14	14q23.1	56349654	56467302
TMEM30B	1	0.090909	0.121212	0.086957	0	TMEM30B	14	14q23.1	60813842	60818284
PRKCH	1	0.090909	0.121212	0.086957	0	PRKCH	14	14q23.1	60858268	61087452
HIF1A	1	0.090909	0.121212	0.072464	0	HIF1A	14	14q23.2	61231872	61284731
FAM71D	1	0.181818	0.121212	0.188406	0	FAM71D	14	14q23.3	66725899	66765021
MPP5	1	0.181818	0.121212	0.188406	0	MPP5	14	14q23.3	66777774	66872290
VTI1B	1	0.212121	0.121212	0.217391	0	VTI1B	14	14q24.1	67187619	67211356
RDH11	1	0.212121	0.121212	0.217391	0	RDH11	14	14q24.1	67213271	67232264
RDH12	1	0.212121	0.121212	0.217391	0	RDH12	14	14q24.1	67238356	67270922
ZFYVE26	1	0.212121	0.121212	0.217391	0	ZFYVE26	14	14q24.1	67282990	67353060
ACTN1	1	0.30303	0.121212	0.289855	0	ACTN1	14	14q24.1	68410593	68515837
GALNTL1	1	0.242424	0.151515	0.289855	0	GALNTL1	14	14q24.1	68796434	68890944
FLJ44817	1	0.242424	0.151515	0.289855	0	FLJ44817	14	14q24.1	69021224	69064969
KIAA0247	1	0.212121	0.151515	0.289855	0	KIAA0247	14	14q24.1	69148063	69251613
LOC10028②	1	0.212121	0.151515	0.289855	0	LOC10028②	14	14q24.1-1	69302753	69304184
SFRS5	1	0.212121	0.151515	0.289855	0	SFRS5	14	14q24.1-1	69303582	69308476
SLC10A1	1	0.212121	0.151515	0.289855	0	SLC10A1	14	14q24.2	69312305	69333760
SLC8A3	1	0.151515	0.151515	0.26087	0	SLC8A3	14	14q24.2	69580687	69616677
SYNJ2BP	1	0.121212	0.121212	0.246377	0	SYNJ2BP	14	14q24.2	69902966	69953561
MED6	1	0.151515	0.121212	0.275362	0	MED6	14	14q24.2	70120710	70137138
TTG9	1	0.151515	0.121212	0.289855	0	TTG9	14	14q24.2	70178257	70211831
MAP3K9	1	0.151515	0.121212	0.289855	0	MAP3K9	14	14q24.2	70264607	70345642
PCNX	1	0.151515	0.121212	0.289855	0	PCNX	14	14q24.2	70443875	70651853
SNORD56B	1	0.212121	0.151515	0.289855	0	SNORD56B	14	14q24.2	70934807	70934878
LOC14547②	1	0.212121	0.121212	0.289855	0	LOC14547②	14	14q24.2	71024331	71026172
SIPA1L1	1	0.212121	0.121212	0.289855	0	SIPA1L1	14	14q24.2	71065795	71275874
RG86	1	0.181818	0.121212	0.289855	0	RG86	14	14q24.2	71469539	72102992
DPE3	1	0.333333	0.121212	0.376812	0	DPE3	14	14q24.2	72206413	72430563
DCAF4	1	0.333333	0.121212	0.391304	0	DCAF4	14	14q24.2	72462793	72496110
ZFYVE1	1	0.333333	0.121212	0.391304	0	ZFYVE1	14	14q24.2	72505912	72563593
ENTPD5	1	0.333333	0.121212	0.449275	0	ENTPD5	14	14q24.3	73502936	73555780
C14orf45	1	0.333333	0.121212	0.449275	0	C14orf45	14	14q24.3	73555812	73602549
ALDH6A1	1	0.333333	0.121212	0.449275	0	ALDH6A1	14	14q24.3	73596625	73620950
ABCD4	1	0.363636	0.121212	0.376812	0	ABCD4	14	14q24.3	73821733	73839521
TMEM90A	1	0.363636	0.121212	0.376812	0	TMEM90A	14	14q24.3	73942349	73962559
BCYRN1	1	0.30303	0.121212	0.347826	0	BCYRN1	14	14q24.3	75406358	75658554
TGFB3	1	0.30303	0.121212	0.347826	0	TGFB3	14	14q24.3	75494195	75517846
C14orf179	1	0.30303	0.121212	0.347826	0	C14orf179	14	14q24.3	75521849	75619846
ESRRB	1	0.363636	0.121212	0.376812	0	ESRRB	14	14q24.3	75907443	76037932
VASH1	1	0.363636	0.121212	0.376812	0	VASH1	14	14q24.3	76297988	76319117
ANGEL1	1	0.363636	0.121212	0.376812	0	ANGEL1	14	14q24.3	76323339	76349037
C14orf16②	1	0.363636	0.121212	0.376812	0	C14orf16②	14	14q24.3	76362478	76406399
C14orf4	1	0.333333	0.121212	0.347826	0	C14orf4	14	14q24.3	76560639	76564788
KIAA1737	1	0.333333	0.121212	0.347826	0	KIAA1737	14	14q24.3	76634331	76653384
ZDHHC22	1	0.333333	0.121212	0.347826	0	ZDHHC22	14	14q24.3	76667366	76677888
TMEM63C	1	0.333333	0.121212	0.347826	0	TMEM63C	14	14q24.3	76717855	76795592
NGB	1	0.333333	0.121212	0.347826	0	NGB	14	14q24.3	76801587	76807409
MIR1260	1	0.333333	0.121212	0.347826	0	MIR1260	14	14q24.3	76802314	76802385
POMT2	1	0.333333	0.121212	0.347826	0	POMT2	14	14q24.3	76811054	76856979

TABLE 3-continued

Gene list for predicting prostate cancer fast relapse using prostate cancer tissues										
Symbol	freq.use	freq.amp.c	freq.del.cc②	freq.amp.o	freq.del.cc②	Gene.Symt	chromoson	cytoband	Transcript②	Transcript.end
ZNF259	1	0.242424	0.121212	0.449275	0	ZNF259	11	11q23.3	1.16E+08	1.16E+08
APOA5	1	0.242424	0.121212	0.449275	0	APOA5	11	11q23.3	1.16E+08	1.16E+08
SIK3	1	0.272727	0.121212	0.449275	0	SIK3	11	11q23.3	1.16E+08	1.16E+08
PAFAH1B2	1	0.242424	0.121212	0.449275	0	PAFAH1B2	11	11q23.3	1.17E+08	1.17E+08
TAGLN	1	0.30303	0.121212	0.449275	0	TAGLN	11	11q23.3	1.17E+08	1.17E+08
PCSK7	1	0.30303	0.121212	0.449275	0	PCSK7	11	11q23.3	1.17E+08	1.17E+08
RNF214	1	0.30303	0.121212	0.449275	0	RNF214	11	11q23.3	1.17E+08	1.17E+08
BACE1	1	0.30303	0.121212	0.449275	0	BACE1	11	11q23.3	1.17E+08	1.17E+08
HYOU1	1	0.393939	0.121212	0.507246	0	HYOU1	11	11q23.3	1.18E+08	1.18E+08
VPS11	1	0.393939	0.121212	0.507246	0	VPS11	11	11q23.3	1.18E+08	1.18E+08
HMBS	1	0.393939	0.121212	0.507246	0	HMBS	11	11q23.3	1.18E+08	1.18E+08
H2AFX	1	0.393939	0.121212	0.507246	0	H2AFX	11	11q23.3	1.18E+08	1.18E+08
DPAGT1	1	0.393939	0.121212	0.507246	0	DPAGT1	11	11q23.3	1.18E+08	1.18E+08
TRPM3	1	0.060606	0.121212	0.014493	0	TRPM3	9	9q21.11	72339786	72926335
MIR548A1	1	0.151515	0.090909	0	0.028986	MIR548A1	6	6p22.3	18679994	18680091
ORC3L	1	0.151515	0.242424	0	0.202899	ORC3L	6	6q15	88356562	88433888
C5orf33	1	0.121212	0.060606	0	0.028986	C5orf33	5	5p13.2	36228451	36277658
RANBP3L	1	0.121212	0.060606	0	0.028986	RANBP3L	5	5p13.2	36284862	36337769
EGFLAM	1	0.121212	0	0	0	EGFLAM	5	5p13.2	38294290	38500408
LIFR	1	0.121212	0	0	0	LIFR	5	5p13.1	38510822	38592506
OSMR	1	0.121212	0	0	0	OSMR	5	5p13.1	38881717	38922516
RICTOR	1	0.121212	0	0	0	RICTOR	5	5p13.1	38973780	39110259
DAB2	1	0.121212	0.030303	0	0.072464	DAB2	5	5p13.1	39407537	39461093
SDAD1	1	0.181818	0.030303	0	0.014493	SDAD1	4	4q21.1	77090092	77131138
CXCL9	1	0.181818	0.030303	0	0.014493	CXCL9	4	4q21.1	77141647	77147666
ART3	1	0.181818	0.030303	0	0.014493	ART3	4	4q21.1	77151361	77252980
CXCL10	1	0.181818	0.030303	0	0.014493	CXCL10	4	4q21.1	77161295	77163675
CXCL11	1	0.181818	0.030303	0	0.014493	CXCL11	4	4q21.1	77173864	77176258
CCNG2	1	0.121212	0.030303	0	0.043478	CCNG2	4	4q21.1	78297381	78310238
RASGEF1B	1	0.121212	0.060606	0	0.115942	RASGEF1B	4	4q21.21	82567243	82612086
SMAD1	1	0.121212	0.030303	0	0	SMAD1	4	4q31.22	1.47E+08	1.47E+08
MMAA	1	0.121212	0	0	0	MMAA	4	4q31.22	1.47E+08	1.47E+08
C4orf51	1	0.121212	0	0	0	C4orf51	4	4q31.22	1.47E+08	1.47E+08
ZNF827	1	0.121212	0	0	0	ZNF827	4	4q31.22	1.47E+08	1.47E+08
MPP4	1	0.060606	0.121212	0.15942	0	MPP4	2	2q33.1	2.02E+08	2.02E+08
ALS2	1	0.060606	0.121212	0.15942	0	ALS2	2	2q33.1	2.02E+08	2.02E+08
CD28	1	0.060606	0.151515	0.086957	0	CD28	2	2q33.2	2.04E+08	2.04E+08
ERO1LB	1	0.181818	0.121212	0.202899	0	ERO1LB	1	1q42.3	2.34E+08	2.35E+08
PLD5	1	0.090909	0.121212	0.086957	0	PLD5	1	1q43	2.4E+08	2.41E+08
LOC100101	0.970588	0.212121	0.090909	0.231884	0	LOC100101	Y	Yp11.2	6318442	6339606
TTY1	0.970588	0.212121	0.090909	0.231884	0	TTY1	Y	Yp11.2	6318472	6339606
LOC100101	0.970588	0.212121	0.090909	0.231884	0	LOC100101	Y	Yp11.2	6334285	6356486
TTY2	0.970588	0.212121	0.090909	0.231884	0	TTY2	Y	Yp11.2	6334285	6356486
LOC10019②	0.970588	0.090909	0.090909	0.217391	0	LOC10019②	18	18p11.23	8350818	8357033
RAB12	0.970588	0.242424	0.090909	0.246377	0	RAB12	18	18p11.22	8599443	8629381
KIAA0802	0.970588	0.242424	0.090909	0.246377	0	KIAA0802	18	18p11.22	8707369	8822776
RALBP1	0.970588	0.272727	0.090909	0.26087	0	RALBP1	18	18p11.22	9465530	9528107
APCDD1	0.970588	0.242424	0.090909	0.246377	0	APCDD1	18	18p11.22	10444625	10478699
NAPG	0.970588	0.242424	0.090909	0.246377	0	NAPG	18	18p11.22	10515873	10542763
FAM38B	0.970588	0.272727	0.090909	0.231884	0	FAM38B	18	18p11.22	10660244	11138762
GNAL	0.970588	0.272727	0.090909	0.217391	0	GNAL	18	18p11.21	11679136	11873145
CHMP1B	0.970588	0.333333	0.090909	0.217391	0	CHMP1B	18	18p11.21	11841389	11844449
IMPA2	0.970588	0.30303	0.090909	0.289855	0	IMPA2	18	18p11.21	11971455	12020877
CIDEA	0.970588	0.272727	0.090909	0.231884	0	CIDEA	18	18p11.21	12244318	12267595
AFG3L2	0.970588	0.272727	0.090909	0.231884	0	AFG3L2	18	18p11.21	12319108	12367195
SLMO1	0.970588	0.272727	0.090909	0.231884	0	SLMO1	18	18p11.21	12397895	12422235
SPIRE1	0.970588	0.212121	0.090909	0.202899	0	SPIRE1	18	18p11.21	12436511	12647913
PTPN2	0.970588	0.212121	0.090909	0.217391	0	PTPN2	18	18p11.21	12775480	12874335
SEH1L	0.970588	0.181818	0.090909	0.217391	0	SEH1L	18	18p11.21	12937983	12977537
CEP192	0.970588	0.181818	0.090909	0.217391	0	CEP192	18	18p11.21	12981361	13115050
C18orf1	0.970588	0.272727	0.090909	0.231884	0	C18orf1	18	18p11.21	13208786	13642754
MC2R	0.970588	0.212121	0.090909	0.231884	0	MC2R	18	18p11.21	13872043	13905536
ZNF519	0.970588	0.090909	0.090909	0.101449	0	ZNF519	18	18p11.21	14094724	14122430
GP2	0.970588	0.242424	0.090909	0.492754	0	GP2	16	16p12.3	20229312	20246337
GSG1L	0.970588	0.424242	0.090909	0.565217	0	GSG1L	16	16p11.2	27706351	27982332
NOVA1	0.970588	0.090909	0.181818	0	0.217391	NOVA1	14	14q12	25984929	26136801
PRKD1	0.970588	0.090909	0.121212	0	0.173913	PRKD1	14	14q12	29115438	29466651
ARHGAP5	0.970588	0.090909	0	0	0.043478	ARHGAP5	14	14q12	31615246	31698686
AKAP6	0.970588	0.090909	0.121212	0	0.101449	AKAP6	14	14q13.1	31868230	32372020
RALGAP1	0.970588	0.090909	0.030303	0	0.115942	RALGAP1	14	14q13.2	35077309	35348184
PTGDR	0.970588	0.030303	0.090909	0.028986	0	PTGDR	14	14q22.1	51804181	51813193
KIAA0586	0.970588	0.121212	0.090909	0.014493	0	KIAA0586	14	14q23.1	57964463	58085303
DACT1	0.970588	0.121212	0.090909	0.014493	0	DACT1	14	14q23.1	58174510	58184792

TABLE 3-continued

Gene list for predicting prostate cancer fast relapse using prostate cancer tissues										
Symbol	freq.use	freq.amp.c	freq.del.ca ^②	freq.amp.o	freq.del.cc ^②	Gene.Symt	chromoson	cytoband	Transcript ^②	Transcript.end
AMIGO1	0.009804	0.121212	0.090909	0.231884	0.014493	AMIGO1	1	1p13.3	1.1E+08	1.1E+08
CD53	0.009804	0	0.090909	0.144928	0.014493	CD53	1	1p13.3	1.11E+08	1.11E+08
C1orf103	0.009804	0	0.121212	0.15942	0.014493	C1orf103	1	1p13.3	1.11E+08	1.11E+08
FAM46C	0.009804	0.121212	0.090909	0.173913	0.014493	FAM46C	1	1p12	1.18E+08	1.18E+08
WARS2	0.009804	0.090909	0.090909	0.072464	0.014493	WARS2	1	1p12	1.19E+08	1.19E+08
HAO2	0.009804	0	0.121212	0.057971	0.014493	HAO2	1	1p12	1.2E+08	1.2E+08
HSD3B2	0.009804	0	0.121212	0.057971	0.014493	HSD3B2	1	1p12	1.2E+08	1.2E+08
HSD3B1	0.009804	0.060606	0.121212	0.072464	0.014493	HSD3B1	1	1p12	1.2E+08	1.2E+08
ZNF697	0.009804	0.030303	0.121212	0.057971	0.014493	ZNF697	1	1p12	1.2E+08	1.2E+08
CHD1L	0.009804	0.060606	0.121212	0.188406	0.014493	CHD1L	1	1q21.1	1.45E+08	1.45E+08
NOS1AP	0.009804	0.030303	0.121212	0.086957	0.014493	NOS1AP	1	1q23.3	1.6E+08	1.61E+08
C1orf156	0.009804	0.090909	0.060606	0.014493	0.086957	C1orf156	1	1q24.2	1.68E+08	1.68E+08
C1orf112	0.009804	0.090909	0.060606	0.014493	0.086957	C1orf112	1	1q24.2	1.68E+08	1.68E+08
RGL1	0.009804	0.090909	0.030303	0.014493	0.043478	RGL1	1	1q25.3	1.82E+08	1.82E+08
APOBEC4	0.009804	0.090909	0.030303	0.014493	0.043478	APOBEC4	1	1q25.3	1.82E+08	1.82E+08
C1orf21	0.009804	0.121212	0.030303	0.014493	0.057971	C1orf21	1	1q25.3	1.83E+08	1.83E+08
TPR	0.009804	0.090909	0.060606	0.014493	0.115942	TPR	1	1q31.1	1.85E+08	1.85E+08
C1orf27	0.009804	0.090909	0.060606	0.014493	0.115942	C1orf27	1	1q31.1	1.85E+08	1.85E+08
PDC	0.009804	0.090909	0.060606	0.014493	0.115942	PDC	1	1q31.1	1.85E+08	1.85E+08
CRB1	0.009804	0.121212	0.151515	0.014493	0.275362	CRB1	1	1q31.3	1.96E+08	1.96E+08
C4BPB	0.009804	0.181818	0.090909	0.362319	0.014493	C4BPB	1	1q32.2	2.05E+08	2.05E+08
DUSP10	0.009804	0.060606	0.181818	0.057971	0.014493	DUSP10	1	1q41	2.2E+08	2.2E+08
NVL	0.009804	0.181818	0.090909	0.304348	0.014493	NVL	1	1q42.11	2.22E+08	2.23E+08
H3F3A	0.009804	0.30303	0.090909	0.405797	0.014493	H3F3A	1	1q42.12	2.24E+08	2.24E+08
LOC44092 ^②	0.009804	0.30303	0.090909	0.405797	0.014493	LOC44092 ^②	1	1q42.12	2.24E+08	2.24E+08
GGPS1	0.009804	0.242424	0.090909	0.289855	0.014493	GGPS1	1	1q42.3	2.34E+08	2.34E+08
TBCE	0.009804	0.242424	0.090909	0.289855	0.014493	TBCE	1	1q42.3	2.34E+08	2.34E+08
ACTN2	0.009804	0.242424	0.090909	0.130435	0.014493	ACTN2	1	1q43	2.35E+08	2.35E+08
MTR	0.009804	0.242424	0.090909	0.15942	0.014493	MTR	1	1q43	2.35E+08	2.35E+08
RYR2	0.009804	0.121212	0.090909	0.115942	0.014493	RYR2	1	1q43	2.35E+08	2.36E+08
LOC100132 ^②	0.009804	0.060606	0.090909	0.014493	0.014493	LOC100132 ^②	1	1q43	2.36E+08	2.36E+08
ZP4	0.009804	0.060606	0.090909	0.014493	0.014493	ZP4	1	1q43	2.36E+08	2.36E+08

^② indicates text missing or illegible when filed

TABLE 4

Gene list for predicting prostate cancer relapse using AT										
Symbol	freq.use	freq.amp.c	freq.del.ca	freq.amp.o	freq.del.co	Gene.Symt	chromoson	cytoband	Transcript.	Transcript.end
RNF160	1	0.142857	0.047619	0	0.037037	RNF160	21	21q21.3	29222337	29287149
BTBD3	1	0	0.142857	0	0	BTBD3	20	20p12.2	11819477	11855244
SPTLC3	1	0	0.142857	0	0	SPTLC3	20	20p12.1	12937627	13095412
ISM1	1	0	0.142857	0	0	ISM1	20	20p12.1	13150418	13229298
TASP1	1	0	0.142857	0	0	TASP1	20	20p12.1	13318036	13567584
MACROD2	1	0	0.142857	0	0	MACROD2	20	20p12.1	13924146	15981842
PSGI	1	0.333333	0.142857	0.481481	0	PSGI	19	19q13.31	48063198	48075712
ST8SLA3	1	0.238095	0	0	0	ST8SLA3	18	18q21.31	53170719	53187160
ONECUT2	1	0.238095	0	0	0	ONECUT2	18	18q21.31	53253915	53309529
TNFRSF110 ^②	1	0.190476	0	0	0	TNFRSF110 ^②	18	18q21.33	58143528	58204485
ZCCHC2	1	0.238095	0	0	0	ZCCHC2	18	18q21.33	58341638	58396799
ZNF407	1	0.190476	0	0	0	ZNF407	18	18q22.3	70471907	70762000
TSHZ1	1	0.190476	0	0	0	TSHZ1	18	18q22.3	71051719	71130890
RBL2	1	0.190476	0	0	0.037037	RBL2	16	16q12.2	52025852	52083062
CDH11	1	0.142857	0.095238	0	0.037037	CDH11	16	16q21	63538184	63713421
LOC2838 ^②	1	0.142857	0.047619	0	0	LOC2838 ^②	16	16q21	63875903	64167705
MAGEL2	1	0.142857	0	0	0	MAGEL2	15	15q11.2	21444087	21444087
NDN	1	0.142857	0	0	0	NDN	15	15q11.2	21481647	21483544
MIR548A3	1	0.047619	0.190476	0	0	MIR548A3	15	15q21.1	44584617	45037888
NEDD4	1	0.142857	0	0	0	NEDD4	15	15q21.3	53906414	54073128
CGNL1	1	0.190476	0	0	0	CGNL1	15	15q21.3	55455997	55630214
OR11G2	1	0.238095	0	0	0.074074	OR11G2	14	14q11.2	19735335	19736373
OR11H4	1	0.238095	0	0	0.074074	OR11H4	14	14q11.2	19780791	19781766
AP4S1	1	0.238095	0	0	0	AP4S1	14	14q12	30564434	30632390
HECTD1	1	0.238095	0	0	0	HECTD1	14	14q12	30639075	30746441
SSTR1	1	0	0.142857	0	0	SSTR1	14	14q21.1	37746955	37752020
PPL5	1	0.142857	0	0	0	PPL5	14	14q22.1	49135165	49151141
RPL36AL	1	0.142857	0	0	0	RPL36AL	14	14q22.1	49155157	49157100
MGAT2	1	0.142857	0	0	0	MGAT2	14	14q22.1	49157239	49159950
C14orf104	1	0.142857	0	0	0	C14orf104	14	14q22.1	49161642	49171699

TABLE 4-continued

Gene list for predicting prostate cancer relapse using AT										
Symbol	freq.use	freq.amp.c	freq.del.ca	freq.amp.o	freq.del.co	Gene.Symt	chromoson	cytoband	Transcript.	Transcript.end
POLE2	1	0.142857	0	0	0	POLE2	14	14q22.1	49180029	49224686
KLHDC1	1	0.142857	0	0	0	KLHDC1	14	14q22.1	49229635	49289615
ARF6	1	0.142857	0	0	0	ARF6	14	14q22.1	49429486	49433523
C14orf182	1	0.142857	0	0	0	C14orf182	14	14q22.1	49518180	49543989
CGRRF1	1	0.142857	0	0	0	CGRRF1	14	14q22.2	54046337	54075085
SAMD4A	1	0.142857	0	0	0	SAMD4A	14	14q22.2	54104387	54329784
TMEM30B	1	0.142857	0	0	0	TMEM30B	14	14q23.1	60813842	60818284
PRKCH	1	0.142857	0	0	0	PRKCH	14	14q23.1	60858268	61087452
ZDHHHC20	1	0.142857	0	0	0	ZDHHHC20	13	13q12.11	20848508	20931424
EFHA1	1	0.142857	0	0	0	EFHA1	13	13q12.11	20964839	21076308
FGF9	1	0.142857	0	0	0	FGF9	13	13q12.11	21143215	21176641
FAM48A	1	0	0.190476	0	0	FAM48A	13	13q13.3	36481451	36531851
FREM2	1	0	0.142857	0	0	FREM2	13	13q13.3	38159173	38359268
C13orf23	1	0	0.142857	0	0	C13orf23	13	13q13.3	38482002	38510253
DHRS12	1	0.142857	0	0	0	DHRS12	13	13q14.3	51240132	51276295
FU37307	1	0.142857	0	0	0	FU37307	13	13q14.3	51285484	51317288
ATP7B	1	0.142857	0	0	0	ATP7B	13	13q14.3	51404806	51483632
ALG11	1	0.142857	0	0	0	ALG11	13	13q14.3	51484551	51501782
UTP14C	1	0.142857	0	0	0	UTP14C	13	13q14.3	51496828	51505736
NEKS	1	0.142857	0	0	0	NEKS	13	13q14.3	51536901	51601216
NEK3	1	0.142857	0	0	0	NEK3	13	13q14.3	51604780	51631998
THSD1	1	0.142857	0	0	0	THSD1	13	13q14.3	51849305	51878631
LOC64728	1	0	0.142857	0	0	LOC64728	13	13q22.2	74709890	74712519
ABCC4	1	0.190476	0	0	0	ABCC4	13	13q32.1	94470084	94751689
DZIP1	1	0.380952	0	0	0	DZIP1	13	13q32.1	95028457	95094959
DNAJC3	1	0.190476	0	0	0	DNAJC3	13	13q32.1	95127403	95245243
TM9SF2	1	0.190476	0	0	0	TM9SF2	13	13q32.3	98951729	99013278
PCCA	1	0.190476	0	0	0	PCCA	13	13q32.3	99539338	99980690
ITGBL1	1	0	0.142857	0	0	ITGBL1	13	13q33.1	1.01E+08	1.01E+08
FGF14	1	0	0.142857	0	0	FGF14	13	13q33.1	1.01E+08	1.01E+08
IRS2	1	0.190476	0	0	0	IRS2	13	13q34	1.09E+08	1.09E+08
KLRC1	1	0	0.142857	0.037037	0	KLRC1	12	12p13.2	10489904	10497247
PRR4	1	0	0.142857	0.037037	0	PRR4	12	12p13.2	10889715	11215481
PRH1	1	0	0.142857	0.037037	0	PRH1	12	12p13.2	10924827	11215478
TAS2R30	1	0	0.142857	0.037037	0	TAS2R30	12	12p13.2	11177151	11178111
PRB3	1	0	0.142857	0.037037	0	PRB3	12	12p13.2	11310124	11313909
FAR2	1	0	0.142857	0	0	FAR2	12	12p11.22	29267865	29378274
OVCH1	1	0	0.142857	0	0	OVCH1	12	12p11.22	29471756	29541887
PRICKLE1	1	0.142857	0	0	0	PRICKLE1	12	12q12	41138408	41269840
NEUROD4	1	0.047619	0.190476	0.259259	0	NEUROD4	12	12q13.2	53699996	53710069
CDK17	1	0.142857	0	0	0	CDK17	12	12q23.1	95196173	95318437
ANKS1B	1	0.190476	0	0	0	ANKS1B	12	12q23.1	97653202	98072604
UBQLN3	1	0	0.142857	0	0	UBQLN3	11	11p15.4	5485106	5487730
UBQLNL	1	0	0.142857	0	0	UBQLNL	11	11p15.4	5492199	5494533
TRIM6	1	0.142857	0	0	0	TRIM6	11	11p15.4	5573923	5590765
TRIM6-TRI	1	0.142857	0	0	0	TRIM6-TRI	11	11p15.4	5574460	5622200
TRIM34	1	0.142857	0	0	0	TRIM34	11	11p15.4	5597750	5622202
SERGEF	1	0.142857	0	0	0	SERGEF	11	11p15.1	17766172	17991214
TPH1	1	0.142857	0	0	0	TPH1	11	11p15.1	17998660	18018912
MRGPRX3	1	0.142857	0	0	0	MRGPRX3	11	11p15.1	18099078	18116602
MRGPRX4	1	0.142857	0	0	0	MRGPRX4	11	11p15.1	18150960	18152404
ELP4	1	0.190476	0.047619	0	0.037037	ELP4	11	11p13	31487873	31761906
PAX6	1	0.190476	0.047619	0	0.037037	PAX6	11	11p13	31762916	31789456
LOC441601	1	0	0.238095	0.037037	0	LOC441601	11	11p11.12	50195575	50214200
PRCP	1	0.142857	0	0	0.074074	PRCP	11	11q14.1	82213057	82289206
C11orf82	1	0.142857	0	0	0.074074	C11orf82	11	11q14.1	82290385	82323348
RAB30	1	0.142857	0	0	0.037037	RAB30	11	11q14.1	82370126	82460533
CCDC82	1	0	0.142857	0	0	CCDC82	11	11q21	95725577	95762732
JRKL	1	0	0.142857	0	0	JRKL	11	11q21	95762806	95766376
LOC2543	1	0.190476	0	0	0	LOC2543	10	10p14	11016910	11034133
CUGBP2	1	0.190476	0	0	0	CUGBP2	10	10p14	11087265	11418679
PTER	1	0.142857	0	0	0	PTER	10	10p13	16518973	16595743
MLLT10	1	0.142857	0	0	0	MLLT10	10	10p12.31	18263108	22072561
DNAJC1	1	0.142857	0	0	0	DNAJC1	10	10p12.31	22085483	22332657
PRINS	1	0.142857	0	0	0	PRINS	10	10p12.1	24576060	24584982
MIR603	1	0.142857	0	0	0	MIR603	10	10p12.1	24604620	24604717
ARHGAP21	1	0.142857	0	0	0	ARHGAP21	10	10p12.1	24912544	25052604
PRTFDC1	1	0.142857	0	0	0	PRTFDC1	10	10p12.1	25177560	25281540
GPR158	1	0	0.190476	0	0	GPR158	10	10p12.1	25504296	25931164
ZEB1	1	0	0.142857	0.037037	0	ZEB1	10	10p11.22	31647430	31858134
FAM13C	1	0	0.142857	0	0	FAM13C	10	10q21.1	60675896	60792359
RNLS	1	0	0.142857	0	0	RNLS	10	10q23.31	90023601	90333063
UPN	1	0	0.142857	0	0	UPN	10	10q23.31	90511143	90527980

TABLE 4-continued

Gene list for predicting prostate cancer relapse using AT										
Symbol	freq.use	freq.amp.c	freq.del.ca	freq.amp.o	freq.del.co	Gene.Symt	chromoson	cytoband	Transcript.	Transcript.end
KDM4C	1	0.238095	0	0	0	KDM4C	9	9p24.1	6710863	7067265
PGM5	1	0.142857	0.047619	0	0	PGM5	9	9q13	70161635	70335798
C9orf71	1	0.142857	0	0	0	C9orf71	9	9q13	70341318	70345604
PIP5K1B	1	0.142857	0	0	0	P5P5K1B	9	9q21.11	70510436	70813912
FAM108B1	1	0.142857	0	0	0	FAM108B1	9	9q21.13	73667188	73715969
PAPPA	1	0.047619	0.142857	0	0	PAPPA	9	9q33.1	1.18E+08	1.18E+08
ZDHHC2	1	0.142857	0	0	0	ZDHHC2	8	8p22	17058207	17124612
CSGALNAC	1	0.142857	0	0	0	CSGALNAC	8	8p21.3	19305952	19504337
INTS10	1	0.142857	0	0	0	INTS10	8	8p21.3	19719198	19753867
LPL	1	0.142857	0	0	0	LPL	8	8p21.3	19840862	19869051
FUT10	1	0.190476	0.047619	0	0.037037	FUT10	8	8p12	33347886	33450207
FAM150A	1	0.142857	0	0	0	FAM150A	8	8q11.23	53609151	53640575
OPRK1	1	0.142857	0	0	0	OPRK1	8	8q11.23	54300829	54326748
ATP6V1H	1	0.142857	0	0	0	ATP6V1H	8	8q11.23	54790668	54918404
RGS20	1	0.142857	0	0	0	RGS20	8	8q11.23	54926921	55034415
TGS1	1	0.142857	0	0	0	TGS1	8	8q12.1	56848345	56900560
LYN	1	0.142857	0	0	0	LYN	8	8q12.1	56954940	57086495
RPS20	1	0.142857	0	0	0	RPS20	8	8q12.1	57143293	57149695
SNORD54	1	0.142857	0	0	0	SNORD54	8	8q12.1	57148952	57149015
MOS	1	0.142857	0	0	0	MOS	8	8q12.1	57188055	57189096
PLAG1	1	0.142857	0	0	0	PLAG1	8	8q12.1	57236022	57286414
CHCHD7	1	0.142857	0	0	0	CHCHD7	8	8q12.1	57286869	57293731
CSPP1	1	0.190476	0	0	0	CSPP1	8	8q13.2	68139157	68271051
ARFGEF1	1	0.142857	0	0	0	ARFGEF1	8	8q13.2	68272451	68418467
CPA6	1	0.142857	0	0	0	CPA6	8	8q13.2	68496959	68821175
TERF1	1	0.142857	0.047619	0	0	TERF1	8	8q21.11	74083651	74122542
MRPS28	1	0.142857	0.047619	0	0.111111	MRPS28	8	8q21.13	80993650	81105062
TPD52	1	0.142857	0.047619	0	0.111111	TPD52	8	8q21.13	81109660	81155566
ZNF704	1	0.190476	0	0	0.111111	ZNF704	8	8q21.13	81713324	81949572
PAG1	1	0.142857	0	0	0.111111	PAG1	8	8q21.13	82042601	82186859
PDP1	1	0.190476	0	0	0	PDP1	8	8q22.1	94998259	95007471
PTDSS1	1	0.190476	0	0	0	PTDSS1	8	8q22.1	97343343	97415951
SDC2	1	0.190476	0	0	0	SDC2	8	8q22.1	97575058	97693214
PGCP	1	0.142857	0.047619	0	0	PGCP	8	8q22.1	97726675	98224899
LAPTM4B	1	0.190476	0	0	0	LAPTM4B	8	8q22.1	98856985	98934007
MATN2	1	0.190476	0	0	0	MATN2	8	8q22.1	98950487	99118123
C8orf47	1	0.190476	0	0	0	C8orf47	8	8q22.2	99145926	99175015
NIPAL2	1	0.142857	0.047619	0	0	NIPAL2	8	8q22.2	99273563	99375798
STK3	1	0.142857	0.047619	0	0	STK3	8	8q22.2	99536037	99907086
VPS13B	1	0.142857	0.047619	0	0	VPS13B	8	8q22.2	1E+08	1E+08
HAS2	1	0.142857	0	0	0	HAS2	8	3q24.13	1.23E+08	1.23E+08
ZHX2	1	0.285714	0	0	0	ZHX2	8	8q24.13	1.24E+08	1.24E+08
DERL1	1	0.285714	0	0	0	DERL1	8	8q24.13	1.24E+08	1.24E+08
WDR67	1	0.285714	0	0	0	WDR67	8	8q24.13	1.24E+08	1.24E+08
ASAP1	1	0.142857	0	0	0	ASAP1	8	8q24.21	1.31E+08	1.31E+08
ADCY8	1	0.142857	0	0	0	ADCY8	8	8q24.22	1.32E+08	1.32E+08
ZFAT	1	0.190476	0	0	0	ZFAT	8	8q24.22	1.36E+08	1.36E+08
ZFATAS	1	0.190476	0	0	0	ZFATAS	8	8q24.22	1.36E+08	1.36E+08
KHDRBS3	1	0.142857	0	0	0	KHDRBS3	8	8q24.23	1.37E+08	1.37E+08
FAM135B	1	0.142857	0.047619	0	0	FAM135B	8	8q24.23	1.39E+08	1.4E+08
COL22A1	1	0.333333	0	0	0	COL22A1	8	8q24.23	1.4E+08	1.4E+08
GPNUMB	1	0.142857	0	0	0	GPNUMB	7	7p15.3	23252841	23281255
RPS2P32	1	0.190476	0	0	0	RPS2P32	7	7p15.3	23496532	23497555
C7orf46	1	0.190476	0	0	0	C7orf46	7	7p15.3	23686274	23708795
HOXA3	1	0.190476	0	0	0	HOXA3	7	7p15.2	27112334	27125740
HOXA4	1	0.190476	0	0	0	HOXA4	7	7p15.2	27134651	27136925
EVX1	1	0.190476	0	0	0	EVX1	7	7p15.2	27248689	27252718
HIBADH	1	0.190476	0	0	0	HIBADH	7	7p15.2	27531586	27669128
C7orf25	1	0.190476	0	0	0	C7orf25	7	7p14.1	42915397	42918215
PSMA2	1	0.190476	0	0	0	PSMA2	7	7p14.1	42922987	42938331
HECW1	1	0.190476	0	0	0	HECW1	7	7p14.1	43118723	43569464
C7orf44	1	0.190476	0	0	0	C7orf44	7	7p13	43645384	43735609
BLVRA	1	0.190476	0	0	0	BLVRA	7	7p13	43754797	43813467
PEX1	1	0.190476	0	0	0	PEX1	7	7q21.2	91954273	91995782
C7orf64	1	0.190476	0	0	0	C7orf64	7	7q21.2	91996023	92004760
MGC16142	1	0.190476	0	0	0	MGC16142	7	7q21.2	92005725	92007014
FAM133B	1	0.190476	0	0	0	FAM133B	7	7q21.2	92028008	92057643
SLC26A5	1	0.142857	0	0	0	SLC26A5	7	7q22.1	1.03E+08	1.03E+08
RELN	1	0.142857	0	0	0	RELN	7	7q22.1	1.03E+08	1.03E+08
ORCSL	1	0.142857	0	0	0	ORCSL	7	7q22.1	1.04E+08	1.04E+08
LHFPL3	1	0.142857	0	0	0	LHFPL3	7	7q22.1	1.04E+08	1.04E+08
STRA8	1	0.142857	0	0	0	STRA8	7	7q33	1.35E+08	1.35E+08
CNOT4	1	0.142857	0	0	0	CNOT4	7	7q33	1.35E+08	1.35E+08

TABLE 4-continued

Gene list for predicting prostate cancer relapse using AT										
Symbol	freq.use	freq.amp.c	freq.del.ca	freq.amp.o	freq.del.co	Gene.Symt	chromoson	cytoband	Transcript.	Transcript.end
MRPS33	1	0.142857	0	0	0	MRPS33	7	7q34	1.4E+08	1.4E+08
HIVEP1	1	0.142857	0	0	0	HIVEP1	6	6p24.1	12120710	12273219
MRS2	1	0.142857	0	0	0	MRS2	6	6p22.2	24511132	24533796
GPLD1	1	0.142857	0	0	0	GPLD1	6	6p22.2	24536384	24597830
ALDH5A1	1	0.142857	0	0	0	ALDH5A1	6	6p22.2	24603176	24645415
SUPT3H	1	0	0.190476	0.074074	0	SUPT3H	6	6p21.1	44904448	45453649
AHI1	1	0	0.142857	0	0	AHI1	6	6q23.3	1.36E+08	1.36E+08
C6orf217	1	0	0.142857	0	0	C6orf217	6	6q23.3	1.36E+08	1.36E+08
PDE7B	1	0	0.142857	0	0	PDE7B	6	6q23.3	1.36E+08	1.37E+08
UTRN	1	0.142857	0	0	0	UTRN	6	6q24.2	1.45E+08	1.45E+08
GRM1	1	0	0.142857	0	0	GRM1	6	6q24.3	1.46E+08	1.47E+08
OPRM1	1	0	0.190476	0	0	OPRM1	6	6q25.2	1.54E+08	1.54E+08
CNKS3	1	0.190476	0	0	0	CNKS3	6	6q25.2	1.55E+08	1.55E+08
RBM16	1	0.190476	0	0	0	RBM16	6	6q25.2	1.55E+08	1.55E+08
TIAM2	1	0.190476	0	0	0	TIAM2	6	6q25.2	1.55E+08	1.56E+08
TFB1M	1	0.190476	0	0	0	TFB1M	6	6q25.3	1.56E+08	1.56E+08
CLDN20	1	0.190476	0	0	0	CLDN20	6	6q25.3	1.56E+08	1.56E+08
ARID1B	1	0.190476	0	0	0	ARID1B	6	6q25.3	1.57E+08	1.58E+08
ZDHHC14	1	0.190476	0	0	0	ZDHHC14	6	6q25.3	1.58E+08	1.58E+08
SLC22A2	1	0.142857	0	0	0	SLC22A2	6	6q25.3	1.61E+08	1.61E+08
PLG	1	0.142857	0	0	0	PLG	6	6q26	1.61E+08	1.61E+08
BASP1	1	0.142857	0	0	0.037037	BASP1	5	5p15.1	17270750	17329944
C5orf22	1	0.190476	0	0	0	C5orf22	5	5p13.3	31568130	31590923
ZFR	1	0.190476	0	0	0	ZFR	5	5p13.3	32390213	32480602
C5orf42	1	0.142857	0	0	0	C5orf42	5	5p13.2	37142087	37285288
WDR70	1	0.190476	0	0	0	WDR70	5	5p13.2	37415169	37788532
F2RL2	1	0	0.142857	0.037037	0	F2RL2	5	5q13.3	75947063	75954997
TRIM36	1	0.047619	0.142857	0	0	TRIM36	5	5q22.3	1.14E+08	1.15E+08
DMXL1	1	0.190476	0.047619	0	0	DMXL1	5	5q23.1	1.18E+08	1.19E+08
SGCD	1	0	0.190476	0	0	SGCD	5	5q33.3	1.56E+08	1.56E+08
HTRA3	1	0.47619	0.142857	0.703704	0	HTRA3	4	4p16.1	8322392	8359735
NCAPG	1	0	0.238095	0	0	NCAPG	4	4p15.32	17421623	17455586
LCORL	1	0	0.238095	0	0	LCORL	4	4p15.32	17453938	17532582
TLR1	1	0.190476	0	0	0	TLR1	4	4p14	38474271	38482808
TLR6	1	0.190476	0	0	0	TLR6	4	4p14	38501728	38534833
FAM114A1	1	0.190476	0	0	0	FAM114A1	4	4p14	38545832	38621822
MIR574	1	0.190476	0	0	0	MIR574	4	4p14	38546048	38546144
TMEM156	1	0.190476	0	0	0	TMEM156	4	4p14	38644836	38710437
KLHL5	1	0.190476	0	0	0	KLHL5	4	4p14	38723054	38800225
WDR19	1	0.190476	0	0	0	WDR19	4	4p14	38860419	38963826
RFC1	1	0.190476	0	0	0	RFC1	4	4p14	38965471	39044391
KLK1	1	0.238095	0	0	0	KLK1	4	4p14	39084868	39129547
RPL9	1	0.238095	0	0	0	RPL9	4	4p14	39132140	39136964
LIAS	1	0.238095	0	0	0	LIAS	4	4p14	39137060	39155667
LOC40112	1	0.238095	0	0	0	LOC40112	4	4p14	39158270	39159917
UGDH	1	0.238095	0	0	0	UGDH	4	4p14	39176770	39205607
C4orf34	1	0.238095	0	0	0	C4orf34	4	4p14	39228941	39316877
EPGN	1	0	0.142857	0	0	EPGN	4	4q13.3	75393068	75398172
AREG	1	0	0.142857	0	0	AREG	4	4q13.3	75699653	75709510
BTC	1	0	0.142857	0	0	BTC	4	4q13.3	75890472	75938907
BMP3	1	0	0.142857	0	0	BMP3	4	4q21.21	82171143	82197710
PRKG2	1	0	0.142857	0	0	PRKG2	4	4q21.21	82228861	82345240
RASGEF1B	1	0	0.142857	0	0	RASGEF1B	4	4q21.21	82567243	82612086
TBC1D9	1	0	0.142857	0	0	TBC1D9	4	4q31.21	1.42E+08	1.42E+08
RNF150	1	0	0.142857	0	0	RNF150	4	4q31.21	1.42E+08	1.42E+08
IL15	1	0	0.142857	0	0	IL15	4	4q31.21	1.43E+08	1.43E+08
INPP4B	1	0	0.142857	0	0	INPP4B	4	4q31.21	1.43E+08	1.44E+08
RPS3A	1	0.142857	0	0	0	RPS3A	4	4q31.3	1.52E+08	1.52E+08
SNORD73A	1	0.142857	0	0	0	SNORD73A	4	4q31.3	1.52E+08	1.52E+08
SH3D19	1	0.142857	0	0	0	SH3D19	4	4q31.3	1.52E+08	1.52E+08
SUMF1	1	0	0.142857	0	0	SUMF1	3	3p25.2	4377829	4483967
EGOT	1	0.190476	0	0	0	EGOT	3	3p26.2	4765878	4768275
BHLHE40	1	0.333333	0	0	0	BHLHE40	3	3p26.2	4996097	5001864
TPRXL	1	0.190476	0.142857	0.259259	0	TPRXL	3	3p25.1	13953808	14082481
TBC1D5	1	0	0.142857	0	0	TBC1D5	3	3p24.3	17173659	17759245
RAB5A	1	0.142857	0.095238	0	0.037037	RAB5A	3	3p24.3	19963576	20001663
C3orf48	1	0.142857	0.095238	0	0.037037	C3orf48	3	3p24.3	19996458	20028770
KAT2B	1	0.142857	0.095238	0	0.037037	KAT2B	3	3p24.3	20056528	20170901
NGLY1	1	0.047619	0.142857	0	0	NGLY1	3	3p24.2	25735440	25799994
OSBPL10	1	0.190476	0.095238	0	0.037037	OSBPL10	3	3p23	31677321	31998243
MITF	1	0	0.142857	0	0	MITF	3	3p14.1	69871323	70100178
MIR1284	1	0.142857	0.047619	0	0	MIR1284	3	3p14.1	71673811	71673931
CEP97	1	0.142857	0.047619	0	0.074074	CEP97	3	3q12.3	1.03E+08	1.03E+08

TABLE 4-continued

Gene list for predicting prostate cancer relapse using AT										
Symbol	freq.use	freq.amp.c	freq.del.ca	freq.amp.o	freq.del.co	Gene.Symt	chromoson	cytoband	Transcript.	Transcript.end
FAM55C	1	0.142857	0.047619	0	0.074074	FAM55C	3	3q12.3	1.03E+08	1.03E+08
LOC1516②	1	0	0.142857	0	0	LOC1516②	3	3q13.12	1.09E+08	1.09E+08
LOC2852②	1	0	0.142857	0	0	LOC2852②	3	3q13.12	1.09E+08	1.09E+08
HHLA2	1	0	0.142857	0	0	HHLA2	3	3q13.13	1.1E+08	1.1E+08
MYH15	1	0	0.142857	0	0	MYH15	3	3q13.13	1.1E+08	1.1E+08
KIAA1524	1	0	0.142857	0	0	KIAA1524	3	3q13.13	1.1E+08	1.1E+08
DZIP3	1	0	0.142857	0	0	DZIP3	3	3q13.13	1.1E+08	1.1E+08
STXBP5L	1	0	0.142857	0	0	STXBP5L	3	3q13.33	1.22E+08	1.23E+08
SPSB4	1	0.142857	0	0	0	SPSB4	3	3q23	1.42E+08	1.42E+08
ACPL2	1	0.142857	0	0	0	ACPL2	3	3q23	1.42E+08	1.42E+08
ZBTB38	1	0.142857	0	0	0	ZBTB38	3	3q23	1.43E+08	1.43E+08
RNF7	1	0.238095	0	0	0	RNF7	3	3q23	1.43E+08	1.43E+08
GRK7	1	0.238095	0	0	0	GRK7	3	3q23	1.43E+08	1.43E+08
ATP1B3	1	0.238095	0	0	0	ATP1B3	3	3q23	1.43E+08	1.43E+08
TFDP2	1	0.238095	0	0	0	TFDP2	3	3q23	1.43E+08	1.43E+08
GK5	1	0.238095	0	0	0	GK5	3	3q23	1.43E+08	1.43E+08
XRN1	1	0.238095	0	0	0	XRN1	3	3q23	1.44E+08	1.44E+08
ATR	1	0.238095	0	0	0	ATR	3	3q23	1.44E+08	1.44E+08
PLS1	1	0.190476	0	0	0	PLS1	3	3q23	1.44E+08	1.44E+08
PCOLCE2	1	0.190476	0	0	0	PCOLCE2	3	3q23	1.44E+08	1.44E+08
LOC201651	1	0	0.142857	0	0	LOC201651	3	3q25.1	1.53E+08	1.53E+08
AADAC	1	0	0.142857	0	0	AADAC	3	3q25.1	1.53E+08	1.53E+08
LOC4010②	1	0	0.142857	0	0	LOC4010②	3	3q25.1	1.53E+08	1.53E+08
MBNL1	1	0	0.142857	0	0	MBNL1	3	3q25.1	1.53E+08	1.54E+08
P2RY1	1	0	0.142857	0	0	P2RY1	3	3q25.2	1.54E+08	1.54E+08
LEKR1	1	0	0.142857	0	0	LEKR1	3	3q25.31	1.58E+08	1.58E+08
GFM1	1	0	0.142857	0	0	GFM1	3	3q25.32	1.6E+08	1.6E+08
LXN	1	0	0.142857	0	0	LXN	3	3q25.32	1.6E+08	1.6E+08
KPNA4	1	0	0.190476	0	0	KPNA4	3	3q26.1	1.62E+08	1.62E+08
PPM1L	1	0	0.142857	0	0	PPM1L	3	3q26.1	1.62E+08	1.62E+08
KCNMB2	1	0	0.190476	0	0	KCNMB2	3	3q26.32	1.8E+08	1.8E+08
ZMAT3	1	0	0.190476	0	0	ZMAT3	3	3q26.32	1.8E+08	1.8E+08
PIK3CA	1	0	0.190476	0	0	PIK3CA	3	3q26.32	1.8E+08	1.8E+08
PEX5L	1	0	0.142857	0	0	PEX5L	3	3q26.33	1.81E+08	1.81E+08
CCDC39	1	0.047619	0.142857	0	0	CCDC39	3	3q26.33	1.82E+08	1.82E+08
FXR1	1	0.142857	0.047619	0	0	FXR1	3	3q26.33	1.82E+08	1.82E+08
ATP11B	1	0.142857	0	0	0	ATP11B	3	3q26.33	1.84E+08	1.84E+08
UTS2D	1	0	0.142857	0	0	UTS2D	3	3q28	1.92E+08	1.93E+08
PYDC2	1	0	0.142857	0	0	PYDC2	3	3q28	1.93E+08	1.93E+08
VSNL1	1	0.047619	0.142857	0	0	VSNL1	2	2p24.2	17585288	17701188
KLHL29	1	0.190476	0	0	0	KLHL29	2	2p24.1	23461803	23784986
MTIF2	1	0.190476	0	0	0	MTIF2	2	2p16.1	55317260	55349820
CCDC88A	1	0.190476	0	0	0	CCDC88A	2	2p16.1	55368484	55500562
MIR217	1	0	0.142857	0	0	MIR217	2	2p16.1	56063606	56063716
MIR216A	1	0	0.142857	0	0	MIR216A	2	2p16.1	56069590	56069699
MIR216B	1	0	0.142857	0	0	MIR216B	2	2p16.1	56081354	56081435
CCDC85A	1	0	0.142857	0	0	CCDC85A	2	2p16.1	56264762	56466814
BCL11A	1	0.238095	0	0	0	BCL11A	2	2p16.1	60531806	60634138
FAM161A	1	0.142857	0	0	0	FAM161A	2	2p15	61905487	61934783
CCT4	1	0.142857	0	0	0	CCT4	2	2p15	61948766	61969296
COMMD1	1	0.142857	0	0	0	COMMD1	2	2p15	61986307	62216710
B3GNT2	1	0.142857	0	0	0	B3GNT2	2	2p15	62276766	62305371
IL18RAP	1	0.142857	0	0	0	IL18RAP	2	2q12.1	1.02E+08	1.02E+08
SLC9A4	1	0.142857	0	0	0	SLC9A4	2	2q12.1	1.02E+08	1.03E+08
TNFA1P6	1	0.190475	0	0	0	TNFA1P6	2	2q23.3	1.52E+08	1.52E+08
STAM2	1	0	0.142857	0	0	STAM2	2	2q23.3	1.53E+08	1.53E+08
EVX2	1	0.142857	0	0	0	EVX2	2	2q31.1	1.77E+08	1.77E+08
HOXD13	1	0.142857	0	0	0	HOXD13	2	2q31.1	1.77E+08	1.77E+08
HOXD12	1	0.142857	0	0	0	HOXD12	2	2q31.1	1.77E+08	1.77E+08
HOXD11	1	0.142857	0	0	0	HOXD11	2	2q31.1	1.77E+08	1.77E+08
HOXD10	1	0.142857	0	0	0	HOXD10	2	2q31.1	1.77E+08	1.77E+08
HOXD9	1	0.142857	0	0	0	HOXD9	2	2q31.1	1.77E+08	1.77E+08
HOXD8	1	0.142857	0	0	0	HOXD8	2	2q31.1	1.77E+08	1.77E+08
CD28	1	0.142857	0	0	0	CD28	2	2q33.2	2.04E+08	2.04E+08
CTLA4	1	0.142857	0	0	0	CTLA4	2	2q33.2	2.04E+08	2.04E+08
ICOS	1	0.142857	0	0	0	ICOS	2	2q33.2	2.05E+08	2.05E+08
PLEKHM3	1	0.142857	0	0	0.037037	PLEKHM3	2	2q33.3	2.08E+08	2.09E+08
CRYGD	1	0.142857	0	0	0	CRYGD	2	2q33.3	2.09E+08	2.09E+08
CRYGC	1	0.142857	0	0	0	CRYGC	2	2q33.3	2.09E+08	2.09E+08
PIKFYVE	1	0.142857	0	0	0	PIKFYVE	2	2q33.3	2.09E+08	2.09E+08
KIAA1486	1	0	0.142857	0	0	KIAA1486	2	2q36.3	2.26E+08	2.26E+08
PDE48	1	0	0.142857	0	0	PDE48	1	1p31.3	66030781	66612851
IL23R	1	0.142857	0	0	0	IL23R	1	1p31.3	67404757	67498239

TABLE 4-continued

Gene list for predicting prostate cancer relapse using AT									
Symbol	freq.use	freq.amp.c	freq.del.ca	freq.amp.o	freq.del.co	Gene.Symt	chromoson	cytoband	Transcript. Transcript.end
RFTN2	0.020833	0	0.142857	0	0.037037	RFTN2	2	2q33.1	1.98E+08 1.98E+08
PLCL1	0.020833	0	0.142857	0	0.037037	PLCL1	2	2q33.1	1.98E+08 1.99E+08
BZW1	0.020833	0.142857	0	0.037037	0	BZW1	2	2q33.1	2.01E+08 2.01E+08
BZWIL1	0.020833	0.142857	0	0.037037	0	BZWIL1	2	2q33.1	2.01E+08 2.01E+08
PPIL3	0.020833	0.142857	0	0.037037	0	PPIL3	2	2q33.1	2.01E+08 2.01E+08
N1F3L1	0.020833	0.142857	0	0.037037	0	N1F3L1	2	2q33.1	2.01E+08 2.01E+08
ORC2L	0.020833	0.142857	0	0.037037	0	ORC2L	2	2q33.1	2.01E+08 2.02E+08
FAM126B	0.020833	0.190476	0	0.037037	0	FAM126B	2	2q33.1	2.02E+08 2.02E+08
NDUFB3	0.020833	0.190476	0	0.037037	0	NDUFB3	2	2q33.1	2.02E+08 2.02E+08
CFLAR	0.020833	0.190476	0	0.037037	0	CFLAR	2	2q33.1	2.02E+08 2.02E+08
CASP10	0.020833	0.142857	0	0.037037	0	CASP10	2	2q33.1	2.02E+08 2.02E+08
CASP8	0.020833	0.142857	0	0.037037	0	CASP8	2	2q33.1	2.02E+08 2.02E+08
ALS2CR12	0.020833	0.142857	0	0.037037	0	ALS2CR12	2	2q33.1	2.02E+08 2.02E+08
TRAK2	0.020833	0.142857	0.047619	0.037037	0	TRAK2	2	2q33.1	2.02E+08 2.02E+08
STRAD8	0.020833	0.142857	0.047619	0.037037	0	STRAD8	2	2q33.1	2.02E+08 2.02E+08
MPP4	0.020833	0.190476	0	0.037037	0	MPP4	2	2q33.1	2.02E+08 2.02E+08
ALS2	0.020833	0.190476	0	0.037037	0	ALS2	2	2q33.1	2.02E+08 2.02E+08
CDK15	0.020833	0.190476	0	0.037037	0	CDK15	2	2q33.1	2.02E+08 2.02E+08
FAM117B	0.020833	0.238095	0	0.037037	0	FAM117B	2	2q33.1	2.03E+08 2.03E+08
ALS2CR8	0.020833	0.190476	0	0.037037	0	ALS2CR8	2	2q33.2	2.03E+08 2.04E+08
NBEAL1	0.020833	0.190476	0	0.037037	0	NBEAL1	2	2q33.2	2.04E+08 2.04E+08
CYP20A1	0.020833	0.190476	0	0.037037	0	CYP20A1	2	2q33.2	2.04E+08 2.04E+08
ABI2	0.020833	0.190476	0	0.037037	0	ABI2	2	2q33.2	2.04E+08 2.04E+08
RAPH1	0.020833	0.190476	0	0.037037	0	RAPH1	2	2q33.2	2.04E+08 2.04E+08
INO80D	0.020833	0.142857	0	0.037037	0	INO80D	2	2q33.3	2.07E+08 2.07E+08
NDUFS1	0.020833	0.142857	0	0.037037	0	NDUFS1	2	2q33.3	2.07E+08 2.07E+08
EEF1B2	0.020833	0.142857	0	0.037037	0	EEF1B2	2	2q33.3	2.07E+08 2.07E+08
SNORD51	0.020833	0.142857	0	0.037037	0	SNORD51	2	2q33.3	2.07E+08 2.07E+08
SNORA41	0.020833	0.142857	0	0.037037	0	SNORA41	2	2q33.3	2.07E+08 2.07E+08
GPR1	0.020833	0.142857	0	0.037037	0	GPR1	2	2q33.3	2.07E+08 2.07E+08
CCNYL1	0.020833	0.142857	0	0.037037	0	CCNYL1	2	2q33.3	2.08E+08 2.08E+08
PECR	0.020833	0.142857	0	0.037037	0	PECR	2	2q35	2.17E+08 2.17E+08
4-Mar	0.020833	0.142857	0	0.037037	0	4-Mar	2	2q35	2.17E+08 2.17E+08
DEPDC1	0.020833	0	0.190476	0	0.037037	DEPDC1	1	1p31.2	68712423 68735388
LRRC7	0.020833	0	0.190476	0	0.037037	LRRC7	1	1p31.1	69998446 70361760
PIN1L	0.020833	0	0.190476	0	0.037037	PIN1L	1	1p31.1	70157593 70158589
ANKRD13C	0.020833	0	0.142857	0	0.037037	ANKRD13C	1	1p31.1	70497273 70593006
HHLA3	0.020833	0	0.142857	0	0.037037	HHLA3	1	1p31.1	70593081 70606294
CTH	0.020833	0	0.142857	0	0.037037	CTH	1	1p31.1	70649543 70677842
USP33	0.020833	0.142857	0	0.037037	0.074074	USP33	1	1p31.1	77934262 77998126
FAM73A	0.020833	0.190476	0	0.037037	0.074074	FAM73A	1	1p31.1	78017897 78116670
TTL7	0.020833	0	0.142857	0	0.037037	TTL7	1	1p31.1	84107645 84237422
PRKACB	0.020833	0	0.142857	0	0.037037	PRKACB	1	1p31.1	84316333 84476770
SAMD13	0.020833	0	0.142857	0	0.037037	SAMD13	1	1p31.1	84536637 84589069
UOX	0.020833	0	0.142857	0	0.037037	UOX	1	1p31.1	84603229 84636165
PKN2	0.020833	0	0.142857	0	0.037037	PKN2	1	1p22.2	88922510 89074527
GTF2B	0.020833	0.142857	0	0.037037	0	GTF2B	1	1p22.2	89090909 89129890
BCAR3	0.020833	0.142857	0	0.037037	0	BCAR3	1	1p22.1	93799937 93919974
TRIM33	0.020833	0.142857	0	0.037037	0	TRIM33	1	1p13.2	1.15E+08 1.15E+08
DENND2C	0.020833	0.142857	0	0.037037	0	DENND2C	1	1p13.2	1.15E+08 1.15E+08
AMPD1	0.020833	0.142857	0	0.037037	0	AMPD1	1	1p13.2	1.15E+08 1.15E+08
NRAS	0.020833	0.142857	0	0.037037	0	NRAS	1	1p13.2	1.15E+08 1.15E+08
CSDE1	0.020833	0.142857	0	0.037037	0	CSDE1	1	1p13.2	1.15E+08 1.15E+08
SIKE1	0.020833	0.142857	0	0.037037	0	SIKE1	1	1p13.2	1.15E+08 1.15E+08
FAM46C	0.020833	0.190476	0	0.037037	0	FAM46C	1	1p12	1.18E+08 1.18E+08
HFE2	0.020833	0.285714	0	0.037037	0	HFE2	1	1q11.1	1.44E+08 1.44E+08
PQLR3GL	0.020833	0.238095	0	0.037037	0	PQLR3GL	1	1q21.1	1.44E+08 1.44E+08
LIX1L	0.020833	0.238095	0	0.037037	0	LIX1L	1	1q21.1	1.44E+08 1.44E+08
RBM8A	0.020833	0.238095	0	0.037037	0	RBM8A	1	1q21.1	1.44E+08 1.44E+08
GNRHR2	0.020833	0.238095	0	0.037037	0	GNRHR2	1	1q21.1	1.44E+08 1.44E+08
PEX11B	0.020833	0.238095	0	0.037037	0	PEX11B	1	1q21.1	1.44E+08 1.44E+08
ITGA10	0.020833	0.238095	0	0.037037	0	ITGA10	1	1q21.1	1.44E+08 1.44E+08
ANKRD35	0.020833	0.238095	0	0.037037	0	ANKRD35	1	1q21.1	1.44E+08 1.44E+08
RNF115	0.020833	0.238095	0	0.037037	0	RNF115	1	1q21.1	1.44E+08 1.44E+08
SLAMF6	0.020833	0.190476	0	0.037037	0	SLAMF6	1	1q23.2	1.59E+08 1.59E+08
CD84	0.020833	0.190476	0	0.037037	0	CD84	1	1q23.2-1c	1.59E+08 1.59E+08
SLAMF7	0.020833	0.142857	0	0.037037	0	SLAMF7	1	1q23.3	1.59E+08 1.59E+08
CD244	0.020833	0.190476	0	0.037037	0	CD244	1	1q23.3	1.59E+08 1.59E+08
UFC1	0.020833	0.238095	0	0.037037	0.037037	UFC1	1	1q23.3	1.59E+08 1.59E+08
USP21	0.020833	0.238095	0	0.037037	0.037037	USP21	1	1q23.3	1.59E+08 1.59E+08
PPOX	0.020833	0.238095	0	0.037037	0.037037	PPOX	1	1q23.3	1.59E+08 1.59E+08
B4GALT3	0.020833	0.238095	0	0.037037	0.037037	B4GALT3	1	1q23.3	1.59E+08 1.59E+08
NR1I3	0.020833	0.238095	0	0.037037	0	NR1I3	1	1q23.3	1.59E+08 1.59E+08

TABLE 4-continued

Gene list for predicting prostate cancer relapse using AT										
Symbol	freq.use	freq.amp.c	freq.del.ca	freq.amp.o	freq.del.co	Gene.Symt	chromoson	cytoband	Transcript.	Transcript.end
PCP4L1	0.020833	0.238095	0	0.037037	0	PCP4L1	1	1q23.3	1.59E+08	1.6E+08
MPZ	0.020833	0.238095	0	0.037037	0	MPZ	1	1q23.3	1.6E+08	1.6E+08
SDHC	0.020833	0.238095	0	0.037037	0	SDHC	1	1q23.3	1.6E+08	1.6E+08
LOC6425(c)	0.020833	0.238095	0	0.037037	0	LOC6425(c)	1	1q23.3	1.6E+08	1.6E+08
C1orf192	0.020833	0.238095	0	0.037037	0	C1orf192	1	1q23.3	1.6E+08	1.6E+08
OLFML2B	0.020833	0.190476	0	0.037037	0	OLFML2B	1	1q23.3	1.6E+08	1.6E+08
NOS1AP	0.020833	0.142857	0	0.037037	0	NOS1AP	1	1q23.3	1.6E+08	1.61E+08
C1orf111	0.020833	0.190476	0	0.037037	0	C1orf111	1	1q23.3	1.61E+08	1.61E+08
RGSS	0.020833	0	0.142857	0	0.037037	RGSS	1	1q23.3	1.61E+08	1.61E+08
KIAA1614	0.020833	0.238095	0	0.037037	0	KIAA1614	1	1q25.3	1.79E+08	1.79E+08
HEATR1	0.020833	0.190476	0	0.037037	0	HEATR1	1	1q43	2.35E+08	2.35E+08
ACTN2	0.020833	0.190476	0	0.037037	0	ACTN2	1	1q43	2.35E+08	2.35E+08
RYR2	0.020833	0.142857	0	0.037037	0	RYR2	1	1q43	2.35E+08	2.36E+08
ZNF238	0.020833	0.238095	0	0.037037	0	ZNF238	1	1q44	2.42E+08	2.42E+08
C1orf100	0.020833	0.238095	0	0.037037	0	C1orf100	1	1q44	2.43E+08	2.43E+08
ADSS	0.020833	0.238095	0	0.037037	0	ADSS	1	1q44	2.43E+08	2.43E+08
C1orf101	0.020833	0.238095	0	0.037037	0	C1orf101	1	1q44	2.43E+08	2.43E+08
PPPDE1	0.020833	0.190476	0.047619	0.037037	0	PPPDE1	1	1q44	2.43E+08	2.43E+08
FAM36A	0.020833	0.238095	0	0.037037	0	FAM36A	1	1q44	2.43E+08	2.43E+08
EFCAB2	0.020833	0.238095	0	0.037037	0	EFCAB2	1	1q44	2.43E+08	2.43E+08
KIF26B	0.020833	0.238095	0	0.037037	0	KIF26B	1	1q44	2.43E+08	2.44E+08

Ⓢ indicates text missing or illegible when filed

TABLE 5

Gene list for predicting prostate cancer fast relapse using AT						
Symbol	freq.use	freq.amp.cⓈ	freq.del.casⓈ	freq.amp.cⓈ	freq.del.coⓈ	Gene5ymb
ⓈRPL23AP82	1	0.75	0.25	0.8	0	RPL23AP82
RABL2B	1	0.75	0.25	0.8	0	RABL2B
CA10	1	0.25	0.25	0.15	0	CA10
MAGEL2	1	0.375	0	0	0	MAGEL2
NDN	1	0.375	0	0	0	NDN
C13orf36	1	0	0.25	0.025	0	C13orf36
SMAD9	1	0	0.25	0.075	0	SMAD9
ALG5	1	0.125	0.25	0.075	0	ALG5
RSU1	1	0.25	0	0	0	RSU1
ADCY2	1	0.25	0	0	0	ADCY2
UBE2E1	1	0.25	0	0	0.025	UBE2E1
RETNLB	1	0	0.25	0	0	RETNLB
TRAT1	1	0	0.25	0	0	TRAT1
GUCA1C	1	0	0.25	0	0	GUCA1C
MORC1	1	0	0.25	0	0	MORC1
TTY8	0.979167	0.125	0.125	0.275	0	TTY8
TTY8B	0.979167	0.125	0.125	0.275	0	TTY8B
TTY7	0.979167	0.125	0.125	0.275	0	TTY7
TTY7B	0.979167	0.125	0.125	0.275	0	TTY7B
LOC100101	0.979167	0.125	0.125	0.275	0	LOC100101
TTY21	0.979167	0.125	0.125	0.275	0	TTY21
YIPF6	0.979167	0.125	0.125	0.275	0	YIPF6
LOC96610	0.979167	0.625	0.125	0.575	0	LOC96610
STX16	0.979167	0.5	0.125	0.45	0	STX16
ZNF440	0.979167	0.875	0.125	0.625	0	ZNF440
FKBP8	0.979167	0.75	0.125	0.575	0	FKBP8
ZNF30	0.979167	0.875	0.125	0.5	0	ZNF30
PSMC4	0.979167	0.875	0.125	0.55	0	PSMC4
MAMSTR	0.979167	0.75	0.125	0.575	0	MAMSTR
RASIP1	0.979167	0.75	0.125	0.575	0	RASIP1
IZUMO1	0.979167	0.75	0.125	0.575	0	IZUMO1
DSG2	0.979167	0.125	0	0	0.05	DSG2
ZNF287	0.979167	0.375	0.125	0.325	0	ZNF287
SLC4A1	0.979167	0.5	0.125	0.5	0	SLC4A1
SPAG9	0.979167	0.5	0.125	0.225	0	SPAG9
NME1	0.979167	0.5	0.125	0.275	0	NME1
NME1-NMI	0.979167	0.5	0.125	0.275	0	NME1-NMI
NME2	0.979167	0.5	0.125	0.275	0	NME2
MBTD1	0.979167	0.375	0.125	0.2	0	MBTD1
UTP18	0.979167	0.375	0.125	0.2	0	UTP18
TOM1L1	0.979167	0	0.125	0.1	0	TOM1L1

TABLE 5-continued

Gene list for predicting prostate cancer fast relapse using AT					
COX11	0.979167	0	0.125	0.1	0
STXBP4	0.979167	0	0.125	0.1	0
RSL1D1	0.979167	0.5	0.125	0.425	0
VPS4A	0.979167	0.625	0.125	0.375	0
COG8	0.979167	0.625	0.125	0.375	0
PDF	0.979167	0.625	0.125	0.375	0
NIP7	0.979167	0.625	0.125	0.375	0
TMED6	0.979167	0.625	0.125	0.375	0
PAR1	0.979167	0.125	0	0	0.075
FSIP1	0.979167	0	0.125	0.125	0
NRG4	0.979167	0.5	0.125	0.45	0
NTRK3	0.979167	0.375	0.125	0.25	0
FBXO33	0.979167	0.125	0.125	0	0.1
DDHD1	0.979167	0.125	0	0	0
FUT8	0.979167	0	0.125	0.175	0
CYP46A1	0.979167	0.5	0.125	0.475	0
RFC3	0.979167	0	0.125	0	0
MIR548F5	0.979167	0	0.125	0.05	0
DCLK1	0.979167	0	0.125	0	0
SOHLH2	0.979167	0	0.125	0	0
CCNA1	0.979167	0	0.125	0	0
MYO16	0.979167	0.125	0	0	0.025
YAF2	0.979167	0	0.125	0.025	0
WDR51B	0.979167	0.125	0.25	0	0.05
OR51E1	0.979167	0.125	0	0	0
OR51E2	0.979167	0.125	0	0	0
FLJ46111	0.979167	0.125	0.125	0.25	0
DNAJC24	0.979167	0.125	0	0	0.075
ASRGL1	0.979167	0.5	0.125	0.45	0
SCGB1A1	0.979167	0.5	0.125	0.45	0
PAK1	0.979167	0.125	0.125	0.2	0
AKR1C1	0.979167	0	0.125	0.1	0
AKR1C2	0.979167	0	0.125	0.1	0
CUBN	0.979167	0.125	0	0	0
MYO3A	0.979167	0.125	0	0	0
CCDC6	0.979167	0.125	0	0	0
KCNMA1	0.979167	0.25	0.125	0.175	0
PDCD4	0.979167	0	0.125	0.05	0
RLN1	0.979167	0	0.125	0	0
SLC24A2	0.979167	0.125	0	0	0.025
LOC440173	0.979167	0.25	0.125	0.175	0
ASTN2	0.979167	0	0.125	0.05	0
LHX3	0.979167	0.875	0.125	0.725	0
QSOX2	0.979167	0.875	0.125	0.725	0
TNFRSF10C	0.979167	0.25	0.125	0.175	0
TERF1	0.979167	0	0.125	0.075	0
C8orf84	0.979167	0	0.125	0.1	0
RDH10	0.979167	0	0.125	0.1	0
UBE2W	0.979167	0.125	0.125	0.1	0
TCEB1	0.979167	0.125	0.125	0.1	0
C7orf30	0.979167	0	0.125	0.05	0
IGF2BP3	0.979167	0	0.129	0.05	0
CALU	0.979167	0.25	0.125	0.3	0
MIR548A1	0.979167	0.125	0	0	0.025
HMGA1	0.979167	0.625	0.125	0.425	0
TCP11	0.979167	0.5	0.125	0.325	0
KLHL31	0.979167	0	0.125	0	0
LRRC1	0.979167	0	0.125	0	0
SLC22A16	0.979167	0.125	0	0	0
RICTOR	0.979167	0	0.125	0	0
FYB	0.979167	0	0.125	0	0
FAM169A	0.979167	0	0.125	0	0
SEMA6A	0.979167	0	0.125	0	0
DMXL1	0.979167	0.125	0.125	0.075	0
TNFAIP8	0.979167	0	0.125	0.025	0
SAR1B	0.979167	0.375	0.125	0.35	0
RNF130	0.979167	0.5	0.125	0.525	0
MIR340	0.979167	0.5	0.125	0.525	0
SLC30A9	0.979167	0.125	0.125	0	0.05
BEND4	0.979167	0.125	0.125	0	0.05
POLR2B	0.979167	0	0.125	0	0
IGFBP7	0.979167	0	0.125	0	0
HELQ	0.979167	0.125	0.125	0.125	0
MRPS18C	0.979167	0.125	0.125	0.125	0
FAM175A	0.979167	0.125	0.125	0.125	0

TABLE 5-continued

Gene list for predicting prostate cancer fast relapse using AT						
DCLK2	0.979167	0.125	0.125	0	0.025	DCLK2
TRIM61	0.979167	0.125	0.125	0	0.05	TRIM61
C4orf39	0.979167	0.125	0.125	0	0.05	C4orf39
NKTR	0.979167	0.25	0.125	0.275	0	NKTR
DOCK3	0.979167	0.375	0.125	0.275	0	DOCK3
LRIG1	0.979167	0.125	0	0	0	LRIG1
GXYLT2	0.979167	0	0.125	0.05	0	GXYLT2
PPP4R2	0.979167	0	0.125	0.05	0	PPP4R2
WDR52	0.979167	0	0.125	0.025	0	WDR52
SIDT1	0.979167	0	0.125	0.025	0	SIDT1
NAT13	0.979167	0	0.125	0.05	0	NAT13
POLQ	0.979167	0	0.125	0.05	0	POLQ
ARGFX	0.979167	0	0.125	0.05	0	ARGFX
FBXO40	0.979167	0	0.125	0.05	0	FBXO40
PLSCR1	0.979167	0.125	0.375	0	0.175	PLSCR1
TM4SF4	0.979167	0.125	0	0	0.025	TM4SF4
WWTR1	0.979167	0.125	0	0	0.025	WWTR1
NMD3	0.979167	0	0.125	0.025	0	NMD3
MRPL47	0.979167	0.125	0.125	0.025	0	MRPL47
TMEM17	0.979167	0.125	0	0	0	TMEM17
EHBP1	0.979167	0	0.125	0	0	EHBP1
C2orf86	0.979167	0	0.125	0.025	0	C2orf86
MDH1	0.979167	0	0.125	0.025	0	MDH1
RPL31	0.979167	0.25	0.125	0.175	0	RPL31
SLC9A2	0.979167	0	0.125	0.05	0	SLC9A2
GCG	0.979167	0.125	0	0	0.125	GCG
FAP	0.979167	0.125	0	0	0.125	FAP
C2orf77	0.979167	0.125	0	0	0	C2orf77
PHOSPHO2	0.979167	0.125	0	0	0	PHOSPHO2
KLHL23	0.979167	0.125	0	0	0	KLHL23
SSB	0.979167	0.125	0	0	0	SSB
METTL5	0.979167	0.125	0	0	0	METTL5
UBR3	0.979167	0.125	0	0	0	UBR3
C1orf64	0.979167	0.625	0.125	0.575	0	C1orf64
CYP4A22	0.979167	0.375	0.125	0.325	0	CYP4A22
C1orf141	0.979167	0	0.125	0.025	0	C1orf141
ABCD3	0.979167	0.125	0.125	0.025	0	ABCD3
RABGAP1L	0.979167	0	0.125	0.05	0	RABGAP1L
RBBP5	0.979167	0.375	0.125	0.35	0	RBBP5
RFX7	0.041667	0.125	0.125	0.025	0.025	RFX7
IPCEF1	0.041667	0.125	0.125	0.025	0.025	IPCEF1
TLR10	0.041667	0.125	0.125	0.025	0.025	TLR10
PHOX2B	0.041667	0.125	0.125	0.025	0.025	PHOX2B
PDCD6IP	0.041667	0.125	0.125	0.025	0.025	PDCD6IP
SR140	0.041667	0.125	0.125	0.025	0.025	SR140
KIF5C	0.041667	0.125	0.125	0.025	0.025	KIF5C
MIR1978	0.041667	0.125	0.125	0.025	0.025	MIR1978
VAMP7	0.020833	0.375	0.125	0.3	0.025	VAMP7
IL9R	0.020833	0.375	0.125	0.3	0.025	IL9R
ATXN10	0.020833	0.625	0.125	0.575	0.025	ATXN10
RNF160	0.020833	0.125	0.125	0.05	0.025	RNF160
C21orf7	0.020833	0.125	0	0.025	0.025	C21orf7
CLDN17	0.020833	0	0.125	0.025	0.025	CLDN17
KRTAP19-3	0.020833	0	0.125	0.025	0.025	KRTAP19-3
KRTAP19-4	0.020833	0	0.125	0.025	0.025	KRTAP19-4
KRTAP19-5	0.020833	0	0.125	0.025	0.025	KRTAP19-5
KRTAP19-7	0.020833	0	0.125	0.025	0.025	KRTAP19-7
KRTAP20-2	0.020833	0	0.125	0.05	0.025	KRTAP20-2
KRTAP20-3	0.020833	0	0.125	0.05	0.025	KRTAP20-3
PSG1	0.020833	0.5	0.25	0.4	0.025	PSG1
ZNF519	0.020833	0.125	0.125	0.075	0.025	ZNF519
ANKRD30B	0.020833	0.125	0.125	0.075	0.025	ANKRD30B
TTR	0.020833	0.125	0	0.025	0.025	TTR
B4GALT6	0.020833	0.125	0	0.025	0.025	B4GALT6
MCART2	0.020833	0.125	0	0.025	0.025	MCART2
KIAA1012	0.020833	0.125	0	0.025	0.025	KIAA1012
SERPINB13	0.020833	0.125	0	0.025	0.025	SERPINB13
TANC2	0.020833	0.375	0.125	0.275	0.025	TANC2
CDH11	0.020833	0.25	0	0.025	0.075	CDH11
LOC283867	0.020833	0.25	0	0.025	0.025	LOC283867
CNTNAP4	0.020833	0.125	0	0.025	0.025	CNTNAP4
SCG5	0.020833	0.125	0	0.025	0	SCG5
MEIS2	0.020833	0	0.125	0.025	0.025	MEIS2
DMXL2	0.020833	0.125	0.125	0.05	0.025	DMXL2
RAB27A	0.020833	0.125	0	0.025	0	RAB27A

TABLE 5-continued

Gene list for predicting prostate cancer fast relapse using AT						
PIGB	0.020833	0.125	0	0.025	0	PIGB
CCPG1	0.020833	0.125	0	0.025	0	CCPG1
MIR628	0.020833	0.125	0	0.025	0	MIR628
DYX1C1	0.020833	0.125	0	0.025	0	DYX1C1
PYGO1	0.020833	0.125	0	0.025	0	PYGO1
PRTG	0.020833	0.125	0	0.025	0	PRTG
NEDD4	0.020833	0.25	0	0.025	0	NEDD4
TEX9	0.020833	0.125	0.125	0.025	0.05	TEX9
ZNF280D	0.020833	0.125	0	0.025	0	ZNF280D
TCF12	0.020833	0.125	0	0.025	0.025	TCF12
NEO1	0.020833	0.25	0.125	0.275	0.025	NEO1
MIPOL1	0.020833	0	0.125	0	0.025	MIPOL1
CDKN3	0.020833	0.125	0	0.025	0	CDKN3
C14orf145	0.020833	0	0.25	0	0.025	C14orf145
TSHR	0.020833	0	0.25	0	0.025	TSHR
STON2	0.020833	0	0.25	0.025	0.025	STON2
SEL1L	0.020833	0	0.25	0.025	0.025	SEL1L
ZMYM2	0.020833	0.125	0.125	0.15	0.025	ZMYM2
NBEA	0.020833	0	0.125	0	0.025	NBEA
SPG20	0.020833	0	0.125	0	0.025	SPG20
COG6	0.020833	0	0.125	0	0.025	COG6
RNASEH2B	0.020833	0.125	0	0.025	0	RNASEH2B
GUCY1B2	0.020833	0.125	0	0.025	0	GUCY1B2
FAM124A	0.020833	0.125	0	0.025	0	FAM124A
SERPINE3	0.020833	0.125	0	0.025	0	SERPINE3
INTS6	0.020833	0.125	0	0.025	0	INTS6
DCT	0.020833	0.125	0.125	0.025	0.1	DCT
DNAJC3	0.020833	0.375	0	0.025	0	DNAJC3
TMTC4	0.020833	0.125	0	0.025	0	TMTC4
AEBP2	0.020833	0.125	0	0.025	0.075	AEBP2
GXYLT1	0.020833	0	0.125	0	0.025	GXYLT1
SRGAP1	0.020833	0.125	0	0.025	0	SRGAP1
C12orf66	0.020833	0.125	0	0.025	0	C12orf66
C12orf56	0.020833	0.125	0	0.025	0	C12orf56
TBK1	0.020833	0.125	0	0.025	0	TBK1
GNS	0.020833	0.125	0	0.025	0	GNS
ZFC3H1	0.020833	0	0.25	0	0.025	ZFC3H1
TBC1D15	0.020833	0	0.25	0.05	0.025	TBC1D15
MRS2P2	0.020833	0	0.25	0.05	0.025	MRS2P2
METAP2	0.020833	0.125	0	0.025	0	METAP2
USP44	0.020833	0.125	0	0.025	0	USP44
NTN4	0.020833	0.125	0	0.025	0	NTN4
CCDC38	0.020833	0.125	0	0.025	0	CCDC38
AMDHD1	0.020833	0.125	0	0.025	0	AMDHD1
HAL	0.020833	0.125	0	0.025	0	HAL
OR52K2	0.020833	0.125	0	0.025	0.025	OR52K2
C11orf40	0.020833	0.125	0	0.025	0.025	C11orf40
API5	0.020833	0.25	0	0.025	0	API5
TTC17	0.020833	0.25	0	0.025	0	TTC17
MIR670	0.020833	0.25	0	0.025	0	MIR670
CCDC82	0.020833	0	0.25	0	0.025	CCDC82
JRKL	0.020833	0	0.25	0	0.025	JRKL
OR8D1	0.020833	0.125	0	0.025	0.025	OR8D1
OR8D2	0.020833	0.125	0	0.025	0.025	OR8D2
C10orf18	0.020833	0.375	0.125	0.225	0.025	C10orf18
LOC254312	0.020833	0.375	0	0.025	0	LOC254312
CUGBP2	0.020833	0.375	0	0.025	0	CUGBP2
PTER	0.020833	0.25	0	0.025	0	PTER
GAD2	0.020833	0.125	0	0.025	0	GAD2
APBB1IP	0.020833	0.125	0	0.025	0	APBB1IP
C10orf50	0.020833	0.125	0	0.025	0	C10orf50
LOC731789	0.020833	0.125	0	0.025	0	LOC731789
PDSS1	0.020833	0.125	0	0.025	0	PDSS1
ABI1	0.020833	0.125	0	0.025	0	ABI1
CCDC7	0.020833	0	0.125	0.025	0.025	CCDC7
FAM13C	0.020833	0	0.25	0	0.025	FAM13C
TM9SF3	0.020833	0.25	0.125	0.275	0.025	TM9SF3
PIK3AP1	0.020833	0.25	0.125	0.275	0.025	PIK3AP1
PLAA	0.020833	0.125	0.125	0.1	0.025	PLAA
IFT74	0.020833	0.125	0.125	0.075	0.025	IFT74
ALDH1A1	0.020833	0	0.125	0	0.025	ALDH1A1
GAS1	0.020833	0.25	0.125	0.175	0.025	GAS1
LPPR1	0.020833	0	0.125	0.025	0.025	LPPR1
MRPL50	0.020833	0	0.125	0.05	0.025	MRPL50
ZNF189	0.020833	0	0.125	0.05	0.025	ZNF189

TABLE 5-continued

Gene list for predicting prostate cancer fast relapse using AT					
ALDOB	0.020833	0	0.125	0.05	0.025
RNF20	0.020833	0	0.125	0.05	0.025
GRIN3A	0.020833	0	0.125	0.05	0.025
TNFSF15	0.020833	0	0.125	0.075	0.025
TNFSF8	0.020833	0	0.125	0.075	0.025
TNC	0.020833	0	0.125	0.075	0.025
PAPPA	0.020833	0	0.25	0.025	0.025
DBC1	0.020833	0	0.125	0.025	0.025
ADAM9	0.020833	0	0.125	0.025	0.025
ADAM32	0.020833	0	0.125	0.025	0.025
ADAM18	0.020833	0	0.125	0.025	0.025
ADAM2	0.020833	0	0.125	0.025	0.025
POTEA	0.020833	0	0.125	0.125	0.025
ST18	0.020833	0	0.125	0.025	0.025
ARMC1	0.020833	0.125	0	0.025	0
MTFR1	0.020833	0.125	0	0.025	0
PDE7A	0.020833	0.125	0	0.025	0
DNAJC5B	0.020833	0.125	0	0.025	0
TRIM55	0.020833	0.125	0	0.025	0
TMEM70	0.020833	0	0.25	0.05	0.025
JPH1	0.020833	0	0.25	0.025	0.025
COL14A1	0.020833	0.125	0	0.025	0.025
MRPL13	0.020833	0	0.125	0	0.025
MTBP	0.020833	0	0.125	0	0.025
C1GALT1	0.020833	0.125	0.125	0.075	0.025
COL28A1	0.020833	0.125	0.125	0.025	0.075
RPA3	0.020833	0.125	0.125	0.025	0.05
GLCC11	0.020833	0.125	0.125	0.025	0.05
ABCA13	0.020833	0.125	0	0.025	0.05
PION	0.020833	0.125	0	0.025	0.075
CDK6	0.020833	0	0.125	0.075	0.025
LAMB1	0.020833	0.125	0	0.025	0
AKR1B1	0.020833	0.125	0	0.025	0
AKR1B10	0.020833	0.125	0	0.025	0
RNF144B	0.020833	0.125	0	0.025	0.025
SOX4	0.020833	0.125	0	0.025	0

Symbol	chromosom②	cytoband	Transcript.②	Transcript.end
RPL23AP82	22	22q13.33	49542380	49584931
RABL2B	22	22q13.33	49552786	49568954
CA10	17	17q21.33	47062673	47592161
MAGEL2	15	15q11.2	21439791	21444087
NDN	15	15q11.2	21481647	21483544
C13orf36	13	13q13.3	36146049	36169976
SMAD9	13	13q13.3	36320207	36392410
ALG5	13	13q13.3	36421910	36471505
RSU1	10	10p13	16672623	16899460
ADCY2	5	5p15.31	7449343	7883195
UBE2E1	3	3p24.2	23822443	23907812
RETNLB	3	3q13.13	1.1E+08	1.1E+08
TRAT1	3	3q13.13	1.1E+08	1.1E+08
GUCA1C	3	3q13.13	1.1E+08	1.1E+08
MORC1	3	3q13.13	1.1E+08	1.1E+08
TTY8	Y	Yp11.2	10138709	10141309
TTY8B	Y	Yp11.2	10138709	10141309
TTY7	Y	Yp11.2	10154433	10162872
TTY7B	Y	Yp11.2	10154433	10162872
LOC100101	Y	Yp11.2	10165262	10168906
TTY21	Y	Yp11.2	10165262	10168906
YIPF6	X	Xq12	67635611	67669027
LOC96610	22	22q11.22	20982463	21007325
STX16	20	20q13.32	56659734	56687989
ZNF440	19	19p13.2	11786107	11807017
FKBP8	19	19p13.11	18503568	18515384
ZNF30	19	19q13.11	40109647	40127917
PSMC4	19	19q13.2	45168913	45179194
MAMSTR	19	19q13.33	53908067	53914789
RASIP1	19	19q13.33	53915654	53935783
IZUMO1	19	19q13.33	53935957	53941979
DSG2	18	18q12.1	27332025	27382813
ZNF287	17	17p11.2	16394356	16413246
SLC4A1	17	17q21.31	39681284	39701029
SPAG9	17	17q21.33	46394535	46553226
NME1	17	17q21.33	46585919	46594450

TABLE 5-continued

Gene list for predicting prostate cancer fast relapse using AT				
NME1-NMI	17	17q21.33	46585919	46604105
NME2	17	17q21.33	46597890	46604105
MBTD1	17	17q21.33	46609785	46692427
UTP18	17	17q21.33	46692896	46730292
TOM1L1	17	17q22	50333051	50394328
COX11	17	17q22	50384258	50401064
STXBP4	17	17q22	50401125	50596449
RSL1D1	16	16p13.13	11835556	11852944
VPS4A	16	16q22.1	67902788	67916448
COG8	16	16q22.1	67920025	67931028
PDF	16	16q22.1	67920025	67922000
NIP7	16	16q22.1	67931047	67934511
TMED6	16	16q22.1	67934650	67943214
PAR1	15	15q11.2	22931882	22934294
FSIP1	15	15q14	37679524	37862332
NRG4	15	15q24.2	74022899	74091841
NTRK3	15	15q25.3	86220992	86600666
FBXO33	14	14q21.1	38936628	38971456
DDHD1	14	14q22.2	52573210	52689797
FUT8	14	14q23.3	64947593	65279716
CYP46A1	14	14q32.2	99220508	99263392
RFC3	13	13q13.2	33290206	33438696
MIR548F5	13	13q13.3	34946406	35413383
DCLK1	13	13q13.3	35241123	35603465
SOHLH2	13	13q13.3	35640347	35686753
CCNA1	13	13q13.3	35903967	35915020
MYO16	13	13q33.3	1.08E+08	1.09E+08
YAF2	12	12q12	40837174	40918318
WDR51B	12	12q21.33	88337634	88443909
OR51E1	11	11p15.4	4621732	4633291
OR51E2	11	11p15.4	4657977	4675653
FLJ46111	11	11p15.4	9072486	9074314
DNAJC24	11	11p13	31347953	31410959
ASRGL1	11	11q12.3	61861350	61917464
SCGB1A1	11	11q12.3	61943099	61947244
PAK1	11	11q14.1	76710708	76862757
AKR1C1	10	10p15.1	4995454	5010159
AKR1C2	10	10p15.1	5021965	5050208
CUBN	10	10p13	16905971	17211823
MYO3A	10	10p12.1	26263008	26541472
CCDC6	10	10q21.2	61218527	61336825
KCNMA1	10	10q22.3	78299365	79067584
PDCD4	10	10q25.2	1.13E+08	1.13E+08
RLN1	9	9p24.1	5324969	5329874
SLC24A2	9	9p22.1	19505978	19776927
LOC440173	9	9q21.33	88813187	88846862
ASTN2	9	9q33.1	1.18E+08	1.19E+08
LHX3	9	9q34.3	1.38E+08	1.38E+08
QSOX2	9	9q34.3	1.38E+08	1.38E+08
TNFRSF10C	8	8p21.3	23016379	23030896
TERF1	8	8q21.11	74083651	74122542
C8orf84	8	8q21.11	74139334	74168062
RDH10	8	8q21.11	74369819	74400069
UBE2W	8	8q21.11	74865394	74953665
TCEB1	8	8q21.11	75021188	75046901
C7orf30	7	7p15.3	23305465	23315706
IGF2BP3	7	7p15.3	23316353	23476521
CALU	7	7q32.1	1.28E+08	1.28E+08
MIR548A1	6	6p22.3	18679994	18680091
HMGAI	6	6p21.31	34312555	34321986
TCP11	6	6p21.31	35193827	35217156
KLHL31	6	6p12.1	53620658	53638466
LRRC1	6	6q12.1	53767737	53896879
SLC22A16	6	6q21	1.11E+08	1.11E+08
RICTOR	5	5p13.1	38973780	39110259
FYB	5	5p13.1	39141114	39255425
FAM169A	5	5q13.3	74109155	74198372
SEMA6A	5	5q23.1	1.16E+08	1.16E+08
DMXL1	5	5q23.1	1.18E+08	1.19E+08
TNFAIP8	5	5q23.1	1.19E+08	1.19E+08
SAR1B	5	5q31.1	1.34E+08	1.34E+08
RNF130	5	5q35.3	1.79E+08	1.79E+08
MIR340	5	5q35.3	1.79E+08	1.79E+08
SLC30A9	4	4p13	41687280	41784309
BEND4	4	4p13	41807629	41849653

TABLE 5-continued

Gene list for predicting prostate cancer fast relapse using AT					
POLR2B	4	4q12	57539866	57592092	
IGFBP7	4	4q12	57592001	57671297	
HELQ	4	4q21.23	84547523	84596050	
MRPS18C	4	4q21.23	84596142	84601954	
FAM175A	4	4q21.23	84601120	84625315	
DCLK2	4	4q31.3	1.51E+08	1.51E+08	
TRIM61	4	4q32.3	1.66E+08	1.66E+08	
C4orf39	4	4q32.3	1.66E+08	1.66E+08	
NKTR	3	3p22.1	42617151	42665238	
DOCK3	3	3p21.31	50687676	51396670	
LRIG1	3	3p14.1	66511911	66633536	
GXYLT2	3	3p13	73020075	73107213	
PPP4R2	3	3p13	73128809	73197702	
WDR52	3	3q13.2	1.14E+08	1.15E+08	
SIDT1	3	3q13.2	1.15E+08	1.15E+08	
NAT13	3	3q13.2	1.15E+08	1.15E+08	
POLQ	3	3q13.33	1.23E+08	1.23E+08	
ARGFX	3	3q13.33	1.23E+08	1.23E+08	
FBXO40	3	3q13.33	1.23E+08	1.23E+08	
PLSCR1	3	3q24	1.48E+08	1.48E+08	
TM4SF4	3	3q25.1	1.51E+08	1.51E+08	
WWTR1	3	3q25.1	1.51E+08	1.51E+08	
NMD3	3	3q26.1	1.62E+08	1.62E+08	
MRPL47	3	3q26.33	1.81E+08	1.81E+08	
TMEM17	2	2p15	62580860	62587109	
EHBP1	2	2p15	62754517	63127124	
C2orf86	2	2p15	63202039	63518591	
MDH1	2	2p15	63669626	63687833	
RPL31	2	2q11.2	1.01E+08	1.01E+08	
SLC9A2	2	2q12.1	1.03E+08	1.03E+08	
GCG	2	2q24.2	1.63E+08	1.63E+08	
FAP	2	2q24.2	1.63E+08	1.63E+08	
C2orf77	2	2q31.1	1.7E+08	1.7E+08	
PHOSPHO2	2	2q31.1	1.7E+08	1.7E+08	
KLHL23	2	2q31.1	1.7E+08	1.7E+08	
SSB	2	2q31.1	1.7E+08	1.7E+08	
METTL5	2	2q31.1	1.7E+08	1.7E+08	
UBR3	2	2q31.1	1.7E+08	1.71E+08	
C1orf64	1	1p36.13	16203318	16205772	
CYP4A22	1	1p33	47375694	47387114	
C1orf141	1	1p31.3	67330447	67366809	
ABCD3	1	1p21.3	94656521	94716849	
RABGAP1L	1	1q25.1	1.72E+08	1.73E+08	
RBBP5	1	1q32.1	2.03E+08	2.03E+08	
RFX7	15	15q21.3	54170023	54322776	
IPCEF1	6	6q25.2	1.55E+08	1.55E+08	
TLR10	4	4p14	38450647	38460985	
PHOX2B	4	4p13	41440856	41445745	
PDCD6IP	3	3p22.3	33815070	33886199	
SR140	3	3q23	1.44E+08	1.44E+08	
KIF5C	2	2q23.1	1.49E+08	1.5E+08	
MIR1978	2	2q23.1	1.49E+08	1.49E+08	
VAMP7	X	Xq28	1.55E+08	1.55E+08	
IL9R	X	Xq28	1.55E+08	1.55E+08	
ATXN10	22	22q13.31	44446342	44619851	
RNF160	21	21q21.3	29222337	29287149	
C21orf7	21	21q21.3	29374744	29470074	
CLDN17	21	21q21.3	30460132	30460807	
KRTAP19-3	21	21q22.11	30785653	30786147	
KRTAP19-4	21	21q22.11	30791045	30791300	
KRTAP19-5	21	21q22.11	30796061	30796280	
KRTAP19-7	21	21q22.11	30855288	30855480	
KRTAP20-2	21	21q22.11	30929454	30929652	
KRTAP20-3	21	21q22.11	30937054	30937327	
PSG1	19	19q13.31	48063198	48075712	
ZNF519	18	18p11.21	14094724	14122430	
ANKRD30B	18	18p11.21	14738239	14842738	
TTR	18	18q12.1	27425728	27432983	
B4GALT6	18	18q12.1	27456207	27518685	
MCART2	18	18q12.1	27593657	27594842	
KIAA1012	18	18q12.1	27663134	27777090	
SERPINB13	18	18q21.33	59405514	59417413	
TANC2	17	17q23.3	58440630	58858800	
CDH11	16	16q21	63538184	63713421	
LOC283867	16	16q21	63875903	64167705	

TABLE 5-continued

Gene list for predicting prostate cancer fast relapse using AT					
CNTNAP4	16	16q23.1	74868677	75150637	
SCG5	15	15q13.3	30721162	30776591	
MEIS2	15	15q14	34970524	35180793	
DMXL2	15	15q21.2	49527231	49702260	
RAB27A	15	15q21.3	53283092	53349878	
PIGB	15	15q21.3	53398425	53435139	
CCPG1	15	15q21.3	53434730	53487835	
MIR628	15	15q21.3	53452430	53452525	
DYX1C1	15	15q21.3	53497246	53587725	
PYGO1	15	15q21.3	53625513	53668343	
PRTG	15	15q21.3	53691042	53822470	
NEDD4	15	15q21.3	53906414	54073128	
TEX9	15	15q21.3	54444936	54525365	
ZNF280D	15	15q21.3	54709666	54813080	
TCF12	15	15q21.3	54998125	55368007	
NEO1	15	15q24.1	71131928	71384599	
MIPOL1	14	14q21.1	36736869	37086619	
CDKN3	14	14q22.2	53933423	53956683	
C14orf145	14	14q31.1	80032574	80475638	
TSHR	14	14q31.1	80491622	80682400	
STON2	14	14q31.1	80806662	80934681	
SEL1L	14	14q31.1	81008994	81069959	
ZMYM2	13	13q12.11	19430810	19558940	
NBEA	13	13q13.2	34414456	35144874	
SPG20	13	13q13.3	35773777	35842318	
COG6	13	13q13.3	39127764	39263803	
RNASEH2B	13	13q14.3	50381893	50442596	
GUCY1B2	13	13q14.3	50466649	50538295	
FAM124A	13	13q14.3	50694508	50753618	
SERPINE3	13	13q14.3	50813169	50834241	
INTS6	13	13q14.3	50833702	50925277	
DCT	13	13q32.1	93889842	93929938	
DNAJC3	13	13q32.1	95127403	95245243	
TMTC4	13	13q32.3	1E+08	1E+08	
AEBP2	12	12p12.3	19483875	19566441	
GXYLT1	12	12q12	40761915	40824941	
SRGAP1	12	12q14.2	62524808	62827881	
C12orf66	12	12q14.2	62872686	62902344	
C12orf56	12	12q14.2	62947032	63070613	
TBK1	12	12q14.2	63132204	63182159	
GNS	12	12q14.2-1	63393489	63439494	
ZFC3H1	12	12q21.1	70289649	70344017	
TBC1D15	12	12q21.1	70519754	70606895	
MRS2P2	12	12q21.1	70528343	70531031	
METAP2	12	12q22	94391953	94433745	
USP44	12	12q22	94435018	94466752	
NTN4	12	12q22	94575714	94708668	
CCDC38	12	12q23.1	94784958	94860560	
AMDHD1	12	12q23.1	94861202	94886501	
HAL	12	12q23.1	94891273	94914203	
OR52K2	11	11p15.4	4427146	4428091	
C11orf40	11	11p15.4	4549229	4555627	
API5	11	11p12	43290081	43322659	
TTC17	11	11p12	43337067	43472072	
MIR670	11	11p11.2	43537782	43537880	
CCDC82	11	11q21	95725577	95762732	
JRKL	11	11q21	95762806	95766376	
OR8D1	11	11q24.2	1.24E+08	1.24E+08	
OR8D2	11	11q24.2	1.24E+08	1.24E+08	
C10orf18	10	10p15.1	5766807	5846950	
LOC254312	10	10p14	11016910	11034133	
CUGBP2	10	10p14	11087265	11418679	
PTER	10	10p13	16518973	16595743	
GAD2	10	10p12.1	26545242	26633498	
APBB1IP	10	10p12.1	26767272	26896739	
C10orf50	10	10p12.1	26918800	26923256	
LOC731789	10	10p12.1	26972043	26982389	
PDSS1	10	10p12.1	27026601	27075733	
ABI1	10	10p12.1	27075531	27189966	
CCDC7	10	10q11.22	32775047	32903499	
FAM13C	10	10q21.1	60675896	60792359	
TM9SF3	10	10q24.1	98267857	98336800	
PIK3AP1	10	10q24.1	98343059	98470270	
PLAA	9	9p21.2	26893369	26937469	
IFT74	9	9p21.2	26937037	27052932	

TABLE 5-continued

Gene list for predicting prostate cancer fast relapse using AT					
ALDH1A1	9	9q21.13	74705407	74757790	
GAS1	9	9q21.33	88749097	88751925	
LPPR1	9	9q31.1	1.03E+08	1.03E+08	
MRPL50	9	9q31.1	1.03E+08	1.03E+08	
ZNF189	9	9q31.1	1.03E+08	1.03E+08	
ALDOB	9	9q31.1	1.03E+08	1.03E+08	
RNF20	9	9q31.1	1.03E+08	1.03E+08	
GRIN3A	9	9q31.1	1.03E+08	1.04E+08	
TNFSF15	9	9q32	1.17E+08	1.17E+08	
TNFSF8	9	9q33.1	1.17E+08	1.17E+08	
TNC	9	9q33.1	1.17E+08	1.17E+08	
PAPPA	9	9q33.1	1.18E+08	1.18E+08	
DBC1	9	9q33.1	1.21E+08	1.21E+08	
ADAM9	8	8p11.23	38973662	39081937	
ADAM32	8	8p11.23	39084207	39261594	
ADAM18	8	8p11.22	39561299	39706645	
ADAM2	8	8p11.22	39720412	39814937	
POTEA	8	8p11.1	43266742	43337486	
ST18	8	8q11.23	53185945	53484993	
ARMC1	8	8q13.1	66677628	66708987	
MTFR1	8	8q13.1	66719442	66783127	
PDE7A	8	8q13.1	66792460	66863876	
DNAJC5B	8	8q13.1	67096345	67175310	
TRIM55	8	8q13.1	67201832	67250273	
TMEM70	8	8q21.11	75050984	75057568	
JPH1	8	8q21.11	75309493	75396118	
COL14A1	8	8q24.12	1.21E+08	1.21E+08	
MRPL13	8	8q24.12	1.21E+08	1.22E+08	
MTBP	8	8q24.12	1.22E+08	1.22E+08	
C1GALT1	7	7p21.3	7188771	7250507	
COL28A1	7	7p21.3	7364769	7541986	
RPA3	7	7p21.3	7643100	7724764	
GLCCI1	7	7p21.3	7974948	8095235	
ABCA13	7	7p12.3	48208389	48657638	
PION	7	7q11.23	76778004	76883654	
CDK6	7	7q21.2	92072173	92303878	
LAMB1	7	7q31.1	1.07E+08	1.07E+08	
AKR1B1	7	7q33	1.34E+08	1.34E+08	
AKR1810	7	7q33	1.34E+08	1.34E+08	
RNF144B	6	6p22.3	18495573	18576830	
SOX4	6	6p22.3	21701951	21706829	

② indicates text missing or illegible when filed

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 28

<210> SEQ ID NO 1

<211> LENGTH: 24

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 1

aacctgagtc tgccaaggac tagc

24

<210> SEQ ID NO 2

<211> LENGTH: 24

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 2

-continued

ttccacacac cactggccat cttc 24

<210> SEQ ID NO 3
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
primer

<400> SEQUENCE: 3

acagaagtct gggatgtgga 20

<210> SEQ ID NO 4
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
primer

<400> SEQUENCE: 4

gcccaaaaag acagacagaa 20

<210> SEQ ID NO 5
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
primer

<400> SEQUENCE: 5

gatcccaagc tcttcctctt 20

<210> SEQ ID NO 6
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
primer

<400> SEQUENCE: 6

acgtttgtgt gtgcatctgt 20

<210> SEQ ID NO 7
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
primer

<400> SEQUENCE: 7

gggtgatttt cctcttttgt 20

<210> SEQ ID NO 8
<211> LENGTH: 20
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
primer

-continued

<400> SEQUENCE: 8

tgattccaat catagccaca

20

<210> SEQ ID NO 9

<211> LENGTH: 25

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 9

tgtcatagtt tagaacgaac taacg

25

<210> SEQ ID NO 10

<211> LENGTH: 23

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 10

ctgaggtatc aaaaactcag agg

23

<210> SEQ ID NO 11

<211> LENGTH: 24

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 11

gtgggctgaa aagctcccgaa ttat

24

<210> SEQ ID NO 12

<211> LENGTH: 24

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 12

attcaaagggt tatctgggct ctgg

24

<210> SEQ ID NO 13

<211> LENGTH: 23

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 13

ctggcacaga acaggcactt agg

23

<210> SEQ ID NO 14

<211> LENGTH: 24

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic

-continued

primer

<400> SEQUENCE: 14

ggaggaactg ggaaccacac aggt 24

<210> SEQ ID NO 15
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
primer

<400> SEQUENCE: 15

ccctagtga tgataagaat aatcagtatg 30

<210> SEQ ID NO 16
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
primer

<400> SEQUENCE: 16

ggacagatga taaatacata ggatggatgg 30

<210> SEQ ID NO 17
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
primer

<400> SEQUENCE: 17

actgtcatag cagtgtgag g 21

<210> SEQ ID NO 18
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
primer

<400> SEQUENCE: 18

acttacctac tgtagggacg g 21

<210> SEQ ID NO 19
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
primer

<400> SEQUENCE: 19

aggaaggcct attcgttctc g 21

<210> SEQ ID NO 20
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence

-continued

<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 20
gaacagtatg ggaggagttc g 21

<210> SEQ ID NO 21
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 21
gccagttgat gtgacaactg c 21

<210> SEQ ID NO 22
<211> LENGTH: 22
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 22
cagctgagag tggtttcttt gc 22

<210> SEQ ID NO 23
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 23
atcaggactt accaggtgtg c 21

<210> SEQ ID NO 24
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 24
accgtgtctg gaaacatagc c 21

<210> SEQ ID NO 25
<211> LENGTH: 21
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic primer

<400> SEQUENCE: 25
agtggcctgt ccttgcttat c 21

<210> SEQ ID NO 26
<211> LENGTH: 21

-continued

```

<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
primer

<400> SEQUENCE: 26

cagagcaaca attctgaccg g                                21

<210> SEQ ID NO 27
<211> LENGTH: 24
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
primer

<400> SEQUENCE: 27

tctttgcact ttctgcatgt cccc                                24

<210> SEQ ID NO 28
<211> LENGTH: 23
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Description of Artificial Sequence: Synthetic
primer

<400> SEQUENCE: 28

gtccatcacg atgccagtgg tac                                23

```

What is claimed is:

1. A method of diagnosing a prostate cancer in a subject comprising determining the number and/or size of copy number variations in DNA from a tumor sample, a sample of tissue adjacent a tumor, and/or in a blood sample, where if the number and/or size of copy number variations exceeds a particular threshold, a diagnosis of prostate cancer is indicated.

2. The method of claim 1, comprising determining the number and size of copy number variations in DNA from a tumor or prostate tissue sample, where if the number of copy number variations exceeds 90 loci, each locus being at least 10 kb in length, a diagnosis of prostate cancer is indicated.

3. The method of claim 1, where said subject is a male having one or more of the following clinical findings: increased serum prostate specific antigen, enlarged prostate on physical exam, difficulty urinating and/or urinary retention, comprising determining the number and/or size of copy number variations in DNA from a blood sample from the subject, where if the number of copy number variations exceeds 4 loci, each locus being at least 10 kb in length, a diagnosis of prostate cancer is indicated.

4. The method of claim 1, comprising determining the presence of deletions in one or more of chromosome regions 8p, 13p, 16q, and/or 17p in DNA from a prostate tissue or a blood sample from the subject, where if there is a deletion of at least 3 megabases in one or more of these regions, a diagnosis of prostate cancer is indicated.

5. The method of claim 1, comprising determining the presence of amplification in one or more of chromosome regions 8q and X in DNA from a prostate tissue or a blood

sample from the subject, where if there is amplification of a locus in one or more of these regions, a diagnosis of prostate cancer is indicated.

6. A method of determining that a prostate cancer patient is at decreased risk for relapse or rapid relapse comprising determining the size of copy number variations in a prostate tumor sample, tissue adjacent a prostate tumor, and/or blood, where if the size of copy number variations is below a particular threshold, the patient is deemed to be at decreased risk for relapse or rapid relapse.

7. The method of claim 6, comprising determining the mean size of copy number variations in DNA from a blood sample from the patient, where if the mean size of copy number variations is 40 kb or less, the patient is deemed to be at decreased risk for relapse.

8. The method of claim 6, comprising determining the mean size of copy number variations in DNA from a sample of tissue adjacent a prostate cancer from the patient, where if the mean size of copy number variations is 95 kb or less, the patient is deemed to be at decreased risk for relapse.

9. The method of claim 6, comprising determining the mean size of copy number variations in DNA from a sample of prostate cancer tissue from the patient, where if the mean size of copy number variations is 385 kb or less, the patient is deemed to be at decreased risk for relapse.

10. The method of claim 6, comprising determining the median size of copy number variations in a blood sample from the patient, where if the median size of copy number variations is 17 kb or less, the subject is deemed to be at decreased risk for relapse.

11. The method of claim 6, comprising determining the median size of copy number variations in a sample of tissue

adjacent a prostate cancer from the patient, where if the median size of copy number variations is 16 kb or less, the subject is deemed to be at decreased risk for relapse.

12. The method of claim **6**, comprising determining the median size of copy number variations in DNA from a sample of prostate cancer tissue from the patient, where if the median size of copy number variations is 185 kb or less, the patient is deemed to be at decreased risk for relapse.

13. A method of determining that a prostate cancer patient is at increased risk for relapse or rapid relapse comprising determining the size of copy number variations in a prostate tumor sample, tissue adjacent a prostate tumor, and/or blood, where if the size of copy number variations exceeds a particular threshold, the patient is deemed to be at increased risk for relapse or rapid relapse.

14. The method of claim **12**, comprising determining the mean size of Copy number variations in a prostate tumor sample, tissue adjacent a prostate tumor, and/or blood, where if the mean size of copy number variations exceeds a particular threshold, the patient is deemed to be at increased risk for relapse or rapid relapse.

15. The method of claim **13**, comprising determining the mean size of copy number variations in DNA from a blood sample from the patient, where if the mean size of copy number variations is 70 kb or more, the patient is deemed to be at increased risk for relapse.

16. The method of claim **14**, comprising determining the mean size of copy number variations in DNA from a sample of tissue adjacent to prostate cancer from the patient, where if the mean size of copy number variations is 246 kb or more, the patient is deemed to be at increased risk for relapse.

17. The method of claim **14**, comprising determining the mean size of copy number variations in DNA from a sample of prostate cancer tissue from the patient, where if the mean size of copy number variations is 817 kb or more, the patient is deemed to be at increased risk for relapse.

18. The method of claim **14**, comprising determining the mean size of copy number variations in DNA from a sample of prostate cancer tissue from the patient, where if the mean size of copy number variations is 1060 kb or more, the patient is deemed to be at increased risk for rapid relapse.

19. The method of claim **13**, comprising determining the median size of copy number variations in a prostate tumor sample, tissue adjacent a prostate tumor, and/or blood, where if the median size of copy number variations exceeds a particular threshold, the patient is deemed to be at increased risk for relapse or rapid relapse.

20. The method of claim **19**, comprising determining the median size of copy number variations in DNA from a blood sample from the patient, where if the median size of copy number variations is 23 kb or more, the patient is deemed to be at increased risk for relapse.

21. The method of claim **19**, comprising determining the median size of copy number variations in DNA from a sample of tissue adjacent a prostate cancer from the patient, where if the median size of copy number variations is 18 kb or more, the patient is deemed to be at increased risk for relapse.

22. The method of claim **19**, comprising determining the median size of copy number variations in DNA from a sample of prostate cancer tissue from the patient, where if the median size of copy number variations is 647 kb or more, the patient is deemed to be at increased risk for relapse.

* * * * *